



2ND Schizophrenia
International
Research
Society
Conference

FINAL PROGRAMME

Florence
10-14 April, 2010



This meeting is jointly sponsored by the Vanderbilt University School
of Medicine and the Schizophrenia International Research Society





Dear Attendees,

The Schizophrenia International Research Society, a non-profit organization dedicated to promoting research and communication among research scientists internationally about schizophrenia, sincerely appreciates your interest in the Society and our conference. The first congress in 2008 was a major success for the field attracting approximately 1500 attendees from 43 countries. We anticipate an even higher attendance at this congress with more of the best investigators in the field of schizophrenia in attendance.

The Schizophrenia International Research Society was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society strives to facilitate international collaboration to discover the causes and better treatments for schizophrenia and related spectrum disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new and newsworthy research on schizophrenia. It is estimated that 1 in every 100 people in the world live with this disease. The Society and its meetings strive to increase the understanding of the personal, familial and societal impact of schizophrenia. Now more than ever there is a need for increased research funding for schizophrenia research around the world.

By attending the 2nd Biennial Conference of the Society you will be exposed to sessions that will assist you to:

- Foster communication and advance knowledge about the multiple treatment possibilities for schizophrenia.
- Develop the best methods to design new intervention studies.
- Discuss strategies for new treatment development.
- Review the status of genetic findings.
- Learn methods to advance genetic research in schizophrenia.
- Review brain imaging data in relation to pathophysiology and disease progression.
- Translate basic neuroscience findings of relevance to clinical practice, and
- Understand differences in schizophrenia research and outcome of the research across diverse geographic areas and cultures.

In addition to learning from the latest, cutting edge research in the field, we hope you will enjoy the beautiful city of Florence and its rich history. Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference.

Sincerely,

The Organizers

John Kane, President

Lynn E. DeLisi, Secretary

René S. Kahn, Treasurer

Wolfgang W. Fleischhacker, Meeting Liaison Chair

Eve Johnstone, 2010 Program Committee Chair

Celso Arango, 2010 Program Committee Co-Chair

Table of Contents

General Information	2
Saturday, 10 April	13
Sunday, 11 April	16
Monday, 12 April	23
Tuesday, 13 April	30
Wednesday, 14 April	38
Sunday Posters	48
Monday Posters	71
Tuesday Posters	94
Index of Presenters and Authors	117



Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2010 Supporting Corporations.

Platinum



Silver



We also recognize and appreciate the 2010 Biennial Schizophrenia International Research Conference support by way of an educational grant from:

- Eli Lilly & Company
- F. Hoffman - La Roche Ltd.

The Junior Travel Award Fellowship Program is sponsored by an R13 grant from the U.S. National Institute of Mental Health to Harvard Medical School (LE DeLisi, PI) (Grant ID: R13MH082446).

2010 Program Committee

Eve Johnstone, Program Committee Chair - UK
 Celso Arango, Program Committee Co-chair - Spain
 Elizabeth Cantor-Graae - Sweden
 Eric Chen - China
 Michael Davidson – Israel
 Sonia Dolfus - France
 Robin Emsley - South Africa
 Susan Essock - USA
 Birte Glenthøj - Denmark
 Anthony Grace - USA
 Shitij Kapur - UK
 Richard Keefe - USA
 Don Linszen - The Netherlands
 Stephen Marder - USA
 John McGrath - Australia
 Bitu Moghaddam - USA

Dieter Naber - Germany
 Jim van Os - The Netherlands
 Cyndi Shannon Weickert - Australia
 Martha Shenton - USA
 Pamela Sklar - USA
 Si Tianmei - China
 Dawn Velligan - USA
 Antonio Vita - Italy
 Til Wykes - UK

Travel Award Selection Committee:

Lynn E. DeLisi, Chair
 Matcheri Keshavan
 Margaret Niznikiewicz
 Larry Seidman
 Martha Shenton



Congratulations to the following 2010 Travel Fellows.

Moogeh Baharnoori
Cali Bartholomeusz
Rachel Batty
Aurelie Boucher
Lisa Buchy
Christopher Chaddock
Bongikosi Chiliza
Renan Pedra De Souza
Melanie Focking
Alexander Fornito
Juan Gallego
Darya Gaysina
Hiroaki Hori
Gisele Huf
Joost Janssen
Renaud Jardri
Shambhi Dutta Joshi
Shi Hyun Kang
James Kirkbride
Yousri Kissi
Deepak Kumar

Alexandre Loch
Mahesh Menon
Jessica Merchan Naranjo
Gemma Modinos
Nashaat Adel Mohamed
Barnaby Nelson
Anna-Karin Neubeck
Hsiao Piau Ng
Gabriela Novak
Owolabi Oluwaseun
Diana Prata
Anca Radulescu
Naren Rao
Igor Riecansky
Darryl Smith
Renate Thienel
Hanan Trotman
Hiroyuki Uchida
Kristen Woodberry
Mei Hong Xiu



Schizophrenia International Research Society Officers, Board and International Advisory Committee

OFFICERS:

John Kane, President
Lynn DeLisi, Secretary
René Kahn, Treasurer

BOARD OF DIRECTORS (2009 – 2010):

William Carpenter - USA
Tim Crow - UK
Lynn E. DeLisi - USA
Wolfgang Fleischhacker - Austria
Philip Harvey - USA
René Kahn - The Netherlands
John Kane - USA
Robin Murray - UK
Henry A. Nasrallah - USA
Charles Schulz - USA

INCOMING OFFICERS:

Robin Murray - UK, President
John Kane - USA, President-Elect
Lynn E. DeLisi - USA, Secretary
René Kahn - The Netherlands, Treasurer

INCOMING BOARD OF DIRECTORS:

Jean Addington - Canada
Mary Cannon - Ireland
Wolfgang Fleischhacker - Austria
Phillip Harvey - USA
Shitij Kapur - UK
Stephen Marder - USA
John McGrath - Australia
Alison Yung - Australia

INTERNATIONAL ADVISORY COUNCIL:

Jean Addington - Canada
Celso Arango - Spain
Francine Benes - USA
David Braff - USA
Eric Chen - China
Michael Davidson - Israel
J.F.W. Deakin - UK
4 Robin Emsley - South Africa

Wolfgang Gaebel - Germany
Wagner Gattaz - Brazil
Birte Glenthøj - Denmark
Anthony Grace - USA
Michael Green - USA
Raquel Gur - USA
Daniel Javitt - USA
Eve Johnstone - UK
Shitij Kapur - UK
Richard Keefe - USA
Jun Soo Kwon - Korea
Verónica Larach - Chile
David Lewis - USA
Mario Maj - Italy
Stephen Marder - USA
Patrick McGorry - Australia
John McGrath - Australia
Dieter Naber - Germany
Christos Pantelis - Australia
Joseph Peuskens - Belgium
Martha Shenton - USA
Masatoshi Takeda - Japan
Nori Takei - Japan
Carol Tamminga - USA
Thara Rangaswamy - India
Si Tianmei - China
Jim van Os - The Netherlands
Antonio Vita - Italy
John Waddington - Ireland
Daniel Weinberger - USA
Til Wykes - UK
Yu Xin - China

Continuing Medical Education

ACCME

The 2010 Schizophrenia International Research Conference is jointly sponsored by the Schizophrenia International Research Society and Vanderbilt University School of Medicine. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). Vanderbilt School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Vanderbilt School of Medicine designates this educational activity for a maximum of 31.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. There will be a \$50.00 USD charge for scientific registrants to obtain CME credits.

It is the policy of Vanderbilt School of Medicine that participants in CME activities be made aware of any affiliation or financial interest that may affect the speaker's presentation(s). Each speaker (plenary, panel, and study group) and poster presenter has completed a conflict of interest form; the information from these forms will be available online at www.schizophreniaconference.com and on the abstract website.

EACCME

Credits will be offered from EACCME. For more information, please inquire at the Registration Desk.

Italian Ministry of Health Credits

Credits will be offered from the Italian Ministry of Health. For more information, please inquire at the Registration Desk.

Learning Objectives:

After participating in the 2010 Schizophrenia International Research Society attendees should be able to:

- Foster communication and advance knowledge about the multiple treatment possibilities for schizophrenia.
- Develop the best methods to design new intervention studies.
- Discuss strategies for new treatment development.
- Review the status of genetic findings.
- Learn methods to advance genetic research in schizophrenia.
- Review brain imaging data in relation to pathophysiology and disease progression.
- Translate basic neuroscience findings of relevance to clinical practice.
- Understand differences in schizophrenia research and outcome of the research across diverse geographic areas and cultures.

Disclosures

Disclosures for 2010 speakers, plenary, special session, symposia, oral presentations and poster presenters, may be found online at: www.schizophreniaconference.com

Conference Evaluation

All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME, EACCME or Italian) credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.schizophreniaconference.org All evaluations must be completed by May 15, 2010.



Videotaping Sessions

Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

General Information

Registration

CONFERENCE REGISTRATION PERIODS

Date	Time	Location
Saturday, 10 April	11:00 a.m. - 6:30 p.m.	Main Entrance Piazza Adua
Sunday, 11 April	8:00 a.m. - 6:00 p.m.	Main Entrance Piazza Adua
Monday, 12 April	8:00 a.m. - 6:00 p.m.	Main Entrance Piazza Adua
Tuesday, 13 April	8:00 a.m. - 6:00 p.m.	Main Entrance Piazza Adua
Wednesday, 14 April	8:00 a.m. - 4:00 p.m.	Main Entrance Piazza Adua

Registration Types:

Delegate: Scientific Attendee

Student: Full-time graduate students, medical students, or in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student's immediate supervisor verifying his/her student status and relevant field will be required for registration.

Accompanying Guest:

The €200.00 fee includes all lunches, coffee breaks and welcoming reception.

Registration Timeframes:

Regular: Register August 2009 - 10 March 2010

Late: Register between 11 March 2010 - onsite

Registration fees by Registration Type:

Registrants who sign up for 2009 - 2010 Member rate will be required to sign up for 2010 membership at \$145 USD for Delegates, \$95 USD for Students. Registration fees below do not include 2010 membership dues. For Membership information to Schizophrenia International Research Society, go to www.schizophreniaresearchsociety.org. Click on the "Join" tab to learn about benefits of membership and to join the Society.

	Regular	Late/Onsite
SIRS Member Delegate (Must have paid 2009 & 2010 Membership)	400.00€	450.00€
SIRS New Member Delegate (New 2010 Member)	440.00€	490.00€
Non-Member Delegate	600.00€	650.00€
SIRS Student Member (Must have paid 2009 & 2010 Membership)	150.00€	200.00€
SIRS New Student Member (New 2010 Member)	190.00€	240.00€
Accompanying Guest	200.00€	200.00€

ABSTRACTS:

Abstracts for all presentations are available online at www.schizophreniaconference.org. A paper abstract book will be available at the Elsevier Table located in the registration area. All abstracts will be published in the journal, *Schizophrenia Research*, appear online and in print to all members and subscribers one month subsequent to the conference.

SCIENTIFIC SESSIONS

CONFERENCE INTRODUCTION & ETHICS SESSION

Saturday, 10 April, 3:00pm - 5:00pm

Auditorium

Travel Fellows are Required to Attend.

John Kane, Introduction

Ethics Session - Stephen Marder & Norman Sartorius

Researchers who address clinical issues in schizophrenia face a number of challenging ethical issues. This session will provide an opportunity for presenters and participants to discuss approaches to addressing these issues. The following topics will be discussed: (1) the capacity of patients in different stages of illness to provide informed consent; (2) ethical issues in intervention studies for prodromal patients; (3) the use of medication-free or placebo periods in acute and long-term pharmacological studies; (4) the use of pharmacological challenges that may exacerbate psychosis; and (5) treatment as usual control conditions for studies of psychosocial treatments. There will also be a special focus on financial conflicts of interest in clinical research.



KEYNOTE LECTURE

Saturday, 10 April, 5:00pm - 6:30pm

Auditorium

Elyn Saks

The Center Cannot Hold: My Journey through Madness

Elyn Saks will narrate her story as a person with schizophrenia, drawing on her memoir, "The Center Cannot Hold: My Journey through Madness." Diagnosed in her early twenties, Saks suffered a number of hospitalizations. She was given "very poor" and "grave" prognoses, that is, expected to be unable to live independently, let alone to work. That has not turned out to be her life, she is a chaired professor at a top law school with appointments also in departments of psychology and psychiatry. She is happily married and has many friends.

Professor Saks' talk will trace the evolution of her illness and the factors, not only medication but also intensive psychotherapy, that have helped her craft a good life for herself. After narrating her story, Saks, mindful that she is an "n" of only one, will draw some policy implications from her experiences.

PLENARY SESSIONS

There will be 3 plenary sessions during the conference that will focus on Genetics, Clinical/Pre-Clinical and Imaging. Panel discussions and presentations will follow each of the main speakers. All plenary sessions will be held in the main Auditorium. Below are the session times and topics:

Sunday, 11 April

8:30am - 10:30am

Clinical Plenary Session - *Anticipating DSM-V: New Paradigms*

William Carpenter, M.D.

Panelists: Alex Hoffer, Richard Keefe, Kim Mueser & Dieter Naber

10:30am - 12:00pm

Pre-Clinical Plenary Session - *New Directions for Animal Modeling in Schizophrenia*

Bitá Moghaddam, Ph.D.

Panelists: Pierre Sokoloff, Inna Gaisler-Salomon, Akira Sawa, Patricio O'Donnell & Peter Uhlhaas

Monday, 12 April

8:30am - 12:00pm

Genetics Plenary Session - *Clinical Implications of Recent Genetic Findings: GWAS, Endophenotypes and Commercial testing*

Michael Owen, FRCPsych, Ph.D.

Panelists: James Kennedy, Thomas Lehner, Mary Claire King, Peter Visscher, Pablo Gejman, Robin Murray, & Dan Rujescu

Tuesday, 13 April

8:30am - 12:00pm

Imaging Plenary Session - *On the matter of neuroimaging in the context of schizophrenia genetics*

Daniel Weinberger, M.D.

Panelists: Alessandro Bertolino, Phillip McGuire, Eva Meisenzahl, Andreas Meyer-Lindenberg, Steven Potkin & Si Tianmei

SPECIAL SESSIONS

The below 3 special sessions will run concurrently on Sunday, 11 April from 1:30pm - 3:30pm.

- *DSM-V Debate*,
Palaffari First-Floor, Co-Chairs: Barbara Cornblatt & Stephan Ruhrmann
- *Gene Expression in Schizophrenia - animal models and postmortem studies*
Auditorium, Chair: Amanda Law
- *Psychosocial Session - An Update on Psychosocial Treatment of Schizophrenia*
Palaffari Second-Floor, Chair: Kim Mueser

SYMPOSIA SESSIONS

The title and location of each Symposium is indicated in the Program. The presentations in each session are scheduled at approximately 25-minute intervals, allowing for 15-minute presentations and 10-minute discussion periods. A twenty-minute general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

Sunday, 11 April	3:30 p.m. - 5:30 p.m.
Monday, 12 April	1:30 p.m. - 3:30 p.m. 3:30 p.m. - 5:30 p.m.
Tuesday, 13 April	3:30 p.m. - 5:30 p.m.
Wednesday, 14 April	8:30 a.m. - 10:30 a.m. 10:30 a.m. - 12:30 p.m. 2:00 p.m. - 4:00 p.m.

ORAL PRESENTATIONS

Oral Presentations will be issue oriented this year. They are scheduled for Tuesday 13 April from 1:30pm - 3:30pm. We will have 5 concurrent oral sessions as listed below.

Gene Environment Interactions in the Prediction of Psychosis <i>Chair: Lynn DeLisi</i>	Palaffari-First Floor
Novel Interventions <i>Chair: Birte Glenthøj</i>	Palaffari-Third Floor
Pathways to Psychosis & Misc Neurochemistry <i>Chair: Celso Arango</i>	Auditorium
Pathways to Psychosis and Factors in Childhood <i>Chair: John Kane</i>	Palaffari-Ground Floor
Predicting the Development of Psychosis <i>Chair: René Kahn</i>	Palaffari-Second Floor



POSTERS

There will be 3 separate poster sessions. Presenters should put-up their poster by 10:00AM and take it down after the evening session no later than 7.45pm. Poster presentations are grouped by general topic area when possible. All three poster sessions are located in Cavaniglia located across the street in the Forte de Basso grounds. Lunch will be served each day with the poster sessions. An additional viewing time will be held in the evenings.

Sunday 11 April

Poster Session I
12:00 p.m. - 1:30 p.m.
Evening: 5:30pm -7:30pm

Monday 12 April

Poster Session II
12:00 p.m. - 1:30 p.m.
Evening: 5:30pm -7:30pm

Tuesday 13 April

Poster Session III
12:00 p.m. - 1:30 p.m.
Evening: 5:30pm -7:30pm


COMPUTER ACCESS

Wireless Internet Access is available in the conference center for a 24-hour fee of €10,00. To purchase and obtain a code for wireless access, please inquire at the registration desk in the Palazzo Entrance. The Society is offering complimentary internet access in the Computer Center located in Limonaia. The computer center is open daily from 7:30am - 5:30pm.

SPEAKER READY ROOM

A speaker ready room is available in Sala 103 in the Auditorium Building of the Firenze Fiera Conference Center. The room will open each day of the conference from 7:30am - 5:30pm. All presenters are required to come to the speaker ready room to upload your presentation, preferably one day prior to the presentation. Presentations from individual computers are not allowed.

FLOOR PLAN




Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia Pavilion. This is a short 3 to 5 minute walk from the Palazzo de Congressi.

Concurrent Symposia, Oral Presentations and Special Sessions will be held on the Ground Floor, First Floor, Second Floor and Third Floor of the Palazzo Degli Affari.

The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.




Palazzo Congressi - Villa Vittoria AUDITORIUM




Keynote and Plenary Sessions and some Special Sessions, Symposia and Oral Presentations will be held in the Auditorium.

Palazzo Congressi - Villa Vittoria

First Floor



Second Floor



The Speaker Ready Room (Sala 103) and other small meeting rooms for journal meetings and committee meetings will be in the Villa Vittoria Building on the 1st Floor. The Villa Vittoria building is connected to the Auditorium. The Sala Verde room is on the 2nd floor of the Villa Vittoria building and is where the plenary telecasts will take place.

Saturday 10 april

	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	8:00	
Auditorium							2:00-2:45	3:00-3:15	3:15-5:00	5:00-6:30				
							Travel Awardee Orientation	Conference Welcome/Orientation	Ethics Symposia	Keynote Lecture - The Center Cannot Hold: My Journey through Madness				
Passi Perduti & Palaffari Lawn											6:30-8:30			
											Opening Night Reception			
Sala Verde										5:00-6:30				
										Televised from Auditorium - Keynote Lecture, Elyn Saks				
Palazzo Entrance				11:00-6:30										
				Registration										
Sala 101					12:00-2:00		2:00-3:00							
					SIRS Executive Board Meeting		Industry Liaison Task Force Meeting							
Sala 103	8:00-6:30													
	Speaker Ready Room													
Limoaia				11:00-6:30										
				Computer Center										

Saturday, 10 April

Legenda:

- Keynote
- Special Session
- Speaker Ready
- Registration
- Computer Center



Saturday 10 April Detailed Schedule of Events

<u>Registration Opens</u>	11:00AM - 6:30 PM
Main Entrance - Piazza Adua	
<u>SIRS Executive Board Meeting</u>	12:00PM - 2:00 PM
Sala 101 - Villa Vittoria Building	
<u>SIRS Industry Liaison Task Force Meeting</u>	2:00PM - 3:00 PM
Sala 101 - Villa Vittoria Building	
For invited task force members only.	
<u>Coffee Available</u>	3:00 PM - 5:15 PM
Passi Perduti	

SCIENTIFIC SESSIONS

<u>Conference Welcome/Orientation</u>	3:00PM - 3:15 PM
Auditorium	
Chair: John Kane, President SIRS	
Travel Fellows are Required to Attend	
<u>Ethics Symposia</u>	3:15PM - 5:00 PM
Auditorium	
Chair: Stephen Marder; Co-Chair: Norman Sartorius	

Overall Abstract: *Travel Fellows are Required to Attend.* Researchers who address clinical issues in schizophrenia face a number of challenging ethical issues. This session will provide an opportunity for presenters and participants to discuss approaches to addressing these issues. The following topics will be discussed: (1) the capacity of patients in different stages of illness to provide informed consent; (2) ethical issues in intervention studies for prodromal patients; (3) the use of medication-free or placebo periods in acute and long-term pharmacological studies; (4) the use of pharmacological challenges that may exacerbate psychosis; and (5) treatment as usual control conditions for studies of psychosocial treatments. There will also be a special focus on financial conflicts of interest in clinical research.

Keynote Lecture

5:00PM - 6:30 PM

Auditorium

The Center Cannot Hold: My Journey through Madness

Elyn Saks



Elyn Saks is Associate Dean and Orrin B. Evans Professor of Law, Psychology, and Psychiatry and the Behavioral Sciences at the University of Southern California Gould School of Law; Adjunct Professor of Psychiatry, UCSD School of Medicine; and Assistant Faculty, New Center for Psychoanalysis. A graduate of Vanderbilt, Oxford, and Yale Law, Saks writes extensively about mental health law. She is a member of the American Law Institute, and has received numerous honors for *The Center Cannot Hold: My Journey Through Madness*, e.g. Time Magazine Top Ten Nonfiction Book of the Year. Saks was recently awarded a “MacArthur Fellowship.”

The Keynote Lecture will be held in the Auditorium and televised in the Sala Verde on the 2nd Floor of Villa Vittoria to accommodate additional attendees.

Opening Night Reception

6:30PM - 8:30 PM

Palaffari Lawn & Passi Perduti in Villa Vittoria Building

*All registered attendees and registered accompanying others are invited to attend.



Sunday 11 april

Sunday, 11 April

	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00
Auditorium		8:30-10:30 Plenary Session - Anticipating DSM-V: New Paradigms			10:30-12:00 Plenary Session - New Directions for Animal Modeling in Schizophrenia			1:30-3:30 Gene Expression in Schizophrenia - animal models and postmortem studies		3:30-5:30 Multiple Mechanisms for the genetic basis for schizophrenia			
Palaffari Ground Floor									3:30-5:30 Brain abnormalities in emerging psychosis				
Palaffari First Floor							1:30-3:30 DSM-V Debate		3:30-5:30 An Update on the Next Wave of Schizophrenia Therapeutics				
Palaffari Second Floor							1:30-3:30 Psychosocial Session - An Update on Psychosocial Treatment of Schizophrenia		3:30-5:30 Making Connections: Abnormal white matter				
Palaffari Third Floor									3:30-5:30 Early Intervention Services for five years?				
Sala Verde		8:30-12:00 Plenary Session Telecast											
Cavaniglia						12:00-1:30 Poster Session #1 & Lunch						5:30-7:30 Poster Viewing	
Palazzo Entrance		8:00-6:00 Registration											
Sala 103		7:30-5:30 Speaker Ready Room											
Limonaia		7:30-5:30 Computer Center											

Legenda:

- Symposia
- Special Session
- Plenary Session
- Poster Session
- Speaker Ready
- Registration
- Computer Center

Sunday 11 April Detailed Schedule of Events

Registration

8:00AM - 6:00 PM

Main Entrance - Piazza Adua

Coffee/Pastries

8:00AM - 10:30 AM

Passi Perduti - just outside main auditorium

SCIENTIFIC SESSIONS

Plenary Session - Anticipating DSM-V: New Paradigms

8:30AM - 10:30 AM

Auditorium

Chair: John Kane; Co-Chair: Wolfgang Fleischhacker

DSM-V: New Paradigms and other Controversies

William Carpenter

Abstract: DSM-V is scheduled for release in 2013. There will be extensive efforts to harmonize with the next addition of ICD. The workgroup for Psychotic Disorders is considering modest changes in criteria for classification and major changes affecting the following: a) subtypes of schizophrenia; b) catatonia; and c) schizoaffective disorder. Two new paradigms may be added: a) the domains of pathology paradigm with dimensions representing critical aspects of psychopathology; and b) a risk syndrome chapter including a psychosis risk syndrome and mild cognitive impairment. The former is intended to address syndrome heterogeneity and focus assessment on pathologies requiring clinical attention. The latter is hotly debated [see the program under special sessions for debate on this topic]. The question of whether bipolar disorders should be grouped with psychotic disorders or mood disorders is being addressed and current status will be discussed. Field trials will begin in 2010. Plans affecting psychotic disorders will be presented. Response from the SIRS community will provide the workgroup with important feedback.

Panelists:

Neurocognition - Richard Keefe

Social Cognition - Alex Hofer

Quality of Life - Dieter Naber

Return to Work - Kim Mueser

Discussant: Eric Chen

The Plenary Session will be telecast from Auditorium to Sala Verde on the 2nd Floor of Villa Vittoria.



New Directions for Animal Modeling in Schizophrenia

10:30AM - 12:00PM

Chair: John Kane; Co-Chair: Wolfgang Fleischhacker

New Directions for Animal Modeling in Schizophrenia

Bitá Moghaddam

Treatment of schizophrenia has been in an impasse for half a century. The most effective treatment for the disease remains clozapine which was developed in 1961. There is, however, a sense of optimism that this is about to change. In the last few years we have witnessed a conceptual shift in the approach of basic and clinical scientists in the field that is resulting in identification of novel targets and translational means of testing the validity of these targets. Essentially, there has been a shift from the static to the dynamic. Decades of focusing on static abnormalities at the single protein level, such as the dopamine D2 receptor, have been inconclusive and not led to more effective treatments. Overall, the mainstream sequential approach of gene to neuron to systems to behavior has not been productive when it comes to understanding the etiology of schizophrenia. Genetics studies indicate that multiple mutations which occur in varying degrees in different patient populations as well as a whole host of rare mutations may contribute to increased risk of developing the disease. At the animal modeling level this does not discount the role of genetics or single protein approaches but the idea of "risk genes" is being replaced with "risk networks" given that complex behavior, normal or abnormal, is driven by dynamic coordination of brain networks. In this panel we will discuss how novel directions in the animal modeling field can facilitate understanding the pathophysiology of schizophrenia and the design of better treatment. This approach is to first identify the nature of behaviorally relevant dynamic abnormalities at the neuronal network level and then identify the common group of neurons that influence the function of these networks that are similarly affected by the by the diverse mutations associated with schizophrenia.

Panelists:

- *The reality of drug development in schizophrenia using animal models.*
Pierre Sokoloff
- *Interfacing NMDA deficiency and other pharmacological model with genetic models.*
Inna Gaisler-Salomon
- *Moving from gene to function in mutant model of schizophrenia*
Akira Sawa
- *Developmental animal models, thinking beyond the lesion models*
Patricio O'Donnell
- *Translational measures of function in animal models of schizophrenia*
Peter Uhlhaas

Poster Session #1

12:00PM - 1:30 PM

Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

PLEASE SEE PAGE 48 FOR A COMPLETE LISTING OF POSTERS.

CONCURRENT SPECIAL SESSIONS

Gene Expression in Schizophrenia - animal models and postmortem studies

1:30PM - 3:30 PM

Auditorium

Chair: Amanda Law

Circuit-Specific Alterations in Cortical GABA Neurotransmission in Schizophrenia

David Lewis

Novel animal models for studying schizophrenia: BAC-driven miRNA-mediated in vivo silencing of gene expression

Karoly Mirnics

Epigenome mapping in developing and diseased prefrontal cortex

Schahram Akbarian

ErbB4 and PI3KCD are Interacting Biological and Genetic Factors That Regulate NRG1-mediated PI3K Signaling and Risk for Schizophrenia.

Amanda Law

DISC1 Pathway Expression in Mouse and Man

David Porteous

Discussant: Paul Harrison

DSM-V Debate

1:30PM - 3:30 PM

Palaffari-First Floor

Chair: Barbara Cornblatt; Co-Chair: Stephan Ruhrmann

Panelists:

Barbara Cornblatt

Scott Woods

Alison Yung

William Carpenter

Frauke Schultze-Lutter

Stephan Ruhrmann

Moderator:

John Kane



Psychosocial Session - An Update on Psychosocial Treatment of Schizophrenia

1:30 - 3:30 PM

Palaffari-Second Floor

Chair: Kim Mueser

First episode psychosis and assertive community treatment

Lisa Dixon

Cognitive Therapy for Schizophrenia

David Kingdon, Douglas Turkington, Marie Finn, Jesse Wright, Shanaya Rathod, Richard Gray, Ron Siddle

Cognitive Remediation

Susan McGurk

Family Psychoeducation

Gabriele Pitschel-Walz

Supported Employment, Social Skills Training, and First Episode Psychosis

Kim Mueser

Discussant: Til Wykes

Coffee Available

2:00 PM - 4:30 PM

Passi Perduti & Palaffari Foyers

CONCURRENT SYMPOSIA

Multiple Mechanisms for the Genetic Basis for Schizophrenia

3:30 PM - 5:30 PM

Auditorium

Chair: Lynn DeLisi; Co-Chair: Pablo Gejman

Schizophrenia: Multiple Rare Alleles in a Genetically Heterogeneous Disease

Mary Claire King

Multiple common Gene variants in SZ: The GWAS Data

Pablo Gejman

Candidate genes from linked chromosomal regions: What happened to Neuregulin and Dysbindin?

Sibylle Schwab, Dieter Wildenauer

Discussant: Pamela Sklar

Brain abnormalities in emerging psychosis:

3:30 PM - 5:30 PM

Are neuroimaging-based endophenotypes valid and reliable markers for basic science research, early recognition and disease prediction?

Palaffari-Ground Floor

Chair: Christos Pantelis; Co-Chair: Phillip McGuire

Are Endophenotypes a Useful Concept?

Stephen Lawrie

Progressive brain changes across the transition to psychosis: Where to from here?

Stephen Wood

Structural and neurofunctional abnormalities in the at-risk mental state (ARMS) of psychosis

Stefan Borgwardt

MRI-based biomarkers for individualized neurodiagnostics in the at-risk mental state and the early phase of psychosis

Nikolaos Koutsouleris

Discussant: Philip McGuire

An Update on the Next Wave of Schizophrenia Therapeutics

3:30 PM - 5:30 PM

Palaffari-First Floor

Chair: Nicholas J. Brandon; Co-Chair: Christopher J. Schmidt

The mGlu2 receptor as a novel drug target for schizophrenia

Kjell Svensson

Development of GlyT1 inhibitors for the treatment of schizophrenia

Christopher Schmidt

mGlu5 Receptor Positive Allosteric Modulators as Putative Antipsychotic Agents

Peter Hutson

Evaluation of PDE10a Inhibitors in Models of the Positive, Negative and Cognitive Domains of Schizophrenia and Advances in the Understanding of the Mechanism and Biology of this Approach

Nicholas Brandon

Discussant: Anthony Grace



Making Connections:

3:30 PM - 5:30 PM

Abnormal white matter development in the early stages of schizophrenia

Palaffari-Second Floor

Chair: Marc L. Seal

Comparison of Grey and White Matter and Neuropsychometric Changes in Early-Onset Schizophrenia (EOS) and Early-Onset Bipolar Disorder with Psychosis (EOBP) versus Controls

Anthony James

Diffusion Tensor Imaging Investigations of White Matter Development in Schizophrenia

Katherine H. Karlsgodt

Changes in White Matter in the Early Stages of Schizophrenia

Marek Kubicki

Diffusion-Tensor-Tractography in First-Episode Schizophrenia

Gary Price

Discussant: Sophia Frangou

Early Intervention Services for five years?

3:30 PM- 5:30 PM

Palaffari-Third Floor

Chair: Merete Nordentoft; Co-Chair: Ashok Malla

A Randomized Controlled Evaluation of "Extended Specialized Early Intervention Service" vs. "Regular Care" for Long-term Management of Early Psychosis : A Pilot Study

Ashok Malla, S. Abadi, R. Joobar, E. Latimer, N. Schmitz, T. Brown, A. Abdel-Baki, R. Norman, M. Nordentoft, S. Iyer

The OPUS –trial; A randomised single-blinded trial of integrated versus standard treatment for patients with a first episode of psychotic illness – results of five-years follow-up and presentation of a new trial

Merete Nordentoft, Pia Jeppesen, Lone Petersen, Anne Thorup, Johan Øhlenschläger, Phuong Le Quach, Torben Christensen, Gertrud Krarup, Per Jørgensen, Mette Bertelsen

How Long should Early Intervention Last in the First Episode Psychosis?: Insights from the Discontinuation Protocol of the Cantabria's First Episode Clinical Programms (PAFIP Clinical Programme)

Jose' Vazquez-Barquero, Rocio P'erez-Iglesias, Benedicto Cresp-Facorro, Ignacio Mata, Jackeline van Don

It takes two to tango: research on ACT in early psychosis and implications for daily practice

Giel Verhaegh

Discussant: Max Birchwood

Poster Viewing

5:30 PM - 7:30 PM

Cavaniglia

*Refer to complete Sunday poster listing.

Monday 12 April

	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Auditorium	8:30-12:00						1:30-3:30			3:30-5:30				
	Plenary Session - Clinical Implications of Recent Genetic Findings: GWAS, Endophenotypes and Commercial testing						Improving Neurocognition in Schizophrenia: Reports from NIMH TURNS and MATRICS-CT			Pharmacogenomics in schizophrenia: How far to the clinic?				
Palaffari Ground Floor							1:30-3:30			3:30-5:30				
							Neural substrates of the association between cannabis and schizophrenia			Vocational Recovery in First Episode Psychosis: International Evidence for Early Intervention				
Palaffari First Floor							1:30-3:30			3:30-5:30				
							The Many Faces of Psychosis			Einheitspsychose? Comparison of schizophrenia and bipolar disorder across genes...				
Palaffari Second Floor							1:30-3:30			3:30-5:30				
							Gene-brain interaction in the pathophysiology of psychosis			Mutant models and psychosis at the crossroads:				
Palaffari Third Floor							1:30-3:30			3:30-5:30				
							New Developments in Family Psychoeducation			New Research in the Early Prediction of Antipsychotic Response				
Sala Verde	8:30-12:00													
	Plenary Session Telecast													
Cavaniglia							12:00-1:30							
							Poster Session & Lunch			5:30-7:30				
Palazzo Entrance	8:00-6:00													
	Registration													
Sala 103	7:30-5:30													
	Speaker Ready Room													
Limonaia	7:30-5:30													
	Computer Center													

Legenda:

 Symposia
 Plenary Session
 Poster Session
 Speaker Ready
 Registration
 Computer Center



Monday 12 April Detailed Schedule of Events

Schizophrenia Bulletin Editorial Board

7:00 AM – 8:30 AM

Sala 202 – Villa Vittoria Building

Coffee/Pastries

8:00AM - 10:30 AM

Passi Perduti – just outside main auditorium

Registration Open

8:00 AM - 6:00 PM

Main Entrance - Piazza Adua

SCIENTIFIC SESSIONS

Plenary Session

8:30AM - 12:00 PM

Clinical Implications of Recent Genetic Findings:

GWAS, Endophenotypes and Commercial testing

Auditorium

Chair: Lynn DeLisi; Co-Chair: Ming Tsuang

Main Address

Michael Owen

This plenary session will begin with an update on the current knowledge about the genetics of schizophrenia by Michael Owen, Chairman of The Department of Psychiatry, Cardiff University.

Abstract: Schizophrenia has long been known to have a strong genetic component. However because its inheritance does not follow a Mendelian pattern, the exact nature of the genetic contribution to the expression of clinical illness have never been elucidated. Recently, advances in high through-put genetic laboratory technology has enabled the screening of large international cohorts with N's in the thousands. These new Genome-wide Association Studies (GWAS) have produced novel findings and stimulated new thinking about the ways in which inheritance may be important in this illness. In addition, discoveries, such as DNA copy number variation throughout the genome (CNVs) have stimulated new thinking about possible alternative genetic mechanisms and have implications for genetic counseling. In 2010 commercial genetic testing has become a reality as more and more companies are being advertized as available for whole genome screens of one's DNA, but these also need to address several accompanying ethical questions that then arise.

Questions/Panelists:

Where have the new GWAS gotten us?

Mary Claire King, Peter Visscher, Pablo Gejman

Is the endophenotype concept useful in defining genes for schizophrenia?

Robin Murray, Dan Rujescu

Will Commercial DNA testing ever be a useful tool in the clinic for schizophrenia?

James Kennedy, Thomas Lehner

The Plenary Session will be telecast from Auditorium to Sala Verde on the 2nd Floor of Villa Vittoria.

Poster Session #2

12:00PM - 1:30 PM

Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

PLEASE SEE PAGE 71 FOR A COMPLETE LISTING OF POSTERS.

CONCURRENT SYMPOSIA

**Improving Neurocognition in Schizophrenia:
Reports from NIMH TURNS and MATRICS-CT**

1:30 PM - 3:30 PM

Auditorium

Chair: Stephen R. Marder; Co-Chair: Robert W. Buchanan

Searching for Cognitive Enhancers in Schizophrenia: The TURNS Program Strategy

Donald C. Goff

Effects of intranasal AL-108 (Davunetide) on neurocognition and functional outcome in schizophrenia

Daniel C. Javitt

MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia

Robert W. Buchanan

Validation of Intermediate (Co-primary) Measures for Clinical Trials of Cognition-enhancing Drugs for Schizophrenia

Michael F. Green

Discussant: Wolfgang Fleischhacker

Neural substrates of the association between cannabis and schizophrenia

1:30 PM - 3:30 PM

Palaffari-Ground Floor

Chair: Nadia Solowij; Co-Chair: F. Markus Leweke

Cross-sensitisation between cannabis and stress: gene-environment interactions underlying psychosis.

Cecile Henquet

Cannabis, cognition and schizophrenia: Structural brain alterations and symptomatology

Nadia Solowij

Acute neural effects of the main ingredients of cannabis: Implications for psychosis

Sagnik Bhattacharrya

Translational studies on (endo-)cannabinoids in schizophrenia: Bench to bedside.

F. Markus Leweke

Discussant: Robin Murray



The Many Faces of Psychosis

1:30 PM - 3:30 PM

Palaffari-First Floor

Chair: Charles Schulz; Co-Chair: Carol Tamminga

The expression of positive and negative symptoms in the realm of daily life.

Inez Myin-Germeys

Deficits in Brain Derived Neurotrophic Factors: Potential as an early-phase Biomarker for Schizophrenia?

Peter Buckley

Classification of Schizophrenia Using fMRI and Genetic Data

Vince Calhoun

Multimodal Imaging Studies of Early Stages and Persistent Schizophrenia

Charles Schulz

Discussant: Carol Tamminga

Gene-brain interaction in the pathophysiology of psychosis

1:30 PM - 3:30 PM

Palaffari-Second Floor

Chair: Tilo Kircher; Co-Chair: Ruben Gur

Emotions, Genes and the Brain

Ruben Gur

Genetic contributions of the dopamine system to schizophrenia

Alessandro Bertolino

Single genetic variants for schizophrenia and the effect on brain structure, function and connectivity

Tilo Kircher

Imaging genetics in psychiatry: disease path or garden path?

Michael Owen

Discussant: Joseph Callicott

New Developments in Family Psychoeducation

1:30 PM - 3:30 PM

Palaffari-Third Floor

Chair: Gabriele Pitschel-Walz; Co-Chair: Lisa Dixon

Effectiveness of psychoeducation for schizophrenia. Is family inclusion necessary?

Tania Lincoln

Training and Dissemination of Family Intervention in Spain

Isabel Montero

Multiple group family treatment for schizophrenia in Italy

Guiseppe Carra

Family Psychoeducation with Patients who have Co-occurring Substance Use Disorders and Severe Mental Illness

Kim Mueser

Discussant: Lisa Dixon

Coffee Available

2:00 PM - 4:30 PM

Passi Perduti & Palaffari Foyers

CONCURRENT SYMPOSIA

Pharmacogenomics in schizophrenia: How far to the clinic?

3:30 PM - 5:30 PM

Auditorium

Chair: Anil K. Malhotra; Co-Chair: Alessandro Bertolino

Issues regarding genetic testing for schizophrenia risk and for antipsychotic drug effects.

James Kennedy, Matthew Lanktree, Gwyneth Zai, Jessica Sturgess, Daniel J Mueller

Methods for obtaining clinically useful pharmacogenetic predictors; An example of a detailed investigation in an haloperidol treated sample

Alessandro Serretti

Use of intermediate phenotypes in pharmacogenetics

Alessandro Bertolino

Pharmacogenomic approaches to rare and common side effects associated with antipsychotic drug treatment

Anil Malhotra

Discussant: James Kennedy



**Vocational Recovery in First Episode Psychosis:
International Evidence for Early Intervention**

3:30 PM - 5:30 PM

Palaffari-Ground Floor

Chair: Eoin Killackey

Successful Return to Work or School in Recent-Onset Schizophrenia: The UCLA Randomized Controlled Trial of Individual Placement and Support

Keith Nuechterlein

Modifying Individual Placement & Support for an Early Intervention in Psychosis cohort; results of a naturalistic UK study

Barnaby Major

Lighting Fires Not Filling Buckets: Meaningful Vocational Recovery in First Episode Psychosis

Eion Killackey

Evidence based supported employment in early psychotic illness: Implementation in the real world.

Miles Rinaldi

Discussant: Kim T. Mueser

Einheitspsychose?

3:30 PM - 5:30 PM

Comparison of schizophrenia and bipolar disorder across genes, brain, and behaviour

Palaffari-First Floor

Chair: Melissa J. Green; Co-Chair: Jim van Os

Murray et al (2004) Revisited: Is Bipolar Disorder Schizophrenia without Developmental Impairment?

Jim van Os

Neuroanatomical changes across the course of schizophrenia and bipolar disorder

Alex Fornito

Neuroimaging and cognition

Andrew McIntosh

Neurocognitive Genetics in Schizophrenia and Bipolar Disorder: Crossing Diagnostic Boundaries

Katherine Burdick

Discussant: Robin Murray

**Mutant models and psychosis at the crossroads:
a critical re-evaluation of techniques and translation**

3:30 PM - 5:30 PM

Palaffari-Second Floor

Chair: Mikhail Pletnikov; Co-Chair: John Waddington

Novel developments in genetic mouse models: a DISC1 story
Mikhail Pletnikov

Psychopathological, cognitive and morphological phenotypes in schizophrenia risk gene mutants: challenges and the example of neuregulin
John Waddington

Copy number variation in schizophrenia: modeling 22q11
Maria Karayiorgou

The dopamine D1 mutant rat: A novel approach to modelling negative and cognitive aspects of schizophrenia
Bart Ellenbroek

Discussant: Paul Harrison

New Research in the Early Prediction of Antipsychotic Response in Schizophrenia

3:30 PM - 5:30 PM

Palaffari-Third Floor

Chair: Christoph U. Correll; Co-Chair: John Kane

Current Status in the Time Course of Antipsychotic Drug Effect, Early Response Prediction, Early Switch Studies and Research on Trajectories of Response to Antipsychotics
Stefan Leucht

Time Course and Relevance of Early Treatment Response in Adolescents With Schizophrenia-Spectrum Disorders
Christoph U. Correll

Differences between Early Responders and Early Non-Responders to Atypical Antipsychotics on Symptom and Functional Outcomes in the Treatment of Schizophrenia
Bruce Kinon, Lei Chen, Virginia Stauffer, Haya Ascher-Svanum, Wei Zhou, Sara Kollack-Walker, John Kane, Shitij Kapur

Early response to antipsychotics - what changes early and how?
Shitij Kapur, Tamara Arenovich, Ofer Agid

Discussant: John Kane

Poster Viewing

5:30 PM - 7:30 PM

Cavaniglia

*Refer to complete Monday poster listing.



Tuesday 13 April

Tuesday, 13 April

	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Auditorium	8:30-12:00 Plenary Session - On the matter of neuroimaging in the context of schizophrenia genetics						1:30-3:30 Oral Presentation - Pathways to Psychosis & Misc Neurochemistry			3:30-5:30 Dysregulation of the dopamine system: the final common pathway to schizophrenia?				
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Palaffari Ground Floor							1:30-3:30 Oral Presentation - Pathways to Psychosis and Factors in Childhood			3:30-5:30 Autistic and cognitive traits in the genetic understanding of the continuum...				
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Palaffari First Floor							1:30-3:30 Oral Presentation - Gene Environment Interactions in the Prediction...			3:30-5:30 Improving Signal Detection in Schizophrenia Clinical Trials by Multiple Methods				
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Palaffari Second Floor							1:30-3:30 Oral Presentation - Predicting the Development of Psychosis			3:30-5:30 Brain Progression in Schizophrenia: Who, Where, When, Why				
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Palaffari Third Floor							1:30-3:30 Oral Presentation - Novel Interventions			3:30-5:30 Future Directions for the Neuropathology of Schizophrenia				
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Sala Verde	8:30-12:00 Plenary Session Telecast													
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Cavaniglia						12:00-1:30 Poster Session #3 & Lunch								
											5:30-7:30 Poster Viewing			
7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00		
Palazzo Entrance	8:00-6:00 Registration													
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Sala 103	7:30-5:30 Speaker Ready Room													
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	
Limonaia	7:30-5:30 Computer Center													
	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00	5:00	6:00	7:00	

Legenda:

- Symposia
- Oral Presentations
- Plenary Session
- Poster Session
- Speaker Ready
- Registration
- Computer Center

Tuesday 13 April Detailed Schedule of Events

Registration Open

8:00 AM - 6:00 PM

Main Entrance - Piazza Adua

Coffee/Pastries

8:00AM - 10:30 AM

Passi Perduti - just outside main auditorium

SCIENTIFIC SESSIONS

Plenary Session:

8:30AM – 12:00 PM

On the matter of neuroimaging in the context of schizophrenia genetics

Auditorium

Chair: René Kahn; Co-Chair: Celso Arango

Main address:

Daniel Weinberger

Abstract: Have neuroimaging studies in schizophrenia been helpful in understanding the pathophysiology of the disease? Certainly, structural imaging studies have shown brain changes to occur during the course of the illness, but what do these changes mean? Similarly, functional imaging studies have found a range of functional abnormalities in schizophrenia patients, but the specificity and stability of these changes are questionable. Indeed, neuroimaging so far has failed to be helpful as a diagnostic or even prognostic tool. So what is next? Now it is claimed that neuroimaging may be helpful in dissecting the functions of genes relevant in psychiatric illness. And some studies using novel mathematical tools suggest that neuroimaging may, after all, be helpful in separating disorders. This panel will review the usefulness of neuroimaging in schizophrenia and review critically its role in future schizophrenia studies with an emphasis on relating brain function to genes. The following questions will be addressed: Will neuroimaging help identify genes relevant in schizophrenia? Will neuroimaging play a role in further defining schizophrenia?

Panelists:

Alessandro Bertolino

Philip McGuire

Eva Meisenzahl

Andreas Meyer-Lindenberg

Steven Potkin

Si Tianmei

The Plenary Session will be telecast from Auditorium to Sala Verde on the 2nd Floor of Villa Vittoria.

Poster Session #3

12:00PM - 1:30 PM

Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

PLEASE SEE PAGE 94 FOR A COMPLETE LISTING OF POSTERS.



ORAL PRESENTATIONS

Oral Presentations - Pathways to Psychosis & Misc Neurochemistry

1:30 PM - 3:30 PM

Auditorium

Chair: Celso Arango

- 1) 1:30 PM - *Subjective Tolerability to Antipsychotics in Schizophrenia, Over 30 Years of Research: Are We on the Verge of a New Science of "Subjective Tolerability Disorders"*
A. George Awad, Lakshmi N. P. Voruganti
- 2) 1:45 PM - *Hyperactive mice show elevated D2High receptors, a model for schizophrenia: calcium/calmodulin-dependent kinase II alpha knockouts*
Gabriela Novak, Philip Seeman
- 3) 2:00 PM - *Impact of neurochemical manipulation on sensory gating in healthy subjects with low gating levels - a validation study*
Philipp A. Csomor, Franz X. Vollenweider
- 4) 2:15 PM - *Glycine Transporter Inhibition Attenuates the Psychotomimetic Effects of Ketamine in Healthy Human Subjects*
Deepak Cyril D'Souza, Nagendra Singh, Jacqueline Elander, Michelle Carbutto, Brian Pittman, Mohini Ranganathan
- 5) 2:30 PM - *Are There Synergistic Interactions Between Antipsychotic Medications and Psychosocial Rehabilitation? Evidence From A Double-Blind Randomized Trial of Risperidone vs. Olanzapine Among Participants In Vocational Rehabilitation*
Douglas L. Noordsy, Stephen R. Marder, Shirley Glynn, Catherine A. Sugar
- 6) 2:45 PM - *Developmental pathways to emotional dysfunction in young people at ultra-high risk of developing psychosis*
Ruchika Gajwani, Max Birchwood, Paul Patterson
- 7) 3:00 PM - *Predictive validity of clinical variables in the "at risk" for psychosis population: international comparison with results from the North American Prodromal Longitudinal Study*
Andrew Thompson, Barnaby Nelson, Alison R. Yung
- 8) 3:15 PM - *A sociodevelopmental pathway to psychosis? New evidence from the AESOP study*
Ulrich Reininghaus, Thomas K. J. Craig, Helen L. Fisher, Gerard Hutchinson, Paul Fearon, Kevin Morgan, Paola Dazzan, Gillian A. Doody, Peter B. Jones, Robin M. Murray, Julian Leff, Craig Morgan

Oral Presentations

1:30 PM - 3:30 PM

Pathways to Psychosis and Factors in Childhood

Palaffari-Ground Floor

Chair: John Kane

- 1) 1:30 PM - *Voice hearing in childhood: results of a 5-year follow-up study*
Agna A. Bartels-Velthuis, Gerard Van de Willige, Jack A. Jenner, Jim Van Os, Durk Wiersma
- 2) 1:45 PM - *Social disadvantage: cause or consequence of impending psychosis?*
Simona A. Stilo, Craig Morgan, Clare Flach, Alessandra Paparelli, Paola Casadio, Jennifer O'Connor, Manuela Russo, Ben Wiffen, Aurora M. Falcone, Candice Joseph, Tiago Reis Marques, Valeria Mondelli, Grant McQueen, Paola Dazzan, Marta Di Forti, Robin M. Murray
- 3) 2:00 PM - *Strategies for the study of gene-environment interactions in schizophrenia*
Preben B. Mortensen, Carsten B. Pedersen, Ditte Demontis, Ole Mors, Anders Børglum, David M. Hougaard, Bent N. Petersen, Robert H. Yolken

- 4) 2:15 PM - *Individuals, schools and neighbourhoods; a multilevel longitudinal study of variation in incidence of psychotic disorders*
Stanley Zammit, Glyn Lewis, Jon Rasbash, Christina Dalman, Jan-Eric Gustafsson, Peter Allebeck
- 5) 2:30 PM - *On the pathway from stress to psychosis*
Tineke Lataster, Dina Collip, Mariëlle Lardinois, Lucia Valmaggia, Jim van Os, Inez Myin-Germeys
- 6) 2:45 PM - *Determining the long-term risk of suicide and premature death following a first episode of psychosis: An incidence cohort approach*
Rina Dutta, Robin M. Murray, Jane Boydell
- 7) 3:00 PM - *Evidence for the behavioral sensitization hypothesis of psychosis: An 8-year longitudinal cohort study investigating the effects of cascading psychological stressors on psychosis outcome*
Johan Lataster, Inez Myin-Germeys, Roselind Lieb, Hans-Ulrich Wittchen, Jim Van Os
- 8) 3:15 PM - *Primary and Readjudication Mortality Results from ZODIAC, A Large Simple Trial of Ziprasidone vs. Olanzapine in Patients with Schizophrenia*
John M. Kane, Brian L. Strom, Sybil M. Eng, Gerald Faich, Robert F. Reynolds, Ralph B. D'Agostino, Jeremy Ruskin, Jamie Geier, Onur N. Karayal, Charlotte Kremer

Oral Presentations

1:30 PM - 3:30 PM

Gene Environment Interactions in the Prediction of Psychosis

Palaffari-First Floor

Chair: Lynn DeLisi

- 1) 1:30 PM - *Developmental Vitamin D deficiency (DVD) and brain dopamine ontogeny*
Darryl Eyles, Xiaoying Cui, Matt Pelekanos, James Kesby, Tom Burne, John McGrath
- 2) 1:45 PM - *In Vivo PET imaging of Cerebral Type 1 Cannabinoid Receptor Availability in Patients with Schizophrenia*
Jenny Ceccarini, Marc De Hert, Ruud van Winkel, Dagmar Koethe, Guy Bormans, Markus Leweke, Joseph Peuskens, Koen Van Laere
- 3) 2:00 PM - *Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies*
Matthew J. Kempton, Daniel Stahl, Steven C. R. Williams, Lynn E. DeLisi
- 4) 2:15 PM - *Default Network and Medial Prefrontal Cortex Dysfunction in Schizophrenia and in First Degree Relatives of Persons with Schizophrenia*
Larry J. Seidman, Susan Whitfield-Gabrieli, Heidi W. Thermenos, Isabelle Rosso, Nikos Makris, Snezana Milanovic, Jill M. Goldstein, John D. E. Gabrieli, Stephen V. Faraone, Ming T. Tsuang
- 5) 2:30 PM - *The time sequence of structural brain abnormalities in schizophrenia*
Eve C. Johnstone, David G. C. Owens, Stephen M. Lawrie, T. W. J. Moorhead
- 6) 2:45 PM - *The STAR consortium: do genes or environment explain the association between schizophrenia and a smaller brain?*
Neeltje E. M. van Haren, Fruhling Rijdsdijk, Hugo Schnack, Marco Picchioni, Matthias Weisbrod, Heinrich Sauer, Theo G. M. van Erp, Tyrone D. Cannon, Dorret Boomsma, Hilleke E. Hulshoff Pol, Robin M. Murray, René S. Kahn
- 7) 3:00 PM - *Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia*
Monica Rais, Neeltje Van Haren, Wiepke Cahn, Hugo Schnack, Hilleke Hulshoff Pol, Rene Kahn
- 8) 3:15 PM - *Childhood and adolescence predictors of psychosis in the general population -based Northern Finland 1986 Birth Cohort*
Pirjo H Mäki, Jouko Miettunen, Marika Kaakinen, Irma K. Moilanen, Anja Taanila, Graham Murray, Peter B. Jones, Matti Joukamaa, Markus Heinimaa, Tuula Hurtig, Sebastian Therman, Juha M. Veijola



Oral Presentations - Predicting the Development of Psychosis

1:30 PM - 3:30 PM

Palaffari-Second Floor

Chair: René Kahn

- 1) 1:30 PM - *Impaired intellect and memory, stepping stones between genetic risk and schizophrenia*
Timothea Touloupoulou, Terry Goldberg, Danny Weinberger, Larry Seidman, Marco Picchioni, Robin Murray
- 2) 1:45 PM - *Stress-induced dopamine release in subjects at clinical high risk for psychosis and in antipsychotic naive patients with psychosis: A [¹¹C]-(+)-PHNO PET study.*
Romina Mizrahi, Jean Addington, Pablo Rusjan, Suridjan Ivonne, Boileau Isabelle, Ng Alvina, Pruessner Jens, Remington Gary, Houle Sylvain, Wilson Alan A.
- 3) 2:00 PM - *The role of glucocorticoids in the emergence of psychosis: potential genetic and epigenetic mechanisms*
Elaine Walker, Michael Compton, Dan Shapiro
- 4) 2:15 PM - *Why transition to psychosis is not the whole story - Neurocognitive markers of transition and poor functional outcome seven to 14 years after identification as ultra-high risk at the PACE clinic*
Ashleigh Lin, Alison R. Yung, Warrick Brewer, Barnaby Nelson, Annie Bruxner, Daniela Spiliotacopoulos, Christina Broussard, Magenta B. Simmons, Christos Pantelis, Patrick McGorry, Stephen J. Wood
- 5) 2:30 PM - *Static and Dynamic Cognitive Deficits in Childhood Precede Adult Schizophrenia: A 30-year Study*
Abraham Reichenberg, Avshalom Caspi, HonaLee Harrington, Renate Houts, Richard Keefe, Robin Murray, Richie Poulton, Terrie Moffitt
- 6) 2:45 PM - *Working memory not processing speed is the basis of higher-order planning deficits in first episode schizophrenia*
Eileen M. Joyce, Verity C. Leeson, Pranev Sharma, Masuma Harrison, Maria A. Ron, Thomas R. Barnes
- 7) 3:00 PM - *The relationship between neuropsychological functioning and symptom dimensions in first-episode psychosis*
Manuela Russo, Eugenia Kravariti, Arsime Demjaha, Paola Dazzan, Craig Morgan, Robin M. Murray, Abraham Reichenberg
- 8) 3:15 PM - *Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis*
Larry J. Seidman, Anthony J. Giuliano, Eric C. Meyer, Jean Addington, Kristen S. Cadenhead, Tyrone D. Cannon, Thomas H. McGlashan, Diana O. Perkins, Ming T. Tsuang, Elaine F. Walker, Scott W. Woods, Robert Heinssen, Barbara A. Cornblatt

Oral Presentations - Novel Interventions

1:30 PM - 3:30 PM

Palaffari-Third Floor

Chair: Birte Glenthøj

- 1) 1:30 PM - *Novel Adherence Interventions: Effectiveness and Translation*
Dawn I. Velligan, Natalie J. Maples, Desiree Castillo
- 2) 1:45 PM - *Effects of transcranial direct current stimulation on probabilistic feedback learning in people with schizophrenia*
Jacqueline A. Rushby, Colleen Loo, Cynthia S. Weickert, Thomas W. Weickert
- 3) 2:00 PM - *A bottom-up biofeedback remediation improves emotion recognition in schizophrenia: evidence from a visual scan path pilot study.*
Kathryn L. McCabe, Carmel M. Loughland, Mick Hunter, Terry Lewin, Vaughan J. Carr

- 4) 2:15 PM - *Learning to self-regulate insula cortex modulates emotion recognition and neural connectivity in schizophrenia*
Sergio M. Ruiz, Ranganatha Sitaram, Sangkyun Lee, Surjo Soekadar, Niels Birbaumer
- 5) 2:30 PM - *The five year course of obsessive-compulsive symptoms in first episode schizophrenia*
Lieuwe De Haan, Bouke Sterk, Luuk Wouters, Don Linszen
- 6) 2:45 PM - *Analyses of protective factors for patients with a good outcome five year after first episode psychosis.*
Nikolai Albert, Mette Bertelsen, Anne Thorup, Lone Petersen, Pia Jeppesen, Gertrud Krarup, Torben Christensen, Merete Nordentoft
- 7) 3:00 PM - *Long term follow up of an Ultra High Risk ("prodromal") group*
Barnaby Nelson, Alison R. Yung, Hok Pan Yuen, Daniela Spiliotacopoulos, Ashleigh Lin, Annie L. Bruxner, Christina M. Broussard, Magenta B. Simmons, Patrick D. McGorry
- 8) 3:15 PM - *Early response to antipsychotics as a marker of treatment response of psychosis*
Jose Maria Pelayo-Teran, Rocio Perez-Iglesias, Ignacio Mata, Teresa Moreno-Calle, Jose Manuel Rodriguez-Sánchez, Maria Luz Ramirez-Bonilla, Jose Luis Vazquez-Barquero, Benedicto Crespo-Facorro

Coffee Available

2:00 PM - 4:30 PM

Passi Perduti & Palaffari Foyers

CONCURRENT SYMPOSIA

**Dysregulation of the dopamine system:
the final common pathway to schizophrenia?**

3:30 PM - 5:30 PM

Auditorium

Chair: Jim Van Os; Co-Chair: Oliver Howes

The neurodevelopmental perspective: Dopamine system overdrive by the hippocampus in an animal model of schizophrenia and reversal by antipsychotic drugs

Anthony Grace

The Role of Environmental Factors

Alain Dagher

Dopamine dysregulation: pathophysiology or endophenotype?

Oliver Howes

Linking dopamine dysregulation to symptoms and clinical phase brain imaging studies

Anissa Abi-Dargham

Discussant: Shitij Kapur



**Autistic and cognitive traits in the genetic understanding
of the continuum in neurodevelopmental disorders and functional psychosis**

3:30 PM - 5:30 PM

Palaffari-Ground Floor

Chair: Lourdes Fañanás; Co-Chair: Marie-Odile Krebs

Autistic traits and developmental markers in adult onset schizophrenia

Marie-Odile Krebs

De novo mutations in synaptic genes in schizophrenia and related neurodevelopmental disorders

Guy Rouleau

Clinical and cognitive extreme phenotypes and CNVs in adolescent and adult functional psychosis

Mar Fatjó-Vilas

Rare pathogenic copy number mutations in mental disorders

David Collier

Discussant: Celso Arango

Improving Signal Detection in Schizophrenia Clinical Trials by Multiple Methods

3:30 PM - 5:30 PM

Palaffari-First Floor

Chair: Wolfgang Fleischhacker

Multifactorial Approach to Training and Surveillance of Raters in CNS Clinical Trials

David Daniel

Improving Signal Detection in Schizophrenia Clinical Trials

Janet Williams

Measuring the mind: Assessing the cognitive effects of new compounds for the treatment of schizophrenia

John Harrison

Functional outcome as a long-term treatment goal: definition and assessment in clinical trials

Nina Schooler

Discussant: Wolfgang Fleischhacker

Brain Progression in Schizophrenia: Who, Where, When, Why

3:30 PM - 5:30 PM

Palaffari-Second Floor

Chair: Robert W. McCarley

Insular cortex grey matter changes before and during transition to psychosis. Further evidence for dynamic brain changes at illness onset

Christos Pantelis

Progression of Gray Matter Loss and Its Clinical Correlates in First Episode Schizophrenia

Robert W. McCarley

Integrative neuroimaging assessment through clinical stages in schizophrenia

Kiyoto Kasai

Progressive Brain changes in health and disease: understanding its functional significance

René Kahn

Discussant: Lynn DeLisi

Future Directions for the Neuropathology of Schizophrenia

3:30 PM - 5:30 PM

Palaffari-Third Floor

Chair: David Cotter; Co-Chair: Paul Harrison

Abnormal N-glycosylation of proteins of the glutamate synapse in schizophrenia

James Meador Woodruff

What Proteomics will add to our Understanding of the Neuropathology of Schizophrenia

David Cotter

The future of post-mortem research - I

Maree Webster

The future of postmortem research

Karoly Mirnics

Discussant: Joel Kleinman

Poster Viewing

5:30 PM - 7:30 PM

Cavaniglia

*Refer to complete Tuesday poster listing.



Wednesday 14 April

	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00
Auditorium			8:30-10:30		10:30-12:30		12:30-1:30	2:00-4:00		4:00-5:00
			Brain Maturation During Adolescence and the Pathophysiology of Schizophrenia		Genetic, epigenetic, and molecular aspects of GABA function in the pathophysiology of schizophrenia		SIRS Membership Business Meeting	Gene-environment interactions in schizophrenia		Summary Panel Discussion
Passi Perduti	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00
			8:00-11:00 Coffee Break					12:30-2:00 Lunch		
Palaffari Ground Floor			8:30-10:30		10:30-12:30				2:00-4:00	
			International Perspectives on Group Based Approaches to Treating Cognition i		Performance-based assessment of disability: Validity across different cultures and age-ranges				Schizophrenia and Homelessness	
Palaffari First Floor			8:30-10:30		10:30-12:30				2:00-4:00	
			Movement disorders should be a criterion for schizophrenia in DSM-V		Improving overall outcomes - Extending CBTp to complex problems				Integration of structural, functional and neurochemical brain changes	
Palaffari Second Floor			8:30-10:30		10:30-12:30				2:00-4:00	
			Psychotic symptoms in the community: where are we today?		Dynamic brain changes in schizophrenia across the lifespan				Newer Antipsychotic Drugs in Early-Onset Psychosis	
Palaffari Third Floor			8:30-10:30		10:30-12:30				2:00-4:00	
			Update on Duration of Untreated Psychosis		Risk factors in the development of psychosis				Cannabis, amphetamines and early psychosis	
Palazzo Entrance	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00
			8:00-4:00 Registration							
Sala 103	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00
			7:30-4:30 Speaker Ready Room							
Limonaia	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00
			7:30-4:30 Computer Center							
Palaffari Lawn	7:00	8:00	9:00	10:00	11:00	12:00	1:00	2:00	3:00	4:00
							12:30-2:00 Lunch			

Wednesday, 14 April

Legenda:

- Symposia
- Special Session
- Break
- Speaker Ready
- Registration
- Computer Center

Wednesday 14 April Detailed Schedule of Events

Registration Open

Main Entrance - Piazza Adua

8:00 AM - 4:00 PM

Coffee/Pastries

Passi Perduti & Palaffari Foyers

8:00AM - 10:30 AM

CONCURRENT SYMPOSIA

Brain Maturation During Adolescence and the Pathophysiology of Schizophrenia: Relevance for Understanding Psychosis, Cognitive Dysfunctions and Implications for Treatment

8:30 AM - 10:30 AM

Auditorium

Chair: Peter J. Uhlhaas; Co-Chair: David A. Lewis

Developmental refinements in synaptic markers of cortical GABA transmission

David A. Lewis

Protracted development of cortical inhibition and its relationship to schizophrenia.

Cynthia Shannon Weickert

Advances in neuroimaging allow prospective study of human brain development

Nitin Gogtay

Development of Task-Related Neural Synchrony and the Pathophysiology of Schizophrenia

Peter J. Uhlhaas

Discussant: Christos Pantelis



**International Perspectives on Group Based Approaches
to Treating Cognition in Schizophrenia**

8:30 AM - 10:30 AM

Palaffari-Ground Floor

Chair: Alice Medalia; Co-Chair: Elizabeth W. Twamley

Compensatory Cognitive Training for Patients with Psychosis
Elizabeth W. Twamley

Efficacy of a Multisite Group Based Cognitive Remediation Program in Malaysia
Muhammed N. M. Alwi

Groups to Improve Awareness About Cognitive Dysfunction in Schizophrenia
Alice Medalia

Integrated Neurocognitive Therapy: A Group Based Approach to Improve Neuro- and Social Cognition
Volker Roder

Discussant: Til Wykes

Movement disorders should be a criterion for schizophrenia in DSM-V

8:30 AM - 10:30 AM

Palaffari-First Floor

Chair: Inez Myin-Germeys

Pandopaminergic D2 supersensitivity related to movement disorders and schizophrenia
Diederik E. Tenback

Movement disorders are spectrum conditions in schizophrenia
P. Roberto Bakker

Instrumental assessment of movement disorders is more sensitive than traditional rating scales in schizophrenia research
Jeroen P. Koning

The theoretical, clinical, and genetic basis to add movement disorders as an A-criterion in DSM-V
Peter N. van Harten

Discussant: Inez Myin-Germeys

Psychotic symptoms in the community: where are we today?

8:30 AM - 10:30 AM

Palaffari-Second Floor

Chair: Michael Davidson

Affective Dysregulation and Reality Distortion

Jim van Os

Prevalence of prodromal risk syndromes among a community sample of adolescents

Mary Cannon

Self-reported psychotic experiences in a-symptomatic Individuals signal risk for severe mental illness & semi; a longitudinal cohort study

Mark Weiser

Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults

John McGrath

Discussant: Shitij Kapur

Update on Duration of Untreated Psychosis; its Impact on Outcome, and Finding Ways to its Reduction

8:30 AM - 10:30 AM

Palaffari-Third Floor

Chair: Lex Wunderink; Co-Chair: Max Birchwood

Reducing DUP in a large urban, multi-cultural city: why we need to use and understand data on pathways to care

Max Birchwood, Paul Patterson, Swaran Singh, Charlotte Connor, Linda McCarthy, Helen Lester

Duration of untreated psychosis and negative symptoms: how do they relate?

Nynke Boonstra, Lex Wunderink, Rianne Klaassen, Sjoerd Sytema, Durk Wiersma

Brain changes following the first psychotic episode: the role of treatment

Paola Dazzan, S. Reinders, K. Morgan, C. Morgan, G. Hutchison, P. Fearon, P. K. McGuire, P. B. Jones, R. M. Murray, J. Lappin

Duration of untreated psychosis, early intervention and symptom development in first-episode psychosis: Experiences from the TIPS study.

Ingrid Melle, Tor Larsen, Ulrik Haahr, Svein Friis, Jan Olav Johannesen, Inge Joa, Stein Opjordsmoen, Bjørn Rund, Erik Simonsen, Per Vaglum, Thomas McGlashan

Discussant: Max Marshall



CONCURRENT SYMPOSIA

Genetic, epigenetic, and molecular aspects of GABA function in the pathophysiology of schizophrenia

10:30 AM - 12:30 PM

Auditorium

Chair: Daniel R. Weinberger; Co-Chair: Alessandro Guidotti

Genetic regulation of GABA activity and risk for schizophrenia

Daniel R. Weinberger

Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia

Schahram Akbarian

GABA-ergic dysfunction in schizophrenia: from postmortem studies to animal models

Karoly Mirnics

GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon

Alessandro Guidotti

Discussant: Dennis Grayson

Performance-based assessment of disability: Validity across different cultures and age-ranges

10:30 AM - 12:30 PM

Palaffari-Ground Floor

Chair: Philip D. Harvey; Co-Chair: Dawn Velligan

Performance Based Assessment of Functional Disability: Different Challenges in Eastern and Western Cultures

Philip D. Harvey

The Cross-Cultural Adaptation of Intermediate Measures of Functional Outcome

Dawn Velligan

The Adaptation of Intermediate Measures of Functional Outcome in Argentina

Delfina d Achával

Relevance of Performance Based Measures of Function in Aging and Its Variants, Including Mild Cognitive Impairment

Elizabeth Twamley, Brent Mausbach, Jesus Bucardo, Thomas Patterson

Discussant: Richard S. Keefe

Improving overall outcomes - Extending CBTp to complex problems

10:30 AM - 12:30 PM

Palaffari-First Floor

Chair: Til Wykes; Co-Chair: Emmanuelle Peters

How effective is CBTp and does this depend on your therapist? Craig Steel, University of Reading, UK
Craig Steel

What works for whom in CBT for psychosis
Emmanuelle Peters

Cognitive therapy to reduce compliance with commanding hallucinations without changing voice activity: the MRC COMMAND trial
Max Birchwood

Competitive memory training (COMET) can change appraisals of voices
Mark van der Gaag

Discussant: Til Wykes

Dynamic brain changes in schizophrenia across the lifespan: Influence of genetic and environmental factors.

10:30 AM - 12:30 PM

Palaffari-Second Floor

Chair: Nitin Gogtay; Co-Chair: Hilleke Hulshoff Pol

Brain Development in Childhood Onset Schizophrenia: Genetic and Environmental Influences
Nitin Gogtay

Progressive brain tissue loss in monozygotic and dizygotic twin pairs discordant for schizophrenia
Hilleke Hulshoff Pol

Longitudinal effects of genetic risk factors on brain morphology
Andrew McIntosh

Genome-wide significant neural risk mechanisms for schizophrenia and the brain connectome
Andreas Meyer-Lindenberg

Discussant: David Lewis



**Risk factors in the development of psychosis:
Common pathophysiological variables provide an
insight into the etiology and treatment of schizophrenia**

10:30 AM - 12:30 PM

Palaffari-Third Floor

Chair: Anthony A. Grace; Co-Chair: Patrick D. McGorry

Seeing is Believing: A Structural Neuroimaging Paradigm of Gene-Environment Interactions in Schizophrenia

Petra Habets

Stress and HPA functioning in First Episode Psychosis

Patrick D. McGorry

Stress and the hippocampus subiculum: Key site for intervention in the prevention and treatment of dopamine hyper-responsivity in psychosis

Anthony A. Grace

Can we explain the epidemiology of schizophrenia on the basis of the pathology of dopamine?

Robin M. Murray

Discussant: Elaine Walker

SIRS Membership Business Meeting - SIRS Members Only

12:30 PM - 1:30 PM

Auditorium

*Installation of New Officers and Executive Board as well as an update on Society business.

Lunch

12:30 PM - 2:00 PM

Palaffari Lawn & Passi Perduti

Weather Back-up Location: Cavaniglia

Coffe Available

2:00 PM - 4:30 PM

Palaffari Foyers, Passi Perduti

CONCURRENT SYMPOSIA

Gene-environment interactions in schizophrenia: advancing basic and clinical research

2:00 PM - 4:00 PM

Auditorium

Chair: Jim van Os; Co-Chair: Mikhail Pletnikov

Momentary Assessment Technology to Assess Gene-Environment Interactions Underlying the Affective Intermediary Phenotype of Stress Sensitivity in Schizophrenia

Jim van Os, Inez Myin-Germeys, Marieke Wichers, Philippe Delespaul

Mechanisms of GEI in schizophrenia

Andreas Meyer-Lindenberg

An Animal Model of a Gene-Environment Interaction: The Role of NRG1 in Cannabis-Induced Schizophrenia

Jonathon Arnold, A. A. Boucher, J. Micheau, I. S. McGregor, T. Karl

Gene-environment interactions in schizophrenia: a new mouse model

Mikhail Pletnikov

Discussant: Mary Cannon

Schizophrenia and Homelessness

2:00 PM - 4:00 PM

Palaffari-Ground Floor

Chair: Carol L. M. Caton; Co-Chair: Jonathan Burns

Correlates of Past Homelessness in the National Epidemiological Survey on Alcohol and Related Conditions

Robert A. Rosenheck

Schizophrenia, the Prevention of Homelessness, and the Global Health Movement

Elie Valencia

SES and Use of Psychiatric Services of People Suffering from Schizophrenia in a Community-Based System of Care

Francesco Amaddeo

Housing First: Ending Homelessness and Transforming Lives

Sam Tsemberis

The relationship between poverty, inequality, homelessness and psychosis in the South African context.

Jonathan Burns

Discussant: Carol Caton



**Integration of structural, functional and neurochemical
brain changes prior to the onset of psychosis**

2:00 PM - 4:00 PM

Palaffari-First Floor

Chair: Phillip McGuire; Co-Chair: Christos Pantelis

Aberrant salience in subjects at high risk of psychosis related to altered dorsolateral prefrontal function
Jon Roiser

Glutamate in the At Risk Mental State
James Stone

Viral load and brain structure in people at 'ultra-high risk' of developing psychosis: a voxel-based morphometry study
Thomas Whitford

Abnormal prefrontal activation related to striatal dopamine dysfunction in people at clinical risk for psychosis
Paolo Fusar-Poli

Discussant: Shitij Kapur

Newer Antipsychotic Drugs in Early-Onset Psychosis: A Translational View

2:00 PM - 4:00 PM

Palaffari-Second Floor

Chair: Sanjiv Kumra; Co-Chair: Frank Tarazi

Is there a role for clozapine in children and adolescents with schizophrenia?
Sanjiv Kumra

Efficacy and Safety of Antipsychotics in Adolescents with Early-Onset Schizophrenia
Christoph U. Correll

Similar Efficacy Results in Short-Term and Long-Term Studies of Adult and Adolescent Patients with Schizophrenia Treated with Aripiprazole
Margaretta Nyilas

Differential effects of antipsychotic drugs in developing vs. mature animals
Frank Tarazi

Discussant: Nina Schooler

**Cannabis, amphetamines and early psychosis:
Evaluating the risks for progression, neurobiologic models
of interaction and implications for treatment**

2:00 PM - 4:00 PM

Palaffari-Third Floor

Chair: Douglas L. Noordsy

Cannabis Use and Prodromal Symptoms of Psychosis

Andrea Auther

Symptomatology and neuropsychological functioning in cannabis using subjects at ultra high risk for developing psychosis and healthy controls

Don Linszen, Nikie Korver, Dorien Nieman, Hiske Becker, J. van de Fliert, Peter Dingemans, Lieuwe de Haan, Mark Spiering, Nicole Schmitz

The Methamphetamine and Psychosis Study (MAPS) – individual profiles and treatment needs

Tania Lecomte

Clozapine vs. risperidone for people with first episode schizophrenia and co-occurring cannabis use disorder

Douglas Noordsy, Jessica Smith, Alan Green

Discussant: John Kane

Summary Panel Discussion

4:00 PM- 5:00 PM

Auditorium

Co-Chairs: Robin Murray, Lynn DeLisi



Posters, Sunday 11 April

1. *Factorial analysis of Psychotic Like Experiences and help seeking behaviour in a community sample of young adults*
Marco Armando, Saba Riccardo, Righetti Valentino, Dario Claudia, Monducci Elena, Girardi Paolo, Nelson Barnaby, Yung Alison, Birchwood Maximilian, Fiori Nastro Paolo
2. *Examining Patient Validity for Clinical: A post-hoc analysis of placebo responders*
Howard A. Hassman, Sean Haley
3. *Improvement of Phenotyping in Genome Wide Association Studies on Schizophrenia: An Application of Latent Class Factor Analysis*
Eske M. Derks, Judith Allardyce, Marco P. Boks, Roel A. Ophoff, GROUP XX
4. *Open Poster Board*
5. *Development of a brief self-report questionnaire for screening the at risk state of psychosis in Taiwan*
Chen-Chung Liu, Yin-Jin Tien, Chun-Houh Chen, Hai-Gwo Hwu
6. *Why Hearing Voices is Dissociative in Origin, Not Psychotic in Kind*
Eleanor Longden, Anna Madill
7. *Attribution Bias in Ultra-High Risk for Psychosis and First-Episode Schizophrenia*
Suk Kyoon AN, Jee In Kang, Jin Young Park, Kyung Ran Kim, Su Young Lee, Eun Lee
8. *Correlates of schizotypy clusters in a large non-clinical sample*
Neus Barrantes-Vidal, Kathryn E. Lewandowski, Thomas R. Kwapil
9. *An Examination of Neuroticism as a Moderating Factor in the Association of Schizotypy Dimensions and Psychopathology in a Non-Clinical Sample*
Neus Barrantes-Vidal, Agnès Ros-Morente, Thomas R. Kwapil
10. *The psychometric evaluation of the Auditory Vocal Hallucination Rating Scale (AVHRS)*
Agna A. Bartels-Velthuis, Gerard Van de Willige, Jack A. Jenner, Durk Wiersma
11. *Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders.*
Virginia Bastera, Ana M. Sanchez-Torres, Manuel J. Cuesta, Victor Peralta
12. *Schizophrenia traveler type*
Robert G. Bota
13. *Same or different? Auditory verbal hallucinations in healthy and psychotic individuals*
Kirstin Daalman, Marco P. Boks, Kelly M. Diederer, Antoin D. de Weijer, Jan Dirk Blom, René S. Kahn, Iris E. Sommer
14. *Educational Level of Raters Impacts Interview Quality in International Antipsychotic Clinical Trials*
David G. Daniel, John J. Bartko, Norman Sartorius, Eduard Evieta

- 15.** *Cognitive and negative symptom dimensions in the At Risk Mental State predict subsequent transition to psychosis*
Arsime Demjaha, Lucia Valmaggia, Daniel Stahl, Majella Byrne, Philip McGuire
- 16.** *Co-morbid substance misuse does not have an effect on cognitive function at ten year follow-up of first-episode psychosis patients.*
Kim Donoghue, Rodolfo Mazzoncini, Jozella Hart, Jolanta Zanelli, Kevin Morgan, Paola Dazzan, Craig Morgan, Peter B. Jones, Robin M. Murray, Gillian A. Doody
- 17.** *Interim analysis of the CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis*
Carsten R. Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, Mette T. R. Madsen, Lone Vesterager, Christian Glud, Mikkel C. Arendt, Merete Nordentoft
- 18.** *Social network characteristics and effect on severity of psychosis in a community sample with high prevalence of stimulant use*
Willough A. Jenkins, Fidel Vila-Rodriguez, Karine Paquet, G. William MacEwan, Allen Thorton, Alasdair Barr, Ric Procyshyn, Donna Lang, William Honer
- 19.** *Cannabis use and cognition in schizophrenia: A literature review*
Else-Marie Løberg, Hugdahl Kenneth
- 20.** *Drug use and first episode psychosis: exploring associations with occupational expectations and achievements*
Karen Newell, Michael Oddi, Kim Donoghue, Craig Morgan, Jayne Simpson, Paola Dazzan, Kevin Morgan, Peter Jones, Paul Fearon, Robin Murray, Gillian Doody
- 21.** *Cognitive performance and smoking in first episode psychosis: the self-medication hypothesis*
Rafael Segarra, Aranzazu Zabala, Natalia Ojeda, Javier Peña, Jon Garcia, Jose I. Eguiluz, Miguel Gutierrez
- 22.** *Cannabis consumption is related to better premorbid adjustment and cognitive performance on first episode schizophrenia patients.*
José Manuel Rodriguez-Sanchez, Rosa Ayesa-Arriola, Ignacio Mata, Cesar Gonzalez-Blanch, Jose Luis Vazquez-Barquero, Benedicto Crespo-Facorro
- 23.** *Cerebellar grey matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults*
Martin Cohen, Paul E. Rasser, Gregory Peck, Vaughan J. Carr, Philip B Ward, Paul M. Thompson, Patrick J. Johnston, Amanda Baker, Ulrich Schall
- 24.** *Seasonality and schizophrenia admissions in Galiza*
Iria Veiga-Ramos, Paloma De Usabel, Laura Vigo-Santamariña, Ana Pampín-Alfonso, Alberte Araújo
- 25.** *Minor physical anomalies in the Maudsley Twin study of Schizophrenia*
Virginia Bastera, Marco M. Picchioni, Timothea Touloupoulou, N. Davies, T. Ribchester, Robin M. Murray



- 26.** *Improving detection of first episode psychosis by mental health care services using a self report questionnaire*
Nynke Boonstra, Lex Wunderink, Sjoerd Sytema, Durk Wiersma
- 27.** *Parental age and the risk of psychiatric disorders*
Jacobine E Buizer-Voskamp, Wijnand Laan, Marco PM Boks, Wouter G Staal, Eric AM Hennekam, Maartje F. Aukes, Rene S. Kahn, Roel A. Ophoff
- 28.** *Is Traumatic Brain Injury a risk factor for psychosis? A systematic review and meta-analysis*
Charlene Molloy, Ronan Conroy, Dearbhla Connor, David Cotter, Mary Cannon
- 29.** *The high risk children of mothers with schizophrenia and other severe mental illness: does a mother's mental illness increase the risk of Sudden Infant Death Syndrome?*
Vera A. Morgan, Maxine L. Croft, Giulietta Valuri, Patsy di Prinzio, Deidra J. Young, Kathryn M. Abel, Roger T. Webb, Susanne Wicks, Christina Dalman, Assen V. Jablensky,
- 30.** *VRINT: a newly developed early psychosis service in Belgium.*
Hella Demunter, Ludi Van Bouwel, Inez Heleven, Kathleen Lacluyse, Marc De Hert, Ruud van Winkel, Joseph Peuskens
- 31.** *The prevalence of psychotic symptoms in children and adolescents in clinical settings: a systematic review.*
Nina M Devlin, Dearbhla Connor, Michelle Harley, Mary Cannon
- 32.** *Onset of Psychotic Illness: Negative Symptoms Increasing Risk for Positive Symptoms Increasing Risk for Impairment?*
Maria-de-Gracia Dominguez, Meram Can Saka, Roselind Lieb, Hans-U. Wittchen, Jim Van-Os
- 33.** *To Compare Mortality In 1175 Patients With Psychosis And Their First Degree Relatives To Corresponding Groups Of Mentally Healthy Controls*
Karin M. Henriksson, Bahman Farahmand, Gunnar Engström, Thomas F. McNeil
- 34.** *Prodromal Symptoms: Differential Effects of Sex and Family History*
Erin M. Jones, Hanan Trotman, Michelle L. Esterberg, Joy Brasfield, Elaine F. Walker, Jean Addington, Kristin S. Cadenhead, Tyrone D. Cannon, Barbara Cornblatt, Thomas H. McGlashan, Diana O. Perkins, Larry J. Seidman, Ming Tsuang, Scott W. Woods, Robert Heinssen
- 35.** *Awareness of Weight Status and Desire for Weight Change Among Psychotic Patients with Severe Mental Illness*
Otto Kausch, Douglas Smith, Michael DeDonno, Richard McCormick, Nilkona Thomas
- 36.** *Emotional and Behavioural Symptoms of Psychopathology among Adolescents with Psychotic-like Experiences*
Ian Kelleher, Jennifer Murphy, Mary Cannon
- 37.** *Self-reported psychotic symptoms among the general population of Buenos Aires city*
Eduardo A. Leiderman

- 38.** *Suicide Attempts at the time of First admission and during Early Course Schizophrenia: A Population Based Study*
Stephen Z. Levine, Shelly Bakst, Jonathan Rabinowitz
- 39.** *Concordance Rates and Early Risk Factors in Schizophrenia; a Twin Study*
Rikke Hilker, Birgitte Fagerlund, Mevete Nordentoft, Birte Glenthøj
- 40.** *Sunlich, Neurulation and the “Madness-Creativity” Nexus. A Schizophrenia-like Birth-Month Effect among Artists and mathematicians*
Giovanni Marzullo
- 41.** *The Australian Schizophrenia Research Bank (ASRB): Quality assurance and control for a comprehensive clinical, neuropsychological, genetic and neuroimaging database for researchers*
Kathryn L McCabe, Carmel M. Loughland, Aslam Nasir, Stan Catts, Assen Jablensky, Frans Henskens, Patricia Michie, Bryan Mowry, Christos Pantelis, Ulrich Schall, Rodney Scott, Vaughan Carr
- 42.** *Prevalence and burden of at-risk criteria of psychosis and help-seeking behaviour – a population survey – feasibility*
Chantal Michel, Frauke Schultze-Lutter, Noemi Schaffner, Schimmelmann G. Benno
- 43.** *Metabolic alterations in the cortex of a mouse model with glutathione deficit – relevance to schizophrenia*
Joao M. N. Duarte, Anita Kulak, Rolf Gruetter, Kim Q. Do
- 44.** *The Differences of 2nd to 4th Digit Length Ratio between Schizophrenia Patients and Normal Controls*
Yu Sang Lee, Hyun-Woo Cho, Jeong-Ho Chae
- 45.** *Verbal and visual memory impairments amongst young offspring and healthy adult relatives of patients with schizophrenia and bipolar-depression: selective generational patterns indicate different predictive pathways*
Michel Maziade, Nancie Rouleau, Chantal Mérette, Marco Battaglia, Cecilia Marino, Valérie Jomphe, Elsa Gilbert, Caroline Cellard, Amélie Achim, Roch-Hugo Bouchard, Marie-Ève Paradis, Marc-André Roy
- 46.** *Specificity and severity of pre-psychotic juvenile behavior: a 20-year follow-up study.*
Selene Fagel, Herman Van Engeland, Leo de Sonnevill, Jolijn Pieterse, Hanna Swaab
- 47.** *Thalamus volume and shape in male adolescents with early-onset first-episode psychosis*
Joost Janssen, Yasser Alemán, Santiago Reig, Hugo Schnack, Mara Parellada, Monserrat Graell, Carmen Moreno, Dolores Moreno, J. M. Mateos-Pérez, J. M. Udias, Manuel Desco, Celso Arango
- 48.** *Disorders of the basic self as a marker of vulnerability for schizophrenia: Preliminary empirical support from non-psychotic help-seeking adolescents.*
Danny Koren, Noa Reznick, Merav Adres, Ravit Scheyer, Alan Apter, Tamar Steinberg, Josef Parnas
- 49.** *Impaired Motor Control in Adolescents at High Risk for Schizophrenia*
Theo Manschreck, Larry Seidman, Stephen Faraone, Ming Tsuang, Brendan Maher



- 50.** *Genetic Modelling of Childhood Social Development and Personality in Twins and Siblings with Schizophrenia*
Marco M Picchioni, Muriel Walshe, Timothea Touloupoulou, Colm McDonald, Mark Taylor, Sheena Waters-Metenier, Elvira Bramon, Antonia Regojo, Robin M Murray, Fruhling Rijdsdijk
- 51.** *Childhood trauma may be related to transition to psychosis in ultra high risk individuals.*
Seda Sahin, Alp Ucok, Evrim Gode, Cagri Yuksel
- 52.** *Abnormal neurodevelopment in attention networks and executive functions in schizophrenia*
Isabelle Amado, Steffen Landgraf, Marie - Chantal Bourdel, Jean-Pierre Olie, Marie - Odile Krebs
- 53.** *Cognitive Deficits in First-Episode Antipsychotic-Naïve Schizophrenic Patients*
Rune Andersen, Birgitte Fagerlund, Bob Oranje, Anders Gade, Hans Rasmussen, Bjørn Ebdrup, Bodil Aggernæs, Birte Glenthøj
- 54.** *Dysfunction in a discrete corticalstriatal circuit reflects liability to schizophrenia*
Robert Asarnow, Jessica Cohen, Russell Poldrack, Susan Bookheimer, Karin Foerde, Vindia Fernandez, Dana Wagshal, Robert Bilder, Barbara Knowlton
- 55.** *The Repeable Battery for the Assessment of Neuropsychological Status (RBANS) in Patients with Schizophrenia: A Preliminary Study in Armenia*
Allen Azizian, Maruke Yeghiyan, Byurakn Ishkhanyan
- 56.** *Accessibility to the semantic attributes of non recalled words in schizophrenia*
Elisabeth Bacon, Marie Izaute
- 57.** *Traumatic Brain Injury and Secondary Psychosis*
Rachel A. Batty, Susan L. Rossell, Andrew Francis, Malcolm Hopwood
- 58.** *Memory Profiles in Schizophrenia: Categorization Validity and Stability*
Morris D Bell, Jason K Johannesen, Tamasine C. Greig, Bruce E. Wexler
- 59.** *Computerized Cognitive Testing in Schizophrenia: Patient Experiences.*
Smita P Bhat, Geetika Nath, Amit Sharma, Susan D. Santi
- 60.** *Social cognition in schizophrenic patients : Effects of semantic and prosody in the comprehension of emotional discourse.*
Perrine Brazo, Simon Vigne, Virginie Beauconsin, Marie-Renée Turbelin, Laurent Lecardeur, Annick Razafimandimby, Nathalie Tzourio-Mazoyer, Sonia Dollfus
- 61.** *Olfactory identification deficits are a feature of schizophrenia after identification as ultra-high risk at the PACE clinic*
Warrick J. Brewer, Ashleigh Lin, Alison R. Yung, Barnaby Nelson, Hok Pan Yuen, Annie Bruxner, Christina Broussard, Daniela Spiliotacopoulos, Magenta Simmons, Christos Pantelis, Patrick D. McGorry, Stephen J Wood

- 62. Relationship of neurocognitive function and impairment of insight in first episode schizophrenia**
Sherry KW Chan, Cindy PY Chiu, May M.L. Lam, Christy L.M. Hui, Gloria H.Y. Wong, Jennifer Y.M. Tang, Kevin K.S. Chan, Eric Y.H. Chen
- 63. Counterfactual Thinking in Schizophrenia patients**
Fernando Contreras, Agnes Caño, Bessy Benejam, José M. Crespo, José M. Menchón, Julio Vallejo
- 64. Anxiety Comorbidities ad Cognitive Evoked Potential in patients with Schizophrenia Anxiety Comorbidities ad Cognitive Evoked Potential in patients with Schizophrenia**
Stefano Pallanti
- 65. P300 event-related potential and neuropsychological outcome in delirious and non-delirious schizophrenia**
Álvaro Díez-Revuelta, José María Porto-Payán, Cristina Tobón-Arbeláez, Abdel Solís-Rodríguez, Manuel Á. Franco-Martín, Vicente Molina, María Victoria Perea, Juan García-Mellado, Vicente Merino
- 66. The Course of Cognitive Deficits in Schizophrenia from Illness Onset to 6 Years Post Onset: Preliminary Results from a Prospective Longitudinal Study**
Birgitte Fagerlund, Rune Andersen, Bob Oranje, Anders Gade, Birte Glenthøj
- 67. Social cognition and psychotic symptoms**
Anne-Kathrin Fett, Ahmet Akdeniz, Lydia Krabbendam, GROUP
- 68. Results of Phase 2b EAGLE trial; A double blind placebo control study evaluating the efficacy and safety of BL-1020, a GABA enhanced antipsychotic for the treatment of schizophrenia**
Yona Geffen, Ravi Anand, Richard Keefe, Michael Davidson
- 69. Are Late-Onset Psychotic Symptoms Potential Precursors of Dementia?**
Caroline Girard, Martine Simard
- 70. Social cognitive endophenotypes for psychotic disorders?**
Melissa J Green, Amy Sparks, Bianca J. Lino, Skye McDonald, Philip B. Mitchell
- 71. Perception of affective prosody in remitted patients with schizophrenia and bipolar disorder I**
Alex Hofer, Susanne Baumgartner, Cord Benecke, Falko Biedermann, Eberhard A. Deisenhammer, Armand Hausmann, Christine Hörtnagl, Georg Kemmler, Moritz Mühlbacher, Georg Schwitzer, Nursen Yalcin, W. Wolfgang Fleischhacker
- 72. What factors predict awareness of cognitive problems in people with schizophrenia?**
Vyv C Huddy, Clare Reeder, Til Wykes
- 73. Attentional modulation of external speech attribution in patients with hallucinations and delusions**
Lana M Ilankovic, Paul P. Allen, Rolf Engel, Joseph Kambeitz, Michael Riedel, Norbert Müller, Kristina Hennig-Fast
- 74. Mechanisms of psychomotor slowing in Schizophrenia**
Roussel Martine, Monestes Jean Louis, Loas Gewnolé, Tourbier Virginie, Yon Valérie, Méribault Cyril, Godefroy Olivier



- 75.** *Investigation into cognitive function in first episode psychosis patients*
Majid M. Saleem, Mike K. Harte, Kay M. Marshall, Jo C. Neill
- 76.** *Neurocognitive function in Schizophrenia and Bipolar Disorder: a five-year follow-up study*
Ana Aparicio, Eva Maria Sanchez-Morla, Vicente Martinez-Vizcaino, Jose Luis Santos
- 77.** *Autobiographical memory deficits and their relationship with symptom dimensions in older patients with chronic schizophrenia*
Lena A. Schmid, Marc M. Lässer, Christina J. Herold, Ulrich Seidl, Johannes Schröder
- 78.** *Genetics of Schizophrenia: Clinical and Neurobiological Implications*
Roger A. Boshes, Theo C Manschreck, William Konigsberg
- 79.** *Executive dysfunction in schizophrenia: possible role of Saitohin gene*
Marta Bosia, Roberto Cavallaro, Margherita Bechi, Adele Pirovano, Cristina Lorenzi, Enrico Smeraldi
- 80.** *Psychosis biological markers and their genetic influences*
Elvira Bramon, Anirban Dutt, Madiha Shaikh, Miguel Constante, Muriel Walshe, Matt Allin, Colm McDonald, John Powell, David Collier, Robin Murray
- 81.** *Identification of two DNA copy number variations (CNVs) segregating with schizophrenia spectrum disorders in two families*
Chia-Hsiang Chen
- 82.** *The XY Hypothesis of Genetic Predisposition to Psychosis: Present Status*
Timothy J. Crow, Lynn E. DeLisi
- 83.** *MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic.*
Moons Tim, Ruud van Winkel, Odette Peerbooms, Bart Rutten, Joseph Peuskens, Stephan Claes, Jim van Os, Marc De Hert
- 84.** *Segment-wise genome-wide association analysis identifies a limited number of replicable candidate regions associated with schizophrenia*
Eske M. Derks, Thomas Gladwin, GROUP XX, Marcella Rietschel, Manuel Mattheisen, Rene Breuer, Thomas G. Schulze, Markus M. Nothen, Douglas Levinson, Jianxin Shi, Sven Cichon, Nelson B. Freimer, Rita Cantor, Roel A. Ophoff
- 85.** *ZNF804A delineates a schizophrenia subtype characterised by relatively spared cognitive performance and brain volume.*
Gary Donohoe, James Walters, Emma Rose, Derek Morris, Thomas Frodl, Ilaria Spolletini, Michael Gill, Michael O'Donovan, Michael Owen, Gianfranco Spalletta, Dan Rujescu, Aiden Corvin
- 86.** *Does the dysbindin gene influence hippocampal volume in psychosis?*
Anirban Dutt, Colm McDonald, Madiha Shaikh, Emma Dempster, Diana Prata, Ian Williama, Katja Schulze, Nicolette Marshall, Muriel Walshe, Matthew Allin, David Collier, Robin M. Murray, Elvira Bramon

- 87.** *Variability of candidate genes (COMT, CNR1 and CHRNA7) in relation to cannabis use and psychotic symptoms in an adolescent psychiatric population.*
Gemma Estrada, Mar Fatjó-Vilas, M^a José Muñoz, Bárbara Arias, Maria Martín, Josep Maria Illa, M^aLuisa Miralles, Gabriel Pulido, M^aEulàlia Navarro, Salvador Miret, Generós Ortet, Ana Monfort, Lourdes Fañanás
- 88.** *Genetic variability in dysbindin-1 gene (DTNBP1) contributes differentially to early and adult onset functional psychoses and it is associated with the familial transmission of IQ and prefrontal cognitive deficits.*
Mar Fatjó-Vilas, Sergi Papiol, Gemma Estrada, Igor Bombín, Víctor Peralta, Araceli Rosa, Mara Parellada, Salvador Miret, Luisa Lázaro, M^aJosé Muñoz, Bárbara Arias, M^aEulalia Navarro, Josefina Castro-Fornieles, Manuel J Cuesta, Celso Arango, Lourdes Fañanás
- 89.** *No relationships between nicotine dependence and schizotypal features in unaffected first-degree relatives of schizophrenic subjects and healthy controls*
Aziz Ferchiou, Audrey Laguerre, Andrei Szöke, Alexandre Méary, Flavie Mathieu, Marion Leboyer, Franck Schürhoff
- 90.** *Rethinking the Genetic Architecture of Schizophrenia*
Kevin J. Mitchell, David J. Porteous
- 91.** *A comparison to controls of brain structure in subjects with methamphetamine psychosis and comorbid HIV infection*
Alasdair M. Barr, William G. Honer, G. William MacEwan, Willough Jenkins, Wayne Su, Tari Buchanan, Helen Craig, Donna J. Lang
- 92.** *Orbitofrontal cortex sulcogyral patterns in first episode schizophrenia: Preliminary findings*
Cali F. Bartholomeusz, Sarah Whittle, Patrick McGorry, Dennis Velakoulis, Christos Pantelis, Stephen J. Wood
- 93.** *Brain volume changes after withdrawal of atypical antipsychotics in first-episode schizophrenia patients*
Geartsje Boonstra, Neeltje E.M. van Haren, Hugo G. Schnack, Wiepke Cahn, Huibert Burger, Maria Boersma, Diederick E. Grobbee, Hilleke E. Hulshoff Pol, Rene S. Kahn
- 94.** *Cortical thickness in patients with schizophrenia and their siblings*
Heleen B.M. Boos, Wiepke Cahn, Neeltje E.M. Van Haren, Eske M. Derks, Rachel M. Brouwer, Hugo G. Schnack, Hilleke E. Hulshoff Pol, Rene S. Kahn
- 95.** *Evidence for widespread thinning of the cerebral cortex in patients with first-episode psychosis with poor insight*
Lisa Buchy, Bodnar D. Michael, Claude Lepage, Yasser Ad-Dab'bagh, Karen Sergerie, Ashok Malla, Ridha Joober, Alan Evans, Martin Lepage
- 96.** *Global and local connectivity changes in schizophrenia investigated by diffusion connectome*
Leila Cammoun, Djalel Meskaldji, Xavier Gigandet, Jean Philippe Thiran, Reto Meuli, Michel Cuenod, Patric Hagmann, Thi Kim Do



- 97.** *Measurement of Morphological Changes in Schizophrenic Patients using Brain Magnetic Resonance Imaging*
Jin Hee Choi, Kang Kim, Tae Yong Kim, Moon Yong Chung, Hyoung Seok So
- 98.** *Open Poster Board*
- 99.** *Regional brain changes in initially antipsychotic-naïve first-episode schizophrenia patients treated with quetiapine: Relation to dose and psychopathology*
Bjørn H. Ebdrup, Arnold Skimminge, Hans Rasmussen, Bodil Aggernaes, Bob Oranje, Henrik Lublin, William Baaré, Birte Glenthøj
- 100.** *Open Poster Board*
- 101.** *Frontal cortical thickness is associated with clinical improvement of negative symptoms in male adolescents with early-onset first-episode psychosis*
Margarita Garcia-Amador, Jansen Joost, Santiago Reig, Mara Parellada, Dolores Moreno, Carmen Moreno, Maria Mayoral, Montserrat Graell, Manuel Desco, Celso Arango
- 102.** *The deficit syndrome in schizophrenia: associations with hippocampal volume and prefrontal cortical thickness*
Petra Habets, Ed Gronenschild, Jim van Os, Machteld Marcelis
- 103.** *Cortical folding patterns and obstetric complications in schizophrenia*
Unn Kristin Haukvik, Marie Schaer, Ragnar Nesvåg, Thomas McNeil, Cecilie B. Hartberg, Erik G. Jönsson, Stephan Eliez, Ingrid Agartz
- 104.** *Review on longitudinal brain volume changes in healthy individuals*
Anna M. Hedman, Neeltje E.M. van Haren, Hugo H. G. Schnack, René S. Kahn, Hilleke E. Hulshoff Pol
- 105.** *Frontal cortical thickness is associated with clinical improvement of negative symptoms in male adolescents with early-onset first-episode psychosis*
Margarita Amador, Joost Janssen, Santiago Reig, Mara Parellada, Dolores Moreno, Carmen Moreno, Maria Mayoral, Montserrat Graell, Manuel Desco, Celso Arango
- 106.** *High resolution deformation-based morphometry reveals a complex pattern of brain morphology changes in schizophrenia*
Tomas Kasparek, Daniel Schwarz, Radovan Prikryl, Radek Marecek, Michal Mikl, Jiri Vanicek, Eva Ceskova
- 107.** *Longitudinal voxel-based morphometric study to evaluate progressive gray matter changes in first-episode schizophrenia*
Yasuhiro Kawasaki, Mikio Kido, Tsutomu Takahashi, Kazue Nakamura, Michio Suzuki
- 108.** *Connection between the corpus callosum and predisposition towards hallucinations – evidence from schizophrenia patients and unaffected relatives*
Christian Knöchel, Viola Oertel-Knöchel, Ralf Schönmeier, Anna Rotarska-Jagiela, Vincent van de Ven, Corinna Haenschel, Peter Uhlhaas, Johannes Pantel, David E. J. Linden

- 109.** *Structural neural correlates of verbal memory in first episode schizophrenia*
Martin Lepage, Tom Howells, Lisa Buchy, Audrey Benoit, Michael Bodnar, Ridha Joobar, Ashok Malla
- 110.** *Atypical Antipsychotics : Clinical Improvements and Structural Cerebral Changes*
Genevieve Letourneau, Emmanuel Stip, Lahcen Ait Bentaleb, Benjamin Stip, Adham Mancini-Marie, Stephane Potvin
- 111.** *Magnetic resonance imaging of the superior temporal gyrus in monozygotic twins concordant and discordant for schizophrenia*
Sheena Waters-Metenier, Timothea Touloupoulou, Alexander Sumich, Ulrich Ettinger, Robin Murray, Marco Picchioni
- 112.** *PECANS –Pan European Collaboration on Antipsychotic Naïve Schizophrenia: Preliminary results on the fMRI reward paradigm*
Mette Odegaard Nielsen, Egill Rostrup, Birte Glenthøj, Shitij Kapur
- 113.** *The neural basis of self-reflective processing in schizophrenia patients: an fMRI study*
Lisette van der Meer, Marieke Pijnenborg, Willem Nolen, Rikus Kneegtering, Andre Aleman
- 114.** *Altered association between hippocampal activation during episodic encoding and striatal dopamine function in people with prodromal symptoms of psychosis.*
Paul Allen, Christopher Chaddock, Oliver D Howes, Paolo Fusar-Poli, Alice Egerton, Philip McGuire
- 115.** *Abnormal cortical response during attentional control processing in healthy siblings of patients with schizophrenia*
Linda Antonucci, Apostolos Papazacharias, Paolo Taurisano, Raffaella Romano, Barbara Gelao, Luciana Lo Bianco, Leonardo Fazio, Annabella Di Giorgio, Grazia Caforio, Marcello Nardini, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino
- 116.** *Effect of tolcapone on brain regions underlying response inhibition in a sample of patients with schizophrenia compared to normal controls*
Jose A. Apud, V.S. Mattay, Roberta Rasetti, Beth Stankevich, Carmela Magalona, Heather Decot, Kelsey Skjei, Giuseppe Blasi, Favio Sambataro, Joseph H. Callicott, Daniel R. Weinberger
- 117.** *Functional Disconnectivity and Formal Thought Disorder in schizophrenia: Integrating clinical, neuropsychological, neuroimaging and functional connectivity data*
Silvia M. Arcuri, Edson Amaro, Matthew R. Bromme, Gilson Vieira, João R Sato, Michael J. Brammer, Steve S.C. Williams, Koichi Sameshima, Luiz Baccalá, Robin G. Morris, Philip K. McGuire
- 118.** *Why does cannabis affect people differently? Comparing those with temporary psychotic symptoms vs. those with no psychotic symptoms following the oral administration of Δ -9-tetrahydrocannabinol – A functional MRI study*
Zerrin Atakan, Sagnik Bhattacharyya, Paul Allen, Stefan Borgwardt, Paolo Fusar-Poli, Rocio Martin-Santos, Jose A. Crippa, Marc Seal, Joseph P. Kambeitz, Manoharan Andiappan, Daniel Stahl, Antonio W Zuardi, Philip McGuire



- 119.** *Brain Asymmetry for Emotional Prosody in Klinedelter's Syndromw: Casual Relations investigated with TMS*
Leonie Bais, Marjolijn Hoekert, Thera P. Links, Rikus Knegtering, André Aleman
- 120.** *Cortical dysfunction in adolescents with schizophrenia during working memory component processes - A functional magnetic resonance imaging study*
Robert A. Bittner, Corinna Haenschel, Alard Roebroek, Fabian Haertling, Anna Rotarska-Jagiela, Konrad Maurer, Rainer Goebel, Wolf Singer, David EJ Linden
- 121.** *Alterations in functional brain network structure induced by subchronic phencyclidine (PCP) treatment parallel those seen in schizophrenia*
Neil Dawson, Des Higham, Judith Pratt, Brian Morris
- 122.** *Brain Activity during Social Cognition tasks in Individuals with Schizophrenia, their Unaffected Siblings, and Healthy Controls.*
Salvador M. Guinjoan, Delfina de Achaval, Mirta Villarreal, Elsa Y. Costanzo, Rocio Berhongaray, Jazmin Douer, Julieta Lopez, Martina C. Mora, Rodolfo Fahrer, Ramon C. Leiguarda,
- 123.** *Similar language activation in non-psychotic individuals with auditory verbal hallucinations and control subjects*
Kelly M. Diederer, Antoin D. De Weijer, Kirstin Daalman, Bas F. Neggers, Rene S. Kahn, Iris E. Sommer
- 124.** *Disruption of the role of frontal theta oscillations in modulating the suppression of default mode processing during task performance in schizophrenia*
Kathrin Doege, Peter F. Liddle, Ana Diukova, Pavan Mallikarjun, Marije Jansen, Dorothee Auer
- 125.** *Similarities in activation due to metacognition during different tasks*
Richard J. Drake, Kunal Kala, Shane McKie, Rebecca Elliott, Danny Koren
- 126.** *Temporal cortex activation during listening to emotional words in patients with non-affective psychosis: an fMRI study with independent component analysis*
Maria J. Escarti, Maria de la Iglesia-Vaya, Eduardo J. Aguilar, Luis Marti-Bonmati, Gracian Garcia-Marti, Julio Sanjuan
- 127.** *Interaction between genetic variation of the dopamine transporter and maternal care in prefrontal and striatal activity during explicit evaluation of emotional stimuli.*
Francesca Ferrante, Paolo Taurisano, Barbara Gelao, Luciana Lo Bianco, Raffaella Romano, Annabella Di Giorgio, Leonardo Fazio, Gianluca Ursini, Tiziana Quarto, Grazia Caforio, Apostolos Papazacharias, Lorenzo Sinibaldi, Marcello Nardini, Bruno Dallapiccola, Giuseppe Blasi, Alessandro Bertolino
- 128.** *Evidence of fronto-temporal connectivity disturbances in patients with schizophrenia revealed by event-related graph analysis.*
Alex Fornito, Jong Yoon, Alana Firl, Renata Ooms, Edward T. Bullmore, Cameron Carter

- 129.** *Subjective well-being in schizophrenia is associated with the neural response in the left caudate nuclei to rewarding stimuli.*
James Gilleen, Sukhi Shergill, Shitij Kapur
- 130.** *The effects of haloperidol and aripiprazole on resting state brain perfusion in healthy volunteers*
Rowena C Handley, Fernando Zelaya, A.A.T. Simone Reinders, Ruth O’Gorman, Atholl Johnston, Heather Taylor, Tiago Marques, Shitij Kapur, Steven Williams, Robin Murray, Philip McGuire, Carmine M Pariante, Paola Dazzan
- 131.** *The contribution of anxiety to fMRI in first episode schizophrenia*
Anthony Harris, Kunaal Prasad, Kerri Brown, Gary Flynn, Kim Felmingham, Leanne Williams
- 132.** *The cortical network of self-other discrimination investigated by rTMS*
Christine Heinisch, Martin Brüne
- 133.** *Resting-state functional connectivity reveals reduced intra-regional communication in children at-risk for psychosis*
Sarah Jacobson, Colm Connolly, Clare Kelly, Gary Donohoe, Mary Cannon, Hugh Garavan
- 134.** *Functional brain-mapping of complex hallucinations in first-episode psychosis*
Renaud Jardri, Dephine Pins, Pierre Thomas
- 135.** *Reduced Task-related Suppression during Semantic Repetition Priming in Schizophrenia*
Bumseok Jeong, Marek Kubicki
- 136.** *Functional magnetic resonance imaging reveals selective neuronal alterations in an animal model of anhedonia*
Melanie S. Keßler, Ciril M. Waelti, Sebastien Debilly, Patrick Mortas, Markus von Kienlin, Joseph G. Wettstein, Edilio Borroni, Celine Risterucci
- 137.** *Characteristics of brain activation during the processing of conflicting emotional stimuli in patients with schizophrenia: An fMRI study*
Jae-Jin Kim, Kyung Mook Choi, Ji Won Chun, Hae-Jeong Park
- 138.** *Prefrontal Cortical Activation in Patients with First Episode Schizophrenia as Measured by Near-infrared Spectroscopy*
Fumiaki Ito, Tomohiro Uchida, Noriyuki Ohmuro, Tetsuo Miyakoshi, Kazunori Matsumoto, Hiroo Matsuoka
- 139.** *GABA levels in the medial prefrontal cortex of patients with schizophrenia: A proton magnetic resonance spectroscopy (H1-MRS) study*
Matthew A. Geramita, Antonina A Savostyanova, Johan van der Veen, Christine Rebsch, Alan S Barnett, Jun Shen, Daniel R Weinberger, Stefano Marengo
- 140.** *Glutamate in the associative striatum of antipsychotic-naïve first episode psychotic patients and subjects with prodromal symptoms of schizophrenia*
Camilo de la Fuente-Sandova, Rafael Favila, Pablo León-Ortiz, Sylvana Stephano, Ariel Graff



- 141.** *Concept for combined 1H and 31P MR spectroscopic investigations in patients with schizophrenia*
Berko Milleit, Alexander Gussev, Stefan Smesny, Reinhard Rzanny, Heinrich Sauer, Jürgen R. Reichenbach
- 142.** *A Genome-wide Linkage Scan of Theta Band Activity as an Endophenotype for Schizophrenia*
Maartje F. Aukes, Marco PM Boks, Anne E Willems, Remko van Lutterveld, Iris E. Sommer, Margriet M. Sitskoorn, Roel A. Ophoff, Behrooz Z. Alizadeh, Rene S. Kahn
- 143.** *MEG does not reveal impaired sensory gating in first-episode schizophrenia*
Silke Bachmann, Matthias Weisbrod, Johannes Schroeder, Andre Rupp
- 144.** *Prediction of Psychosis by Mismatch Negativity*
Mitja Bodatsch, Stephan Ruhrmann, Michael Wagner, Ralf Müller, Frauke Schultze-Lutter, Ingo Frommann, Jürgen Brinkmeyer, Wolfgang Gaebel, Wolfgang Meier, Joachim Klosterkötter, Anke Brockhaus-Dumke
- 145.** *Impaired Long-Term Potentiation of the Visual Evoked Potential in Schizophrenia*
Idil Cavus, Robert Guglielmino, Judith Ford, Brian Roach, John Krystal, Ralitzia Gueorguieva, Daniel Mathalon
- 146.** *Go and NoGo P300 are not impaired in subjects at ultra high-risk for psychosis*
Müge Devrim-Üçok, H. Yasemin Keskin-Ergen, Çağrı Yüksel, Seda Şahin, Alp Üçok
- 147.** *Increased EEG Synchronization in Schizophrenia Patients by the Glutathione Precursor, N-Acetyl-Cysteine*
Cristian Carmeli, Maria G. Knyazeva, Michel Cuenod, Kim Q. Do
- 148.** *Age effects on habituation and prepulse inhibition of the human startle reflex, preliminary results*
Mikkel Erlang, Birte Y. Glenthøj, Bob Oranje
- 149.** *A novel $\alpha 5$ GABAAR agonist reverses hippocampal overdrive of dopamine neuron activity in the MAM model of schizophrenia*
Kathryn M. Gill, Daniel J. Lodge, Anthony A. Grace
- 150.** *Relationship between Steady-State Gamma Driving and Cognitively Elicited Gamma Frequency Responses in Schizophrenia*
Mei-Hua Hall, Grantley Taylor, Toni Mahowald, Dean F. Salisbury, Deborah L. Levy
- 151.** *The Stability of Prepulse Inhibition and habituation of the Startle Reflex in Schizophrenia: - A 6 Year Follow-up Study of Antipsychotic Naïve, First-Episode Schizophrenia patients.*
Trine Bjørg Hammer, Bob Oranje, Birte Glenthøj
- 152.** *Circadian dynamics of the parameters of spectral analysis of heart rate variability in treating schizoaffective disorder*
Sergejus Andruskevicius
- 153.** *Smooth pursuit and visual scanpaths: Related or independent deficits in schizophrenia?*
Sara A. Beedie, David M. St.Clair, Dan P. Rujescu, Philip J. Benson

- 154.** *Hippocampus-accumbens interactions in a developmental animal model of schizophrenia*
Pauline Belujon, Anthony A Grace
- 155.** *Multivariate eye movement psychophysiology accurately differentiates schizophrenia cases from unaffected controls*
Philip J. Benson, Sara A. Beedie, Ina Geigling, Dan Rujescu, David St. Clair
- 156.** *Reduced cardio-respiratory coupling indicates suppression of vagal activity in healthy relatives of patients with schizophrenia*
Sandy Berger, Michael K. Boettger, Manual Tancer, Vikram K. Yeragani, Karl-J. Bär
- 157.** *Cortical dysfunction during visual working memory in schizophrenia and schizophrenia-like psychosis of epilepsy: A magnetoencephalography study*
Leonides Canuet, Ryouhei Ishii, Masao Iwase, Koji Ikezawa, Ryu Kurimoto, Hidetoshi Takahashi, Michiyo Azechi, Antonio Currais, Takayuki Nakahachi, Kazutaka Ohi, Yuka Yasuda, Hidenaga Yamamori, Motoyuki Fukumoto, Ryota Hashimoto, Masatoshi Takeda
- 158.** *The capture of visual attention using auditory cues in schizophrenia*
Matthew Kean, Trevor Crawford, Felicity Wolohan, Veena Kumari, Ulrich Ettinger
- 159.** *Negative Correlation between Negative Symptoms and Testosterone Levels with reference to a 'Susceptibility Locus' for Deficit Schizophrenia*
A.G. Alias
- 160.** *COMT Met hemizygotes have lower striatal D2/3 receptor binding than Val hemizygotes – preliminary results in adults with 22q11 deletion syndrome*
Thérèse van Amelsvoort, Erik Boot, Jan Booij, Janneke Zinkstok, Frank Baas, Don Linszen
- 161.** *Plasma Homovanillic Acid levels during the first-year after the diagnosis of a First Episode of Schizophrenia: association with negative symptoms*
Inmaculada Baeza, Elena de la Serna, Ramon Deulofeu, Javier Goti, Miquel Bernardo, Josefina Castro-Fornieles
- 162.** *Altered mRNA Levels Of Chemokines And Cytokines In Schizophrenia And Bipolar Disorder*
Marcella Bellani, Alessandra Bergami, Luisa Tomelleri, Cinzia Perlini, Stefania Cerruti, Adele Ferro, Veronica Marinelli, Michele Tansella, Roberto Furlan, Gian Vito Martino, Paolo Brambilla
- 163.** *Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia*
Brian Dean, Tiffany Cowie, Suresh Sundram, Christos Pantelis, Andrew Gibbons, Elizabeth Scarr
- 164.** *Th1, Th2 and Th3 Cytokine Serum Levels in Schizophrenia: A Case-Control Study*
Samar Samoud, Yousri ElKissi, Mouna Ayachi, Neila Hannachi, Samia Gaabout, Bechir Ben Hadj Ali, Jalel Boukadida
- 165.** *Prolactin levels in first episode drug-naïve women with non affective psychosis*
Clemente Garcia-Rizo, Emilio Fernandez-Egea, Miguel Bernardo, Brian Kirkpatrick



- 166.** *Altered state of the antioxidative defense system (AODS) in neuroleptic-naive first episode schizophrenia*
Christine Milleit, Berko Milleit, Uta-Christina Hipler, Susan Thiel, Diana Neuhaus, Kristin Rödiger, Heinrich Sauer, Stefan Smesny
- 167.** *Lipidomic analysis in the population cohort reveals potential role of saturated triglycerides and fatty liver in schizophrenia*
Matej Oresic, Suoma Saarni, Marko Sysi-Aho, Jing Tang, Samuli I Saarni, Tuulikki Seppänen-Laakso, Jonna Perälä, Jaana Suvisaari
- 168.** *Niacin sensitivity increased in at risk mental state patients converting to psychosis within one year*
Stefan Smesny, Berko Milleit, Miriam R. Schaefer, Christine Milleit, Gregor Berger, Heinrich Sauer, Paul G. Amminger
- 169.** *Decreased Neuregulin C-terminal Fragments in Schizophrenia Prefrontal Cortex Brodmann's Area 6*
Adel Barakat, Elizabeth L. Scarr, Brian Dean, Genevieve Evin
- 170.** *Proteomic Analysis of Hippocampal Sub-regions in Schizophrenia and Bipolar Disorder reveals most prominent changes in CA2/3 and implicates abnormalities in clathrin mediated endocytosis*
Melanie Föcking, Patrick Dicker, Niamh Connolly, Lance Hudson, Jane English, Michael Dunn, David Cotter
- 171.** *Markers of synaptic plasticity are reduced in the dorsolateral prefrontal cortex of patients with schizophrenia*
Samantha J. Fung, Sinthuja Sivagnanasundaram, Cynthia Shannon Weickert
- 172.** *Analyses of fyn-tyrosine kinase in schizophrenia*
Kotaro Hattori, Haruko Tanaka, Hirofumi Uchiyama, Noriko Yamamoto, Yoshimi Iijima, Takashi Fujii, Hiroaki Hori, Toshiya Teraishi, Masahiko Tatsumi, Mayu Omori, Nagahisa Okamoto, Yukiko Kinoshita, Junko Matsuo, Yumiko Kawamoto, Kunimasa Arima, Hiroshi Kunugi
- 173.** *Scoring Algorithm for Predicting Long-Term Global Functioning in Patients with Schizophrenia*
Ofer Agid, Cynthia Siu, Douglas Vanderburg, Elizabeth Pappadopulos, Carla Brambilla, Shitij Kapur
- 174.** *How are large scale studies of medication changing our treatment strategies in schizophrenia?*
Rashid Zaman, Mark Agius, Michael Gilhooley, Abigail Davis
- 175.** *Lu AE58054, a potent and selective 5-HT₆ antagonist, reverses subchronic PCP-induced cognitive impairment in a rat novel object recognition test*
Jørn Arnt, Benny Bang-Andersen, Frank Bymaster, Michael Cohen, Neil DeLapp, Bruno Giethlen, Ben Grayson, Mads Kreilgaard, David McKinzie, Jo Neill, Søren M Nielsen, David Nelson, Mette N. Poulsen, John Schaus, Louise M Witten
- 176.** *Decline in the Rate and Cost of Psychiatric Hospitalization Following Initiation of Depot Antipsychotics in the Treatment of Schizophrenia*
Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries, Robert R. Conley
- 177.** *Brain Distribution and Binding of [¹¹C]Cariprazine: In Vivo PET Studies in Non-Human Primates and Whole Hemisphere Postmortem Autoradiographic Studies in Human Brain Slices*
Balázs Gulyás, Miklós Tóth, Andrea Varrone, Attila Horváth, István Laszlovszky, Béla Kiss, Christer Halldin

- 178. Open Poster Board**
- 179. Sertindole and haloperidol revisited; the psychometric triangle**
Per Bech, Per Tanghøj, Kate T Andreasson, Kerstin Overø
- 180. Intramuscular Ziprasidone Has Improved Tolerability Over Haloperidol and Comparable Efficacy for Control of Agitation in Schizophrenia in Chinese Patients**
Liang Shu, Hongyan Zhang, Gang Wang, Jingping Zhao, Shiping Xie, Xiufeng Xu, Jianguo Shi, Hehuang Deng, Keqing Li, Chengge Gao, Xiaoping Wang, Onur Karayal, Douglas Vanderburg, Sharon Pan, Haiyun Tang
- 181. Evaluation of the effect of aripiprazole on verbal cognitive functioning in a broad range of patients with schizophrenia in a prospective, multicentre, open-label study.**
Chris Bervoets, Eric Constant, Bernard Sabbe, Manuel Morrens, Kristof Vansteelandt, Jean Yves Loze, Veronique Halkin, Annick DePatoul, Didier Pitsi, Joseph Peuskens
- 182. Sibutramine in the Treatment of Antipsychotic-Induced Weight Gain: A Randomized, Placebo-Controlled Double-Blind Study**
Falko Biedermann, Monika Lechleitner, Alex Hofer, Regina Huber, Nadja Eltanaihi- Futhmü, Christoph Ebenbichler, Georg Kemmler, W. Wolfgang Fleischhacker
- 183. Beyond clozapine: what to do pharmacologically with clozapine resistant schizophrenia?**
Jan PAM Bogers
- 184. Clinical Remission in Schizophrenia Patients Treated with Aripiprazole for Up to One Year**
M^a Carmen Campos Mangas, Miguel Angel Ruiz Feliu
- 185. Antipsychotic Prescribing Patterns and Insight in an Ethnically Diverse Epidemiological Sample of First Episode Psychosis Patients**
Monica A. Charalambides, Julia Lappin, Craig Morgan, Paola Dazzan, Kevin Morgan, Maxine Patel, Paul Fearon
- 186. The Risks and Benefits of Antipsychotic Polypharmacy: Potential for Neuroleptic Malignant Syndrome**
Robert O. Cotes, Douglas L. Noordsy, Margaret McDermott, Joel N. Peterson, Marcy Traum
- 187. Antipsychotics combination at medical discharge from psychiatry hospitalisation unit**
Cristina Domenech, Esther Pousa, Jesus Cobo, Irene Falgas, Maria Giro, Gemma Garcia-pares
- 188. Long-Term Treatment with Long-Acting Injection of Risperidon in Patients with Schizophrenia - 2-Year Follow-Up**
Jozef Dragasek, Ildiko Lukacsova, Judita Sokoliova, Eva Palova
- 189. Short-Term Tolerability, Safety, and Pharmacokinetic Profile of Asenapine in Older Patients With Psychosis**
Steven L. Dubovsky, Colleen Frobose, Phillip Phiri, John Panagides



- 190.** *Allosteric modulation of muscarinic M4 receptors in the treatment of schizophrenia: a pharmacological comparison of LY2033298 vs VU0152099*
Clotilde Mannoury La Cour, Delphine S Dupuis, Mathilde Soulet, Aurélie Marcepoil, Mauricette Brocco, Mark J Millan, Guillaume De Nanteuil
- 191.** *Effectiveness of 300mg/4weeks Olanzapine Long-Acting Injection from Data Mining of an Open-Label Extension Study.*
Yulia Dyachkova, Alessandra Barraco, Agoston Toth, Hemant Anand
- 192.** *Prescribing patterns of antipsychotics within forensic psychiatric care*
Lars R Eriksson
- 193.** *Anticholinergic Drug Use in Clinical Settings in the Second-Generation Antipsychotic Era.*
Carlos Garcia-Ribera, Shuwall Mitchel, Mojal Sergi, Ruiz Ada, Greenwald Blaine
- 194.** *Rater Training on PANSS and SANS*
Richa Gaur, Hossein Kaviani, Shubhi Bansal, Nathan Lee
- 195.** *Single dose tolcapone administration improves working memory and sensorimotor gating in psychotic patients*
Panos Bitsios, Stella Giakoumaki, Evengelia M. Tsapakis, Panos Roussos, Anna Chrysoulaki, Ismini Kopsahili
- 196.** *Socio-demographic characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment non-adherence*
Jamie Karagianis, Katarina Kelin, Richard Newton, Malina I. Simu, Liang-Jen Chuo, Raúl I. Escamilla, Renee E. Granger, Wendy Ye, Alan J. M. Brnabic, William Montgomery, Haya Ascher-Svanum
- 197.** *Efficacy of Lurasidone in Schizophrenia: Results of a Pooled Analysis Based on a 5-Factor Model of Schizophrenia*
Antony Loebel, Josephine Cucchiaro, Robert Silva, Masaaki Ogasa, Joseph Severs, Stephen R. Marder
- 198.** *A Flexible-dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Other Oral Antipsychotics*
Andreas Schreiner, Dagmar Hoeben, Marjolein Lahaye, Christophe Tessier, Jozef Peuskens, Filippo Nardini, Walter Albrecht, Miro Jakovljevic, Slavica Djukic-Dejanovic
- 199.** *Patient functioning with flexible doses of Paliperidone ER – A 6-month prospective study*
Andreas Schreiner, Dagmar Hoeben, Marjolein Lahaye, Christophe Tessier, Mikhail V. Ivanov, Bruno Millet, Brigitta Rembeck, Jacek Turczynski, Enrico Smeraldi
- 200.** *Principal Outcomes of the Sertindole Cohort Prospective (SCoP) Study*
Joseph Peuskens, Per Tanghøj, Aurélie Mittoux
- 201.** *Maintaining Favourable Adherence by Consistent Self-Administration of Medication - Medication Event Monitoring System (MEMS) Trial to Evaluate the Compliance of Patients with Schizophrenia in Japan -*
Yueren Zhao, Masashi Moriwaki, Yoko Kinoshita, Kunihiro Kawashima, Hajime Ohga, Hideaki Tabuse, Nakao Iwata

- 202.** *Impact of specific types of early adversity events on adult psychosis-like symptoms: Preliminary results based in the UB-Twin Sample*
Silvia Alemany, Nadia Vilahur, Ximena Goldberg, Helen Vossen, Araceli Rosa, Fañanás Lourdes
- 203.** *Maternal Stress During Pregnancy and Risk of Schizophrenia in Adult Offspring*
Mary Clarke, Matti Huttunen, Antti Tanskanen, Mary Cannon
- 204.** *Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study*
Dan Cohen, Christoph Correll, Marc De Hert
- 205.** *Death and other severe life events in the (nuclear) family during fetal life and childhood and the later risk of psychosis - a national cohort study*
Christina Dalman, Susanne Wicks, Cecilia Magnusson, Lena Jörgensen, Johan Hallqvist
- 206.** *Time and Task-Dependent Inhibition of Dopamine responses to Novelty, Appetitive and Aversive stimuli induced by Haloperidol: An in-vivo Microdialysis Study.*
Davide Amato, Sridhar Natesan, Shitij Kapur, Christian Muller
- 207.** *Maternal lipopolysaccharide administration leads to developmental alterations in hippocampal neuronal density and expression of cortical dopaminergic receptors in rat offspring*
Moogeh Baharnoori, Sanjeev Bhardwaj, Lalit Srivastava
- 208.** *Repeated Phencyclidine (PCP) increases impulsivity in the 5-Choice Continuous Performance Test in rats.*
Sam A. Barnes, Jo C. Neill
- 209.** *Neonatal Treatment with Methylazoxymethanol Acetate (MAM) as a Neurodevelopmental Model of Schizophrenia: Behavioral, Pharmacological and Morphological Characterization*
Ana M. Basso, Peter Curzon, Min Zhang, Kelly B. Gallagher, Katherine Salte, Jordan Brown, Arthur L. Nikkel, R. Scott Bitner, Mark Day, Michael W. Decker, Gerard B. Fox, Lynne E. Rueter, Chih-Liang Chin
- 210.** *Enhanced synaptic plasticity at hippocampal output synapses in the MK-801 model of psychosis*
Joachim Behr, Julia Bartsch
- 211.** *Late prenatal immune activation in mice leads to behavioral abnormalities relevant to the negative symptoms of schizophrenia*
Byron K Y Bitanirwe, Daria Peleg-Raibstein, Forouhar Mouttet, Joram Feldon, Urs Meyer
- 212.** *Repeated adolescent restraint stress triggers enhanced anxiety-related behaviour and PPI deficits on heterozygous neuregulin 1 mice*
Aurelie A. Boucher, Areeg Hamdi, Adena Spiro, Max Bennett, Jonathon C. Arnold
- 213.** *Understanding the adverse side-effects of antipsychotic drugs with the use of a preclinical model*
Heidi N. Boyda, Ric M. Procyshyn, Lurdes Tse, Daniel M. Wong, Angela Liu, June Lam, Alasdair M. Barr
- 214.** *Attentional performance of DVD-deficient rats in the 5-choice continuous performance test*
Thomas H Burne, Karly Turner, John J. McGrath, Darryl W. Eyles



- 215.** *Isolation rearing in rats with a neonatal ventral hippocampal lesion: A model of environmental effects in schizophrenia pathophysiology*
Gwendolyn G. Calhoon, Carrie E. John, Patricio O'Donnell
- 216.** *The mGluR2/3 agonist LY379268 Modulates Ketamine-induced BOLD fMRI in Awake Rats: Utility as a Pharmacodynamic Biomarker?*
Chih-Liang Chin, Gerark Marek, Vince Hradil, Nathan Rustay, Min Zhang, Mario Mezler, Gerard Fox, Mark Day
- 217.** *A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia*
Stéphanie Vuillermot, Joram Feldon, Urs Meyer
- 218.** *Predictors of successful participation in peer support groups for psychosis*
Stynke Castelein, Richard Bruggeman, Joeske T. van Busschbach, Henderikus Knegtering, Mark van der Gaag, Durk Wiersma
- 219.** *Expectancy Theory and Learning Persistence in Schizophrenia*
Alice Medalia
- 220.** *Open Poster Board*
- 221.** *Deep brain stimulation of the mediodorsal thalamic nucleus and its implications for the treatment of schizophrenia*
Judith A. Pratt, Samuel G. Ewing
- 222.** *DoPill, an electronic pill dispenser, helping evaluate and control medication adherence in patients with schizophrenia*
Catherine Guevremont, Juliette Sablier, Millie Lum, Philippe Vincent, Constantin Tranulis, Frédérique Nadeau Marcotte, Emmanuel Stip
- 223.** *Loss to Outcomes Stakeholder Survey: The LOSS Study*
Jun Xia, Clive E. Adams, Nishant Bhagat, Vinaya Bhagat, Pranatham Bhoopathy, Hany El-Sayeh, Vanessa Pinfold, Yahya Takritii
- 224.** *Clinical High Risk for Psychosis: The Risk of False Positive*
Jean Addington, Barbara Cornblatt, Kristin Cadenhead, Ty Cannon, Robert Heinssen, Thomas McGlashan, Diana Perkins, Ming Tsuang, Elaine Walker, Scott Woods, Larry Seidman
- 225.** *Open Poster Board*
- 226.** *Predictors of Insight in First-Episode Psychosis*
Jose M. Pelayo-Teran, Rosa Ayesa-Arriola, Jose M. Rodriguez-Sanchez, Chiara Morelli, Rocio Perez-Iglesias, Ignacio Mata
- 227.** *Does the Early Course of Cognitive Function in First-Episode Schizophrenia Predict Functional Outcome?*
Verity Leeson, Eileen M. Joyce, Isobel Harrison, Thomas R. E. Barnes

- 228. Open Poster Board**
- 229. The kraepelinian schizophrenia sub-type: assessment of the validity of the "5 years" diachronic criteria**
Marie Cecile Bralet, Trang Ton, Serge Mitelman
- 230. Predictors of relapse after first-episode psychosis during a 3-year follow-up**
Olalla Caseiro-Vázquez, Rocío Pérez-Iglesias, Ignacio Mata, Obdulia Martínez, Gema Pardo, Rosa Ayesa-Arriola, Jose L. Vázquez-Barquero, Benedicto Crespo-Facorro
- 231. Readmission Risk in Schizophrenia and Related Disorders: Involuntary First Hospitalization as a Predictor.**
Florina Cealicu Toma, Javad Moamai
- 232. Gender differences in patients presented with first-episode psychosis in Hong Kong**
W C Chang, Jennifer Y. M. Tang, Cindy P. Y. Chiu, Christy L. M. Hui, May M. L. Lam, Gloria H. Y. Wong, C. W. Law, Steve Tso, Kathy Chan, S. F. Hung, Dicky W. S. Chung, Eric Y. H. Chen
- 233. Persistence of psychotic symptoms in an Irish community sample - an 8 year cohort study.**
Dearbhla J. Connor, Michelle Harley, Ian Kelleher, Mary Cannon
- 234. Pre-treatment, baseline and treatment correlates of outcome in an epidemiological cohort of first episode psychosis patients.**
Philippe Conus, Sue M. Cotton, Benno G. Schimmelmann, Patrick D. McGorry, Martin Lambert
- 235. Quality of life in patients who have remitted from their first episode of psychosis**
Sue M. Cotton, John Gleeson, Mario Alvarez-Jimenez, Patrick D. McGorry
- 236. Is Quality of life in schizophrenia related to illness awareness? A study with stabilized outpatients**
Rosó Duñó, Esther Pousa, Maria Giró, Irene Falgàs, Cristina Domènech, Adolf Tobeña
- 237. Open Poster Board**
- 238. Differential 3-year Effects of First vs. Second-generation Antipsychotics on Subjective Wellbeing in Schizophrenia using Marginal Structural Models (MSMs)**
Martin Lambert, Benno G. Schimmelmann, Alexander Schacht, David Suarez, Josep M. Haro, Diego Novick, Peter M. Wehmeier, Christian G. Huber, Hans P. Hundemer, Ralf W. Dittmann, Dieter Naber
- 239. Subjective well-being in psychotic depot-treated patients is related to personality traits.**
Scott McGreal, Tim J. Lambert
- 240. Prevention of Mothers' Mental Illness Deterioration: a retrospective review of 34 Japanese patients**
Keiko Akimoto, Masaru Taira, Motoo Watanabe, Takeshi Hashimoto, Kiyoshi Maeda
- 241. Assessing Recovery in People with Serious Mental Illness**
Alan S Bellack, Amy Drapalski, Deb Medoff



- 242.** *Psychometric properties of the french version of the Personal and social performance scale (PSP) among individuals with schizophrenia*
Olivier Blanc, Antonio Delgado, Christophe Lancon, Raymund Schwan, Franck Schürhoff, Jean-Alexandre Lesturgeon, Pierre Thomas, Pierre-Michel Llorca
- 243.** *Game Theoretical Approach to Theory of Mind Deficits in Schizophrenic Patients with Delusion(s) of Reference*
Kevin K.S. Chan, Gloria H.Y. Wong, Christy L.M. Hui, Jennifer Y.M. Tang, Sherry K.W. Chan, May M.L. Lam, Cindy P.Y. Chiu, Eric Y.H. Chen
- 244.** *Social Functioning and Cognition in Patients with Schizophrenia: Impact on Quality of Life.*
Delfina de Achaval, Jazmin Douer, Elsa Y. Costanzo, Mirta Villarreal, Rocio Berhongaray, Julieta Lopez, Martina C. Mora, Rodolfo Fahrer, Ramon C. Leiguarda, Salvador M. Guinjoan
- 245.** *Socio-demographic characteristics and social adjustment as predictors of a first psychosis in subjects at ultra high risk*
Sara Dragt, Dorien H. Nieman, Hiske E. Becker, J. Reinaud van de Fliert, Lieuwe de Haan, Don H. Linszen
- 246.** *Metabolic Risk Factors and Weight Gain in People Admitted to a Psychiatric Intensive Care Unit.*
David J Ash, Cherrie A. Galletly, Tushar Singh, Cassandra A. Burton, Tracy Air
- 247.** *Neurocognitive domains impaired in schizophrenia and its estimated heritabilities in healthy individuals: an EUTwinsS Network based study.*
Ximena L Goldberg, Silvia Alemany, Nadia Vilahur, Araceli Rosa, Marco Picchioni, Sheena Owens, Irene Rebollo, Robin Murray, Lourdes Fañanás, Timothea Touloupoulou
- 248.** *Differences in Self-esteem and Self-evaluation in Paranoia; Are self-appraisals a defensive strategy or a reflection of early adversities?*
Carmen Valiente, María Provencio, Regina Espinosa, Filiberto Fuentenebro
- 249.** *People's perception of their Involuntary Admission at one year follow-up and readmission rates to hospital.*
Brian O'Donoghue, John Lyne, Michele Hill, Conall Larkin, Larkin Feeney, Eadbhard O'Callaghan
- 250.** *A journey into the minds of those at ultra high risk for developing psychosis.*
Michael L Birnbaum
- 251.** *Patient-, Family-, and Services-Level Predictors of the Duration of Untreated Psychosis*
Michael T. Compton, Tynessa L. Gordon, Sandra M. Goulding, Michelle L. Esterberg, Tandra Carter, Amy S. Leiner, Ruth S. Shim, Paul S. Weiss, Benjamin Druss, Elaine F. Walker, Nadine J. Kaslow
- 252.** *Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort*
Philippe Conus, Martin Lambert, Sue M. Cotton, Charles Bonsack, Patrick D. McGorry, Benno G Schimmelmann
- 253.** *Early Detection of psychosis in General Practice*
Jan De Lepeleire, Paul De Cort, Guido Pieters

- 254.** *Do schizophrenic out-patients receive appropriate somatic care?*
Saana Eskelinen, Jaana Suvisaari
- 255.** *Resource Utilization Costs in Psychotic Patients: The Canadian OSCAR Study*
L. Kopala, G Smith, R. Williams, GW MacEwan, A. McIntyre, I. Kowalchuck, N. Schnurr, R. Balshaw, N. Lesnikova, W. G. Honer
- 256.** *Open Poster Board*
- 257.** *The relationship between social problem-solving and emotional regulation in people with schizophrenia.*
Marianne Ayre, Carmel Loughland, Miles Bore, Amanda Baker
- 258.** *Vitamin D in severely mentally ill hospitalized patients*
Nigel Bark, Rodica Varadi, Sung Ai Kim, Konda Govardhan, Sunitha Gali, Shah Kaushal, James Rim
- 259.** *Normalization of semantic categorization deficit in first-episode schizophrenia patients following symptomatic recovery: a three-year prospective longitudinal study.*
Eric Yu-Hai Chen, Christy Lai-Ming Hui, Eva Lai-Wah Dunn, May Yin-King Miao, Wai-Song Yeung, Chi-Keung Wong, Wah-Fat Chan, Wai-Nang Tang
- 260.** *Colour vision impairment in schizophrenia is not explained by impaired attention or cognitive deficits*
Elvina M Chu, Daniel R. Altmann, Thomas R. E. Barnes, Eileen M. Joyce, Maria A. Ron
- 261.** *Increased sensitivity to the stresses of daily life: preliminary findings of a momentary assessment study in the prodromal phase of psychosis*
Judith M Drees, Dana Beck, Svenja Schulze-Rauschenbach, Nadine Striepens, Andreas Bechdolf, Tineke Lataster, Inez Myin-Germeys, Michael Wagner
- 262.** *Jumping to Conclusions and Psychosis*
M. Aurora Falcone, Ben Wiffen, Jennifer O'Connor, Anna Kolliakou, Candice Joseph, Heather Taylor, Manuela Russo, Simona Stilo, Corinne Prescott, Alessandra Paparelli, Zefiro Mellacqua, Grant McQueen, Victoria Bennett, Marta Di Forti, Robin Murray, Daniel Freeman
- 263.** *Testosterone in Newly Diagnosed, Antipsychotic-Naïve Men with Nonaffective Psychosis: A Test of the Accelerated Aging Hypothesis*
Emilio fernandez-Egea, Clemente Garcia-Rizo, Brian Miller, Azucena Justicia, Miguel Bernardo, Brian Kirkpatrick
- 264.** *Ethnicity and Detention: Determinants of ethnic differences in the process and outcome of Mental Health Act (MHA) assessments*
Ruchika Gajwani, Swaran.P. Singh, Rubina Jasani
- 265.** *Odour Identification Assessment in Schizophrenia Patients Using a New Olfacto-Visual Tool: Relations between olfactory deficit and symptomatology*
Marie-Line Hamtat, Jack Doron, Olivier Grondin, Katia M'Bailara, Alain Desage, Vanessa Meyer, Gilles Sicard



- 266.** *CERP – Centres of Excellence in Relapse Prevention. An international educational programme to enhance relapse prevention in schizophrenia.*
Tim J Lambert, John Kane, Werner Kissling, Eduard Parellada
- 267.** *The Impact of a Genome-Wide Supported Psychosis Variant in the ZNF804A Gene on Memory Function in Schizophrenia*
Ryota Hashimoto, Kazutaka Ohi, Yuka Yasuda, Motoyuki Fukumoto, Masao Iwase, Naomi Iike, Michiyo Azechi, Koji Ikezawa, Masahiko Takaya, Hidetoshi Takahashi, Hidenaga Yamamori, Ryouhei Ishii, Hiroaki Kazui, Nakao Iwata, Masatoshi Takeda
- 268.** *COMT Val158Met polymorphism in interaction with daily stress: How COMT connects to psychosis*
Dina Collip, Ruud van Winkel, Odette Peerbooms, Tineke Lataster, Viviane Thewissen, Marielle Lardinois, Marjan Drukker, Bart Rutten, Jim Van Os, Inez Myin-Germeys
- 269.** *Systematic Review & Standardised Recalculation of incidence rates for schizophrenia across the life span.*
Judith Allardyce, Margriet van der Werf, Hanssen Manon, Sebastian Kohler, Jim van Os
- 270.** *Initial age and amount of cannabis exposure are strongly associated with psychosis vulnerability in a sample of 18,000 Dutch adolescents.*
Christian D. Schubart, Willemijn A. van Gastel, Elemi J Breetvelt, Iris E. Sommer, René S. Kahn, Marco P. Boks
- 271.** *Age at onset of psychosis in patients with schizophrenia: evidence for a sex-dependent interaction between BDNF Val66Met genotype and cannabis use.*
Jeroen Decoster, Jim van Os, Gunter Kenis, Cécile Henquet, Joseph Peuskens, Marc De Hert, Ruud van Winkel
- 272.** *Cannabis as cause of psychosis: Effects on incidence and persistence of psychotic symptoms*
Rebecca Kuepper, Jim van Os, Inez Myin-Germeys, Roselind Lieb, Hans-Ulrich Wittchen, Cecile Henquet
- 273.** *Open Poster Board*
- 274.** *The Genetic Association between Cancer and Schizophrenia: An Epidemiological Approach*
Gilad Gal, Itzhak Levav, Raz Gross

Posters, Monday 12 April

1. *Measuring autistic traits in patients with schizophrenia*
Tove Lugnegård, Maria Unenge Hallerbäck, Christopher Gillberg
2. *Working Memory Impairments in Schizophrenia as Valid Predictors of Illness Severity and Functional Outcome*
Oded Meiron, Abraham Weizman
3. *Examination regarding the effect of intervention to At Risk Mental State cases and the cases of false false-positive*
Keiko Morita, Kiyooki Takeshi, Naohisa Tsujino, Naoyuki Katagiri, Hiroyuki Kobayashi, Takahiro Nemoto, Masafumi Mizuno
4. *Detection of patients at risk for psychosis by screening the help-seeking population referred to mental health care services by a self-report questionnaire*
Roeline M. Nieboer, Lex Wunderink, Nynke Boonstra, Judith Rietdijk, Sara Dragt, Helga Ising, Rianne Klaassen, Dorien Nieman, Mark van der Gaag
5. *Prescription of antipsychotic medication to patients at ultra high risk for developing psychosis in a naturalistic setting*
Dorien Nieman, Hiske Becker, Lieuwe de Haan, Mark van der Gaag, Damiaan Denys, Don Linszen
6. *Validity of a short diagnostic instrument in psychiatry: the mini-SCAN*
Fokko J. Nienhuis, Peter de Jonge, Gerard v.d.Willige, Cees A.Th Rijnders, Durk Wiersma
7. *Assessment of emotional and behavioural aspects of interpersonal competencies in psychosis and its risk states – preliminary validation data*
Julia Paruch, Alexandra Nikolaidis, Joachim Klosterkötter, Stephan Ruhrmann
8. *Neurological Soft Signs in Psychometrically Identified Schizotypy*
Jessica A Kaczorowski, Neus Barrantes-Vidal, Thomas R Kwapil
9. *Basic Symptoms of Prodromal Schizophrenia in a Non-Clinical Sample*
Amber Saldias, Richard J Drake, Max Marshall
10. *Schizotypal Personality Disorder and the 22q11.2 Deletion Syndrome: The Relationship Between Prodromal Symptoms and Autistic Features*
Michelle L Esterberg, Opal Ousley, Joseph Cubells, Elaine F Walker
11. *Motivational Deficits in Schizophrenia: Cross-sectional and longitudinal relationships with functioning*
George Foussias, Steve Mann, Konstantine K. Zakzanis, Rob van Reekum, Ofer Agid, Gary Remington
12. *Phenomenological differences between Hispanic and Caucasian Schizophrenia subjects*
Juan A. Gallego, Katherine E. Burdick, Pamela DeRosse, Giovanna Musso, Todd Lencz, Anil K. Malhotra



13. *Sex Differences in Symptom Presentation in Individuals at Risk for Psychosis*
Carrie W. Holtzman, Molly K. Larson, Jean Addington, Kristin Cadenhead, Tyrone D. Cannon, Barbara Cornblatt, Robert Heinssen, Thomas McGlashan, Diana Perkins, Larry J. Seidman, Ming Tsuang, Scott W. Woods, Elaine F. Walker
14. *Diagnostic Stability of Brief Psychotic Disorder*
Yeon Ho Joo, Imyel Kim, Youjin Hong, Joong Sun Lee, Jung-Seo Yi, Byung-Su Kim
15. *Negotiating access to first-episode psychosis services: The experience of first-time primary caregivers.*
Terence V. McCann, Dan I. Lubman, Eileen Clark
16. *Impaired effective and white matter microstructural connectivity in familial Schizophrenia*
Christopher Craddock, Gareth Barker, Andrea Mechelli, Philip McGuire, Robin Murray, Colm Mc Donald
17. *Anomalous self experience in the prodromal phase of schizophrenia and other psychotic disorders*
Barnaby Nelson, Alison Yung
18. *Visual hallucinations in psychosis spectrum disorders - underestimated?*
Margreet Oorschot, Viviane Thewissen, Jim van Os, Inez Myin-Germeys
19. *Adolescent Cannabis Use and Psychotic Symptoms a One-Year Follow-Up Study*
Willemijn A van Gastel, Christian D. Schubart, Rene S Kahn, Marco PM Boks
20. *The analysis of genetic variability at COMT, CNR1, CNR2 and FAAH genes on cannabis use, schizotypy and psychotic-like experiences: a study in a Spanish general population.*
Barbara Arias, Mar Fatjo-Vilas, Gemma Estrada, MCarmen Aguilera, Marina Mitjans, Jorge Moya, Ignacio Ibañez, Helena Villa, MAngeles Ruiperez, Generos Ortet, Lourdes Fañanas
21. *Impact of methamphetamine use in first episode psychosis*
Bonga Chiliza, Renata Schoeman, Piet Oosthuizen, Liezl Koen, Dana Niehaus, Robin Emsley
22. *Suicidal Behavior Among Schizophrenia Spectrum in Patients with a History of Substance Abuse*
Nada B. Djordjevic, Suzana M. tosic Golubovic, Violeta V. Slavkovic
23. *The Effect of Cannabis on Serum Brain Derived Neurotrophic Factor Levels and its Correlation with Psychotic Symptoms*
Nesrin Dilbaz, Asli Enez-Darcin, Sercin Yalcin-Cavus, Hasan Kaya, Esmay Yenilmez, I. Tuncer Okay
24. *The Influence of Substance Misuse in the First Episode Psychosis on the Course and Outcome: 3 Years Prospective Follow-Up Study*
Dragoslava D. Gugleta, Tomic Golubovic M. Suzana, Violeta V. Slavkovic, Stankovic Jankovic S Dora
25. *Motivators for Smoking Cessation and Knowledge and Perception of Smoking Risks/Consequences Among People with Schizophrenia Compared to Normal Controls*
Deanna L. Kelly, Heather Gallagher, Suzanne Lo, Katherine Wright, Eric Moolchan, Stephanie Feldman, Fang Liu, Robert McMahon, Charles Richardson, Heidi Wehring, Douglas Boggs, Stephen Heishman

- 26. Mantoux Tuberculin Skin Test Among Patients Referred for Alcohol Abuse**
Evangelos G. Neroutsos, George N. Vagionis, Markella P. Fiste, Retziou C. Afroditi,
 Ouzonidou G. Konstantoula, Roupaka D. Aikaterini
- 27. Does screening for auditory hallucinations among adolescents using a single question predict psychopathology on clinical interview?**
Nina M Devlin, Ian Kelleher, Mary Cannon, Helen Keeley
- 28. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from a Large Simple Trial of Ziprasidone vs. Olanzapine in Real-World Use among 18154 patients with Schizophrenia**
Brian L. Strom, Sybil M. Eng, Gerald Faich, Robert F. Reynolds, Ralph B. D'Agostino, Jeremy Ruskin,
 John M. Kane, Jamie Geier, Onur N. Karayal, Charlotte Kremer
- 29. Bimodal Rhythms of General Conceptions and the Birth-Month Phenomenon in Schizophrenia, Neural Tube Defects, Laterality, etc.: The Exaggeration Hypothesis Revisited**
Giovanni Marzullo, Charles E. Boklage
- 30. The Australian Schizophrenia Research Bank (ASRB): Demographic, clinical and neuropsychological profiles for the first 500 participants with schizophrenia**
Vaughan Carr, Carmel Loughland, Kathryn McCabe, Aslam Nasir, Catts Stan, Assen Jablensky,
 Frans Henskens, Patricia Michie, Byran Mowry, Christos Pantelis, Ulrich Schall, Rodney Scott
- 31. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study**
John J McGrath, Darryl W Eyles, Carsten B Pedersen, Cameron Anderson, Pauline Ko, Thomas H Burne,
 Bent Norgaard-Pedersen, David M Hougaard, Preben B Mortensen
- 32. Psychometric properties of the Arabic version of the Schizotypal Personality Questionnaire in Tunisian university students**
Anwar Mechri, Leila Gassab, Aymen Lahmar, Slah Smairi, Fawzia Beltaief, Lotfi Gaha
- 33. Prevalence and burden of at-risk criteria of psychosis and help-seeking behaviour – a population survey - attitudes**
Chantal Michel, Benno G. Schimmelmann, Noemi Schaffner, Frauke Schultze-Lutter
- 34. Prevalence and burden of at-risk criteria of psychosis and help-seeking behaviour – a population survey – pathway-to-care**
Chantal Michel, Benno G. Schimmelmann, Noemi Schaffner, Frauke Schultze-Lutter
- 35. Revisiting social breakdown syndrome: The Australian National Survey of High Impact Psychosis (SHIP)**
Vera A. Morgan
- 36. First Episode Psychosis in Palermo Italy: Preliminary data**
Alice Mule', Valentina Rumeo, Adriano Schimmenti, Laura Ferraro, Robin M. Murray, Danielle La Barbera
- 37. Prevalence of Symptoms of Psychosis in Mid-Level Medical College Students in Kenya**
David M., Anne W.



- 38. Cannabis Use and Psychotic Experiences in a Healthy Population sample.**
Alessandra Paparelli, Marta Di forti, Paola Casadio, Simona A. Stilo, Sonija Luzi, Clare Flach, Manuela Russo, Jennifer O' Connor, Aurora M. Falcone, Zefiro Mellacqua, Victoria Bennett, Anna Kolliakou, Heather Taylor, Carmine Pariante, John Powell, Robin M Murray
- 39. Can genetic diversity explain the increased risk of schizophrenia among second generation immigrants?**
Carsten Bøcker Pedersen, Ditte Demontis, Michael S Pedersen, Esben Agerbo, Preben Bo Mortensen, Anders Børglum, David Hougaard, Ole Mors, Elizabeth Cantor-Graae
- 40. Men and women in psychosis: are they so different?**
Cristina Pujol-Riera, Alba Roca, Rafael Rodriguez, Irene Ramos, Sara Cardona, Cristina Marqueta, Yesika Galindo, Benjamin Piñeiro
- 41. Premorbid functioning and treatment response among patients with recent onset schizophrenia: Prospective study with risperidone long-acting injectable-PROPEL study**
Jonathan Rabinowitz, Oleksandr Napryeyenko, Benjaminas Burba, Guadalupe Martinez, Nikolay Neznanov, Tsvi Fischel, Franck Baylé, Giulio Corrivetti, Enrico Smeraldi, Andreas Schreiner
- 42. Imprisonment and diagnostic delay among male offenders with schizophrenia**
Mika Rautanen
- 43. Are social anxiety and paranoia associated, and which comes first?**
Judith Rietdijk, Jim van Os, Ron de Graaf, Philippe Delespaul, Mark van der Gaag
- 44. Chronic inflammation in schizophrenia – effect of obesity on inflammation markers**
Suoma E. Saarni, Britt-Marie Loo, Samuli Saarni, Perälä Jonna, Heliövaara Markku, Lönnqvist Jouko, Julia Antti, Suvisaari Jaana
- 45. Impact of ethnic and socioeconomic origins on neurological soft signs in schizophrenia**
Anwar Mechri, Marie Chantal Bourdel, Héli Slama, David Gourion, Lotfi Gaha, Marie Odile Krebs
- 46. The effects of neurofunctional reorganization therapy on corporal schema and sensory integration in schizophrenic patients: a pilot study.**
Catherine Millette, Francois Guillem, Emmanuel Stip
- 47. Neonatal phencyclidine induces long-term object memory deficits in male and female rats: reversal by risperidone, but not haloperidol**
L. Rajagopal, M.K. Harte, J.C. Neill
- 48. Neurological Abnormalities and Fluctuating Asymmetry: the role of prenatal environment.**
Nadia Vilahur, Araceli Rosa, Silvia Alemany, Ximena Goldberg, Helen Vossen, Lourdes Fañanas
- 49. Subjective deficits in an adolescent general population sample**
Benno G. Schimmelmann, Heiner Meng, Eginhard Koch, Franz Resch
- 50. The dimensional structure of prodromal symptoms in early-onset psychosis: indication of special needs in the early detection of younger adolescents**
Frauke Schultze-Lutter, Benno G. Schimmelmann, Eginhard Koch

- 51. *Identifying the markers of mental illness in primary school-aged children: A series of case studies examining cognitive, motor, language and psychosocial factors.***
Renee R. Testa, Nola Ross, Marc L Seal, Bruce Tonge, Christos Pantelis
- 52. *The structure of the extended psychosis phenotype in early adolescence***
Johanna T.W. Wigman, Wilma A.M. Vollebergh, Quinten A.W. Raaijmakers, Jurjen Iedema, Saskia van Dorsselaer, Johan Ormel, Frank C. Verhulst, Jim van Os
- 53. *Clinical and neuropsychological characteristics in child and adolescent at high risk for schizophrenia: comparative study between first degree relatives***
Elena De la Serna, Inmaculada Baeza, Josep Toro, Susana Andres, Olga Puig, Vanessa Sanchez-Guistau, Soledad Romero, Miguel Bernardo, Josefina Castro-Fornieles
- 54. *Thalamic development in Childhood onset Schizophrenia; a volumetric analysis***
Avinash Hosanagar, Anand Mattai, Francois Lalonde, Deanna Greenstein, Liv Clasen, Brian Weisinger, Judith L. Rappaort, Nitin Gogtay
- 55. *What can the N170 tell us about face processing in schizotypy?***
Rachel A. Batty, Susan L. Rossell, Andrew Francis
- 56. *Cognitive Dysfunction and Community Functioning in Schizophrenia: Results from the MATRICS Psychometric and Standardization Study (PASS)***
Robert S. Kern, James M. Gold, Dwight Dickinson, Michael F. Green, Keith H. Nuechterlein, Richard S. E. Keefe, Stephen R. Marder, Catherine A. Sugar
- 57. *The Multidimensional Structure of Processing Speed in Healthy Individuals and Schizophrenia Patients***
Emma E.M. Knowles, Mark Weiser, Michael Davidson, Anthony S. David, Avi Reichenberg
- 58. *Obsessive-compulsive symptoms do not affect visual recognition and working memory in chronic schizophrenia***
Eirini Theochari, Spiros Kleisas, Stamatina Kalogerakou, Charalambos Karouzos, Eleftheria Tsaltas, Dimitrios Kontis
- 59. *Is Theory of Mind linked to social impairment in elderly patients with schizophrenia?***
Aurélie Lagodka, Thierry Gallarda, Marie-Chantal Bourdel, Rémi Gadel, Maud Champagne, Dominique Willard, Marie-Odile Krebs, Jean-Pierre Olié, Isabelle Amado
- 60. *Autobiographical Memory Deficits in Older Patients with Chronic Schizophrenia***
Marc M. Lässer, Lena A. Schmid, Christina J. Herold, Ulrich Seidl, Johannes Schröder
- 61. *Neurocognitive functioning of prodromal and early state of schizophrenia: baseline assessment of SOPRES in Taiwan***
Hai-Gwo Hwu, Chen-Chung Liu, Mau-Sun Hua
- 62. *Effect of explicit instruction on the Verbal Learning Test in patients with schizophrenia***
Mie Matsui, Naoki Hashimoto, Atsushi Toyomaki, Ichiro Kusumi, Tsukasa Koyama



- 63.** *Neurocognition in first-episode schizophrenia: A meta-analytic review.*
Raquelle I. Mesholam-Gately, Anthony J. Giuliano, Kirsten P. Goff, Stephen V. Faraone, Larry J. Seidman
- 64.** *Theory of mind and global empathy performance in schizophrenia: the role of anxiety, remission status and symptom type.*
Jason M. Morrison, Gail Myhr
- 65.** *Neuropsychological functioning of individuals with familial risk for psychosis in the Northern Finland 1986 Birth Cohort*
Sari Mukkala, Annamari Tuulio-Henriksson, Jouko Miettunen, Jukka Loukkola, Jennifer Barnett, Graham Murray, Erika Jääskeläinen, Pirjo Mäki, Irma Moilanen, Peter Jones, Juha Veijola
- 66.** *Attention, Working Memory and Executive Function in adolescents with Early Onset Psychosis, Asperger Syndrome and Healthy Controls.*
Jessica Merchán-Naranjo, Cloe L Lorente, María Mayoral, Marisa Giráldez, Marta Rapado, Arango Celso, Parellada Mara
- 67.** *Ketamine as a model of semantic deficits in schizophrenia*
Erica Neill, Susan Rossell
- 68.** *Divergent thinking as a potential target for cognitive intervention in early psychosis*
Takahiro Nemoto, Kiyooki Takeshi, Nao Togi, Maiko Haneda, Naohisa Tsujino, Shinya Ito, Naoyuki Katagiri, Keiko Morita, Hiroyuki Kobayashi, Masafumi Mizuno
- 69.** *Recent Advances in Translating and Culturally Adapting the MATRICS Consensus Cognitive Battery for International Use*
Keith H. Nuechterlein, Michael F. Green, Robert S. Kern
- 70.** *Can we identify cognitive profiles in psychosis with pre-morbid estimates? Findings from a first episode cohort study*
Jennifer A O'Connor, Anthony S David, Monica Aas, Aurora Falcone, Avi Reichenberg, Poonam Sood, Manuela Russo, Benjamin Wiffen
- 71.** *A neurocognitive assessment of the performance of individuals at ultra-high risk of psychosis, using the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS)*
Noriyuki Ohmuro, Fumiaki Ito, Yumiko Hamaie, Tomohiro Uchida, Hirotoshi Sato, Masahiro Katsura, Atsushi Sakuma, Kazunori Matsumoto, Hiroo Matsuoka
- 72.** *The Relationship between Social Cognitive Functioning and Psychotic Symptom Clusters in First Episode Psychosis*
Alicia Papas, Linda Byrne, Andy Thompson
- 73.** *CFA confirmation of a latent cognitive structure common to Spanish and North American patients with schizophrenia*
Pedro Sánchez, Natalia Ojeda, David J. Schretlen, Javier Peña, Edorta Elizagarate, Ana B. Yoller, Jesus Ezcurra, Miguel Gutierrez

- 74.** *Does Neuropsychological Normality Preclude Functional Disabilities in Outpatients with Chronic Schizophrenia?*
Rafael Penadés, Rosa Catalán, Nuria Pujol, Guillém Masana, Clemente García-Rizo, Miguel Bernardo
- 75.** *Normative data of the SCIP-S in schizophrenia and type I bipolar disorder*
Oscar Pino, Emilio Rojo, Georgina Guilera, Juana Gómez-Benito, Javier Rejas, Benedicto B. Crespo-Facorro, Eduard Vieta, Manuel J. Cuesta, Miguel Bernardo, Nuria Segarra, Anabel Martínez-Arán, Manuel Franco, Rafael Tabarés-Seisdedos
- 76.** *wais-iii short form in schizophrenia*
Jose M. Porto, Cristina Tobón, Abdel A. Solis, Francisco C. Poppe, Felipe Soto, Georgina Fumeros, Vicente Merino, Susana Gil, María J. Viñas, Elisabeth Lucas, Juan A. García, Lorena Bartolomé, Beatriz Mongil, María V. Perea, Manuel A. Franco
- 77.** *Insight in psychosis: the role of neurocognition and the additional explained variance of social cognition and symptom dimensions*
Piotr J. Quee, Liset van der Meer, Richard Bruggeman, Lieuwe de Haan, Wiepke Cahn, Lydia Krabbendam, Niels C.L. Mulder, Durk Wiersma, André Aleman
- 78.** *Metacognitive indexes and symptomatology in persons with schizophrenia*
Paolo Stratta, Ilaria Riccardi, Melania D'Arcangelo, Alessandro Rossi
- 79.** *A Meta-Analysis of Computerized Assessment Batteries in Schizophrenia Medication Trials*
Henry Riordan, Luke Eastman, Laura Hoffman, Neal Cutler, Paul Moberg
- 80.** *Genetic association analysis of SIRT1 with schizophrenia in a Japanese population.*
Yasuhisa Fukuo, Taro Kishi, Masashi Ikeda, Tsuyoshi Kitajima, Kunihiro Kawashima, Tomo Okochi, Tomoko Tsunoka, Takenori Okumura, Yoko Kinoshita, Yoshio Yamanouchi, Toshiya Inada, Norio Ozaki, Nakao Iwata
- 81.** *Increased frequency of novel NRG1 gene variants in schizophrenia and the effect of nucleotide variation on mRNA isoform transcriptional regulation.*
Janice M Fullerton, Yash Tiwari, Peter R Schofield, Cyndi Shannon Weickert
- 82.** *Dystrobrevin binding protein gene (DTNBP1) in Bipolar Disorder: a review and a meta-analysis*
Darya Gaysina, Gerome Breen, Inti Pedroso, Peter McGuffin
- 83.** *Association of schizophrenia susceptibility genes with intermediate phenotypes: new findings from genomic imaging*
Oliver Gruber, Sarah Trost, Thomas Wobrock, Harald Scherk, Thomas Schneider-Axmann, Wolfgang Reith, Jobst Meyer, Peter Falkai
- 84.** *Breakpoint analysis of NRXN1 deletions in schizophrenia.*
Louise K. E. Hoeffding, Andrés Ingason, Thomas Hansen, Thomas Werge, Dan Rujescu



- 85.** *The methylenetetrahydrofolate reductase gene (MTHFR) and risk for schizophrenia. Are functional MTHFR gene polymorphisms associated with age of onset?*
Erik G. Jönsson, Peter Saetre, Maria Vares, Thomas Werge, Ole A Andreassen, Tadao Arinami, Shinichiro Nanko, Ene Choo Tan, Doug Hyun Han, Joshua Roffman, Jan-Willem Muntjewerff, Pawel Jagodzinski, Elisabet Vilella, Elitza Betcheva, Yusuke Nakamura, Björn Regland
- 86.** *Clozapine-induced weight change associated with G-2548A polymorphism of the leptin gene in patients with chronic schizophrenia*
Shi Hyun Kang, Jong-il Lee, Hye Ree Han, Minah Soh
- 87.** *Evidence That Putative ADHD Low Risk Alleles at SNAP25 May Increase the Risk of Schizophrenia*
Liam S. Carroll, Kimberley M. Kendall, Michael C. O'Donovan, Michael J. Owen, Nigel M. Williams
- 88.** *Complexin2 gene polymorphisms modify cognitive performance in schizophrenia*
Sabrina Klaus, Martin Begemann, Sergi Papiol, Dörthe Malzahn, Heidi Friedrichs, Katja Ribbe, Ahmed El-Kordi, Konstantin Radyushkin, Fritz Bensele, Kerstin Reim, Joachim Riggert, Peter Falkai, Heike Bickeböller, Klaus-Armin Nave, Nils Brose, Hannelore Ehrenreich
- 89.** *The effect of a genome-wide supported variant in CACNA1C on neural correlates of episodic memory encoding and retrieval*
Axel Krug, Stephanie Witt, Sören Krach, Andreas Jansen, N. Jon Shah, Markus M. Nöthen, Marcella Rietschel, Tilo Kircher
- 90.** *Relationship Between the Dopamine Transporter Gene (DAT) Core Promoter Polymorphism -67A/T and Striatal DAT Binding with [123I] FP-CIT SPECT*
Anna Mane, Jose J. Mateos, Francisco Lomeña, Amalia Lafuente, Sergi Mas, Judit Gallego, Javier Pavia, Miguel Bernardo, Eduard Parellada
- 91.** *Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia*
Renan P. Souza, Gary Remington, Herbert Y. Meltzer, Jeffrey A. Lieberman, James L. Kennedy, Albert H. Wong
- 92.** *Heritability of cortical gyrification and implications for schizophrenia: preliminary results from the STAR / EUTwinsS studies*
Raka Maitra, Marco Picchioni, Christian Gaser, Timothea Touloupoulou, Robin Murray, Heinrich Sauer, Igor Nenadic
- 93.** *Widespread, heritable, brain alterations in individuals with schizophrenia and individuals 'at risk': evidence for a cortical thickness intermediate phenotype*
Machteld C. Marcelis, Petra Habets, Irene Weltens, Ed Gronenschild, Jim van Os
- 94.** *Variation in Grey Matter Volume with Degree of Insight in First Episode Psychosis and Chronic Schizophrenia*
J. McFarland, D. Cannon, H. Schmidt, M. Ahmed, S. Hehir, L. Emsell, P. McCarthy, C. McDonald
- 95.** *Semantic Fluency Deficits and Grey Matter Difference Before Transition to Psychosis: A Voxel Wise Correlational Analysis*
Julia H. Meijer, Nicole Schmitz, Dorien H. Nieman, Lieuwe de Haan, Hiske E. Becker, Don H. Linszen

- 96.** *Longitudinal MRI changes in hippocampal shape following the first-episode of schizophrenia*
Zefiro B. Mellacqua, Julia Lappin, James Cole, Kevin Morgan, Camilla Carlson, Craig Morgan, Paul Fearon, Jolanta Zanelli, Peter B. Jones, Robin Murray, Paola Dazzan
- 97.** *Voxel-based morphometry comparison between chronic schizophrenia and bipolar patients and healthy controls*
Vicente Molina, Gemma Galindo, Benjamin Cortés, Juan A. Hernández
- 98.** *Longitudinal changes of structural brain asymmetry in psychosis and healthy controls*
Kevin D. Morgan, Anne Cannon, Julia Lappin, Craig Morgan, Paul Fearon, Bertha Rogers, Pedro Rosa, Peter B. Jones, Robin M. Murray, Paola Dazzan
- 99.** *Gyrification in twins discordant for schizophrenia*
Igor Nenadic, Raka Maitra, Christian Gaser, Matthias Weisbrod, Marco Picchioni, Timothea Touloupoulou, Robin Murray, Heinrich Sauer
- 100.** *Reduced brain cortical folding in schizophrenia*
Ragnar Nesvåg, Marie Schaer, Unn K. Haukvik, Lars M Rimol, Elisabeth H. Lange, Cecilie B. Hartberg, Erik G. Jönsson, Ingrid Melle, Ole A. Andreassen, Ingrid Agartz, Stephan Eliez
- 101.** *Decreased Fractional Anisotropy in Inter-Hemispheric Connection between Bilateral Superior Temporal Gyrus Gray Matter in Chronic Schizophrenia*
Hsiao Piau Ng, Marek Kubicki, Yogesh Rathi, James Malcolm, Paula Pelavin, Ron Kikinis, Martha E. Shenton
- 102.** *Effects of catechol-O-methyltransferase Val158Met on grey matter volume in adolescents born preterm*
Chiara Nosarti, Muriel Walshe, Larry Rifkin, Robin Murray, Matthew Allin
- 103.** *Increase of grey matter in lentiform nucleus in schizophrenia and unaffected relatives measured with voxel-based volumetry (VBM): medication effect or genetic liability?*
Viola Oertel-Knöchel, Silke Matura, Anna Rotarska-Jagiela, Jörg Magerkurth, Corinna Haenschel, Johannes Pantel, David E.J. Linden, Christian Knöchel
- 104.** *The neurohistological effects of ketamine induced N- methyl-D- aspartate receptor hypofunction in the prefrontal cortex of the cerebrum of rats*
Olasunmbo O. Owolabi, Gbenga O. Afolayan, Ayodele Obembe, Ezekiel A. Caxton-Martins
- 105.** *Role of insular cortex in phase locking of frontal theta oscillations in schizophrenia: preliminary evidence from cortical surface analysis*
Lena K. Palaniyappan, Kathrin Doege, Pavan Mallikarjun, Elizabeth B. Liddle, Peter F. Liddle
- 106.** *Contribution of genetic variability in Interleukin-1 cluster (2q13) to the risk of functional psychosis and its associated brain abnormalities*
Sergi Papiol, Vicente Molina, Mar Fatjó-Vilas, Ana Monfort, Araceli Rosa, Bárbara Arias, Javier Sanz, J. Calama, A.I. Hernández, C. Martín, Lourdes Fañanás



- 107.** *Effect of OLIG2 in white matter integrity in healthy subjects and patients with schizophrenia*
Diana P. Prata, Richard Kanaan, Gareth Barker, Sukhwinder Shergill, James Woolley, Lyudmila Georgieva, Marco Picchioni, Fergus Kane, Muriel Walsh, Matt Allin, Timothea Touloupoulou, Elvira Bramon, Colm McDonald, Vincent Giampietro, Michael O'Donovan, Philip McGuire
- 108.** *Septum pellucidum cavities and schizophrenia 25 years on: A Review and Meta-analysis*
S. Arkoma, B. Kennedy, S.W. Lewis
- 109.** *Voxel-Based Morphometry and Default Mode Network in schizophrenia: relation to cognition, symptoms and social functioning*
Nuria Pujol, Rafael Penadés, Rosa Catalan, Clemente García
- 110.** *Early Onset Psychosis: Longitudinal Brain Changes at Two Years Follow-Up*
Marta Rapado-Castro, Santiago Reig, Mara Parellada, Dolores Moreno, Josefina Castro-Fornieles, Ana González-Pinto, Soraya Otero, Inmaculada Baeza, Montserrat Graell, Joost Janssen, Manuel Desco, Celso Arango
- 111.** *Grey matter reduction in first-episode psychosis: relationship to diagnosis*
Rocío Pérez-Iglesias, Diana Tordesillas-Gutierrez, Nikolaos Koutsouleris, Roberto Roiz-Santiañez, Eva Meisenzahl, Enrique Marco de Lucas, Elsa Gómez-Ruiz, Rosa Ayesa-Arriola
- 112.** *Reduced ability to engage default-mode brain regions during the resting-state periods of a working memory task in recent-onset schizophrenia*
Sarah C. Jacobson, Katherine H. Karlsgodt, Jacqueline H. Sanz, Theo G.M. van Erp, Keith H. Nuechterlein, Carrie E. Bearden, Tyrone D. Cannon
- 113.** *"Turn it up to 11": The relationship between brain noise and learning in schizophrenia.*
Michele C. Korostil, Natasha Kovacevic, Anthony R. McIntosh
- 114.** *Chronic derealisation phenomenon in a 17-year old boy after twofold cannabis use: When acute becomes chronic*
Stephan Kupferschmid, Daniela Hubl, Andrea Federspiel, Kay Jann, Martinus Hauf, Benno G. Schimmelmann
- 115.** *Altered functional connectivity in subjects with ultra-high risk for psychosis using resting state fMRI*
Jun Soo Kwon, Geumsook Shim, Jungsu S. Oh, Wi Hoon Jung, Joon Hwan Jang, Chi-Hoon Choi, Euitae Kim, Hye-Yoon Park, Jung-Seok Choi, Myung Hun Jung
- 116.** *Functional MRI of working memory related activation in monozygotic twins discordant for schizophrenia: preliminary results from the EUTwinsS study*
Kerstin Langbein, Gianluca Mingoia, Gerd Wagner, Sigrid Scherpiet, Jürgen R. Reichenbach, Ralf G.M. Schlösser, Heinrich Sauer, Igor Nenadic
- 117.** *Association of genetic variation of the dopamine D2 receptor gene with activity in cortical and subcortical motor brain regions in humans*
Leonardo Fazio, Giuseppe Blasi, Tiziana Quarto, Paolo Taurisano, Apostolos Papazacharias, Raffaella Romano, Barbara Gelao, Annabella Di Giorgio, Luciana Lo Bianco, Luca Ursini, Grazia Caforio, Teresa Popolizio, Bruno Dallapiccola, Wolfgang Sadée, Marcello Nardini, Alessandro Bertolino

- 118.** *Trait and state brain-activation markers of schizophrenia*
Elizabeth B. Liddle, Peter F. Liddle, Alan T. Bates, Debasis Das, Madeleine J. Groom, Marije Jansen, Georgina M. Jackson, Chris Hollis
- 119.** *Functional network disconnectivity in schizophrenia: Evidence from three fMRI experiments.*
Peter F. Liddle, Pavan Mallikarjun, Ana Diukova, Dorothee Auer
- 120.** *Altered connectivity in the auditory and attention systems of schizophrenia patients with auditory verbal hallucinations*
Edith J. Liemburg, Ans Vercammen, Rikus Knegeting, Branislava Curcic-Blake, André Aleman
- 121.** *State and Trait Variables during Emotion Processing in Schizophrenia*
Luciana Lo Bianco, Giuseppe Blasi, Annabella Di Giorgio, Grazia Caforio, Paolo Taurisano, Leonardo Fazio, Barbara Gelao, Raffaella Romano, Apostolos Papazacharias, Annamaria Porcelli, Chiara Castellana, Marcello Nardini, Alessandro Bertolino
- 122.** *Left temporal dysfunction, attention control deficit and auditory hallucination: An fMRI study*
Else-Marie Løberg, Hugo A. Jørgensen, Merethe Nygård, Jan Øystein Berle, Kenneth Hugdahl
- 123.** *Prefrontal activity and COMT genotype effects in Schizophrenia.*
Pilar Lopez, Leslie Young, David Garcia, Reyes Garcia de Eulate, Juan Marin, Felipe Ortuño, Jose L. Zubieta
- 124.** *Increased limbic system activity associated with appetite dysfunction in schizophrenic patients following an Olanzapine treatment*
Emmanuel Stip, Ovidiu V. Lungu, Karyne Anselmo, Adrianna Mendrek, Benjamin Stip, Olivier Lipp, Marie-Claude Delisle, Pierre Lalonde, Lahcen Ait Bentaleb
- 125.** *Recruitment of bilateral frontal regions in schizophrenia during novel metamorphic processing: an fMRI Study*
Nira Mashal
- 126.** *Differential epistatic effects between DAAO and G72 in healthy controls and patients with schizophrenia and bipolar disorder*
A. Mechelli, S.A. Papagni, D.P. Prata, J. Kambeitz, C.H. Fu, M Picchioni, T. Touloupoulou, E. Bramon, M. Walshe, R.M. Murray, D.A. Collier, P. McGuire
- 127.** *Exploring the neural basis of gaze perception errors in schizophrenia*
Mahesh Menon, Sofia Raitsin, Ariel Graff, Christine Hooker, Shitij Kapur
- 128.** *Medial prefrontal cortical activation during working memory differentiates schizophrenia and bipolar psychotic patients: a pilot study*
Snezana M. Milanovic, Heidi W. Thermenos, Ariel Brown, Jill M. Goldstein, Susan W. Gabrieli, Nikos Makris, Richard Juelich, Ming T. Tsuang, Stephen L. Buka, Larry J. Seidman
- 129.** *Altered default-mode network activity in schizophrenia: a resting state fMRI study*
Gianluca Mingoa, Gerd Wagner, Kerstin Langbein, Sigrid Scherpiet, Ralf Schloesser, Christian Gaser, Heinrich Sauer, Igor Nenadic



- 130.** *Neural Basis of Self-Referential Processing in Psychosis Proneness*
Gemma Modinos, Remco Renken, Johan Ormel, André Aleman
- 131.** *Match and mismatch in auditory feedback to spoken words. An fMRI study.*
Stephanie Loos, Christian Kargel, Ulises Martinez, Arndt Hesse, Francesco Musso, Jürgen Brinkmeyer, Georg Winterer, Stefan Klingberg, Thilo Kircher, Gudrun Sartory, Jens Wiltfang, Bernhard W. Müller
- 132.** *Neural correlates of ketamine-induced psychopathological symptoms*
Arne Nagels, Sören Krach, Andre Kirner-Veselinovic, Tilo Kircher
- 133.** *An optimized fMRI pulse sequence for measuring BOLD signal change in subcortical brain areas*
Sebastian F.W. Neggers, Iris E.C. Sommer, Rene S. Kahn
- 134.** *Dysfunctional Neural networks of timing in Schizophrenia: an ALE meta-analysis*
Felipe Ortuño, Francisco Guillen, Jose Gomez, Pilar Lopez, Patricio Molero, Jorge Pla
- 135.** *The His 452 Tyr polymorphism of the 5-HT_{2A} receptor gene modulates activity in prefrontal cortex during attentional control in healthy subjects*
Apostolos Papazacharias, Giuseppe Blasi, Paolo Taurisano, Linda Antonucci, Leonardo Fazio, Annabella Di Giorgio, Gianluca Ursini, Lorenzo Sinibaldi, Raffaella Romano, Barbara Gelao, Luciana Lo Bianco, Grazia Caforio, Rita Masellis, Teresa Popolizio, Marcello Nardini, Alessandro Bertolino
- 136.** *Left pre-frontal lobe dysfunction in medication naive schizophrenia*
Nicoletta M. van Veelen, Matthijs Vink, Nick F. Ramsey, René S. Kahn
- 137.** *Two-channel near infrared spectroscopy (NIRS) activation timing curves of oxyhemoglobin during frontal tasks in schizophrenia*
Masao Iwase, Michiyo Azechi, Koji Ikezawa, Ryouhei Ishii, Hidetoshi Takahashi, Takayuki Nakahachi, Leonides Canuet, Ryu Kurimoto, Hiroaki Kazui, Motoyuki Fukumoto, Naomi Iike, Kazutaka Ohi, Hidenaga Yamamori, Yuka Yasuda, Ryota Hashimoto, Masatoshi Takeda
- 138.** *GABA and glutamate-glutamine levels in the frontal cortex in schizophrenia: a magnetic resonance spectroscopy study*
Lawrence S. Kegeles, Xiangling Mao, Arielle Stanford, Najate Ojeil, Beatriz Alvarez, Felipe Castillo, Roberto Gil, Anissa Abi-Dargham, Sarah H. Lisanby, Dikoma C. Shungu
- 139.** *Magnetic resonance spectroscopy (31P chemical shift imaging) in monozygotic discordant twins with schizophrenia spectrum disorders*
Kerstin Langbein, Igor Nenadic, Reinhard Rzanny, Matthias Weisbrod, Heinrich Sauer, Stefan Smesny
- 140.** *Mismatch negativity is reduced in schizophrenia patients with deficit syndrome*
Mitja Bodatsch, Stephan Ruhrmann, Ralf Müller, Joachim Klosterkötter, Anke Brockhaus-Dumke
- 141.** *Induced theta deficiencies for schizophrenia patients in an N-back task*
Marije Jansen, Pavan Mallikarjun, Ana Diukova, Peter F. Liddle

- 142.** *P300 amplitude reduction in subjects at ultra high-risk for psychosis*
H. Yasemin Keskin-Ergen, Alp Üçok, Evrim Göde, Müge Devrim-Üçok
- 143.** *Auditory hallucinations and the P3a: Attention switching to speech in schizophrenia*
Verner J Knott, Derek J Fisher, Alain Labelle
- 144.** *Attribution Bias and Event-Related Potential using a Real-time Based Attribution Experiment (the 'Colour Test')*
Su Young Lee, Jung Ai Kim, Jae Hee Seo, Ji Min Kim, Suk Kyoan An
- 145.** *Impaired generation of visual mismatch negativity is linked to the deficit syndrome in Schizophrenia*
Jan Libiger, Aleš Urban, Jan Kremláčk, Jaromír Hons
- 146.** *Mismatch negativity to duration deviants in first episode psychosis and in the prodrome.*
Patricia T Michie, Rebbekah Atkinson, Sally Hunt, Raymond Inkpen, Wendy Stojanov, Sean Halpin, Ulrich Schall
- 147.** *ERP abnormalities during Semantic Processing in Adolescents at-risk for Psychosis*
Jennifer Murphy, Caroline Rawdon, Deirdre Twomey, Richard Roche, Mary Cannon
- 148.** *Clonidine normalizes sensorimotor gating deficits in chronic patients with schizophrenia*
Bob Oranje, Birte Y. Glenthøj
- 149.** *Comparison of clinical routine EEG and quantitative EEG in first episode of psychosis and At-Risk Mental State individuals*
Marlon O. Pflueger, Ute Gschwandtner, Ronan Zimmermann, Manuela Gaggiotti, Vitaliy Semenin, Anita Riecher-Rössler, Peter Fuhr
- 150.** *Relationship between electrodermal activity and heart rate in patients with acute schizophrenia*
Karl-J. Bär, Tobias Rachow, Sandy Berger, Anna K. Israel
- 151.** *Memory abnormality (semantic and visual patterns) in schizophrenia*
Tatiana D. Savina, Olga V. Gerasimova, Vera A. Orlova, Nina P. Tscherbakova
- 152.** *Neurophysiological Deficits in Prodromal and Recent-Onset Schizophrenia*
Carol Jahchan, Kristin Cadenhead, David Braff, Gregory Light
- 153.** *Visual event-related P3a from passive task in patients with schizophrenia*
Yang-Whan Jeon, E-Jin Park, Jung-Seo Yi, Seung Hyun Kim
- 154.** *N2 event-related potential in schizophrenia – diffusion in time and space*
Stefan Kaiser, Mirjam Rentrop, Alexander Roth, Katlehn Rodewald, Joe Simon, Stephan Walther, Matthias Weisbrod
- 155.** *Disturbances in executive control in patients with schizophrenia*
Menahem I. Krakowski, Pierfillipo De Sanctis, John Foxe



- 156.** *The medial prefrontal and orbitofrontal cortices interact to regulate neuronal activity in nucleus accumbens subregions.*
Daniel J. Lodge
- 157.** *Cortical Thickness Deficits and Gamma Band Oscillations in Schizophrenia*
Sharmili Sritharan, Christine Gruetzner, Anna Rotarska-Jagiela, Wolf Singer, Peter J. Uhlhaas
- 158.** *Increased Serum BDNF Induced by Cognitive Training in Schizophrenia is Negatively Associated with Baseline SAA*
Alexander Genevsky, Melissa Fisher, Coleman T. Garrett, Colleen Cook, Sophia Vinogradov
- 159.** *Duration of untreated psychosis and ethnicity*
Bouke Sterk, Eline Slief, Kay Lankveijer, Don Linszen, Lieuwe de Haan
- 160.** *Is Serine Recemase An Indicator of Schizophrenia?*
Deepak Kumar, Rukhsana Navoaz, Kaneez Fatima
- 161.** *BDNF mRNA expression of peripheral blood mononuclear cells was decreased in patients with schizophrenia*
Bun-Hee Lee, Yong-Ku Kim
- 162.** *TH-1/TH-2 cytokine imbalance more pronounced in neuroleptic-naïve first episode schizophrenia*
Berko Milleit, Christine Milleit, Uta-Christina Hipler, Kristin Rödiger, Diana Neuhaus, Heinrich Sauer, Stefan Smesny
- 163.** *Does stress contribute to inflammatory and metabolic abnormalities in first episode psychosis?*
Valeria Mondelli, Monica Aas, Martino Belvederi Murri, Marta Di Forti, Helen Fisher, Rowena Handley, Nilay Hepgul, Tiago Reis Marques, Craig Morgan, Heather Taylor, Katherine J Aitchison, Paola Dazzan, Robin M Murray, Carmine M Pariante
- 164.** *HPA (hypothalamus, pituitary, adrenal gland) Axis and Oxidative Stress in Early Phases of Psychosis.*
Dorte Nordholm, Birte Glenthoj, Paola Dazzan, Valeria Mondelli, Henrik Poulsen, Carmine Pariante, Merete Nordentoft
- 165.** *Elevated serum sphingomyelin associates with reduced gray matter density: Evidence from twins discordant for schizophrenia*
Matej Oresic, Tuulikki Seppänen-Laakso, Sebastian Therman, Daqiang Sun, Jing Tang, Ulla Mustonen, Theo G.M. van Erp, Marko Sysi-Aho, Jaana Suvisaari, Leena Peltonen, Matti Huttunen, Arthur Thompson, Arthur W Toga, Jaakko Kaprio, Jouko Lönnqvist, Tyrone Cannon
- 166.** *Antioxidant status in first episodes of early onset psychosis compared with Asperger and healthy control adolescents.*
Mara Parellada, Juan C. Leza, Karina McDowell, Juan A. Micó, Carmen Moreno, Marisa Giraldez, Celso Arango

- 167.** *Microarray Analysis of Parvalbumin-Containing Inhibitory Neurons in the Superior Temporal Gyrus in Schizophrenia*
Charmaine Y. Pietersen, Maribel P. Lim, Jack Chen, Robert Stephens, Robert M. McCarley, Tsung-Ung W. Woo
- 168.** *Selection of Reference Gene Expression in a Schizophrenia Brain Cohort*
Debora A. Rothmond, Samantha J. Fung, Jenny Wong, Carlotta Duncan, Shan-Yuan Tsai, Cynthia S. Weickert
- 169.** *Proteomic Analysis of the Basic Sub-proteome (pH 6-11) in the Hippocampus in Schizophrenia and Bipolar Affective Disorder.*
Klaus Oliver Schubert, Melanie Föcking, Patrick Dicker, Michael J. Dunn, David R. Cotter
- 170.** *Neurological Soft Signs in schizophrenia and the influence of Family History and Schizotypal Personality: A family-based study*
Helen Vossen, Salvador Miret, Mar Fatjó-Vilas, Silvia Campanera, Neus Barrantes-Vidal, Victor Peralta, Lourdes Fañanas
- 171.** *Algorithm-based treatment of First-Episode Schizophrenia: Response Rates over Three second-Generation Antipsychotic Trials*
Ofer Agid, Tamara Arenovich, Gautam Sajeev, Robert B. Zipursky, Shitij Kapur, George Foussias, Gary Remington
- 172.** *Proteomic and functional analysis suggests that 5-HT₆ receptors compromise cognition by recruiting mTOR.*
Clotilde Mannoury La Cour, Julie Meffre, Martial Séveno, Mark J Millan, Anne Dekeyne, Joel Bockaert, Philippe Marin
- 173.** *Compound 1, a Potent and Selective DAO Inhibitor, Demonstrates Efficacy in Several Preclinical Animal Models of Schizophrenia*
Steven Grauer, Paul Dollings, Michael Popiolek, Mark Pausch, Joseph Zaccardi, Julie Brennan, Rachel Navarra, Keith Pitts, Girija Krishnamurthy, Karen Marquis, John Butera, Nicholas Brandon
- 174.** *A three arm dose finding study of lurasidone: Efficacy and tolerability data*
Philip D. Harvey, Mitsukuni Murasaki, Josephine Cucchiaro, Masaaki Ogasa, Antony Loebel
- 175.** *A double blind, placebo controlled study of the safety and tolerability of quetiapine 1200 mg/d versus 800 mg/d in patients with persistent symptoms of schizophrenia or schizoaffective disorder*
William G. Honer, G. William MacEwan, Alain Gendron, Emmanuel Stip, Alain Labelle, Richard Williams, Hans Eriksson
- 176.** *Schizotypal personality in healthy adults is related to blunted HPA axis reactivity*
Hiroaki Hori, Toshiya Teraishi, Yuji Ozeki, Junko Matsuo, Yumiko Kawamoto, Yukiko Kinoshita, Shiho Suto, Teruhiko Higuchi, Hiroshi Kunugi
- 177.** *The pharmacological management of agitated patients in emergency psychiatric hospitals in Rio de Janeiro - Brazil: the results of two pragmatic randomized clinical trials.*
Gisele Huf, Evandro S. F. Coutinho, Clive E. Adams



- 178.** *Investigation the role of dopamine D1 and 5-HT1A receptors in the reversal of sub-chronic phencyclidine induced deficits in cognition and social behavior, by the atypical antipsychotic clozapine*
Nagi Idris, Ben Grayson, Mike Harte, Jo Neill
- 179.** *Effects of Add-on Mirtazapine on Neurocognition in Schizophrenia: an Open Label Extension Phase of a Double-Blind, Randomized, Placebo-Controlled Study, and Both Phases.*
Jan H Stenberg, Viacheslav Terevnikov, Marina Joffe, Jari Tiihonen, Evgueni Tchoukhine, Mark Burkin, Grigori Joffe
- 180.** *Anti-depressive effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone: A randomized, naturalistic study.*
Erik Johnsen, Rune A. Kroken, Hugo A. Jørgensen
- 181.** *Gene Expressions in Frontal Cortex of Rats Induced by Chronic Administration of Risperidone*
KwangSoo Kim, Won Myoung Bark
- 182.** *A Double-Blind, Randomized, Risperidone-comparative Study to Evaluate the Efficacy and Safety of Blonanserin in patients with Schizophrenia*
Seunghyun Kim, Jaewon Yang, Yangwhan Jeon, Wonmyong Bahk, Yongku Kim, Heecheol Kim, Junsoo Kwon, Heeyeon Jung, Chanhyung Kim, Sangyeol Lee, Younghoon Kim, Jungseo Yi, Dukin Jon, Hyunsang Cho, Seunghwan Lee, Bohyun Yoon
- 183.** *Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia*
Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Kyung-Yeol Bae, Su-Jin Yang, Jin-Sang Yoon
- 184.** *LY2140023 Monohydrate: An Agonist at the mGlu2/3 Receptor for the Treatment of Schizophrenia*
Bruce J. Kinon, Lu Zhang, Judy E. Williams, Olawale O. Osuntokun, Brian A. Millen, Sara Kollack-Walker
- 185.** *The Pharmacology of Cariprazine, a Novel D3-Preferring D3/D2 Antagonist-Partial Agonist Antipsychotic*
Bela Kiss, Nick Seneca, Judit Szikra, Zsolt Nemethy, Katalin Saghy, Judit Laszy, Istvan Gyertyan
- 186.** *Large effect of baseline treatment with long acting antipsychotic drugs on randomized treatment outcomes*
Thomas Barnes, Peter Jones, Graham Dunn, Karen Hayhurst, Richard Drake, Shon Lewis
- 187.** *The addition of tiagabine to antipsychotic medication in the treatment of recent-onset schizophrenia by modification of developmental pruning of prefrontal circuitry*
Hannah M Liebman, Wilson Woo
- 188.** *Analysis of the effects of ketamine and phencyclidine on attention and working memory in rats*
Kirstie J. Lloyd, Julie K. Foss, Janice W. Smith
- 189.** *Assessment of the Maximum Tolerated Dose (MTD) of Lurasidone in Patients With Schizophrenia*
Larry Ereshefsky, Stanford Jhee, Debra Phillips, Myron Peterson, Masaaki Ogasa, Lev Gertsik, Antony Loebel

- 190.** *Pro-cognitive effects of metabotropic glutamate receptor (mGluR)2/3 and 5 agonists in rats: a comparison to GlycineB/NMDA receptor modulators*
Florence Loiseau, Sylvie Girardon, Dorothée Sicart, Anne Dekeyne, Mark J. Millan
- 191.** *Changes in the enteroendocrine and neuroendocrine axes in patients with weight gain during treatment with antipsychotics.*
Anna Madsen, Henrik B. Mortensen, Birgitte Søgaard, Henrik Lublin
- 192.** *Contemporaneous improvement of cognitive dysfunctions and psychotic symptoms in drug naive acute psychosis with aripiprazole*
Masatsugu Moriwaki, Taro Kishi, Osamu Furukawa, Kiyoshi Fujita, Nakao Iwata
- 193.** *Partial agonists in schizophrenia – why some succeed and others don't. Insights from preclinical comparisons.*
Sridhar Natesan, Greg G. Reckless, Karen B.L. Barlow, Jose N. Nobrega, Shitij Kapur
- 194.** *Open Poster Board*
- 195.** *A Flexible-dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Oral Risperidone*
Andreas Schreiner, Dagmar Hoeben, Marjolein Lahaye, Christophe Tessier, Theodore Tzotzoros, Jacques Louvrier, Lars Helldin, Nesrin Dilbaz, D. Naber, Laisve Dembinskiene
- 196.** *A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia*
Andreas Schreiner, Peter Korcsog, D.J.H. Niehaus, Kaire Adamsoo, Alp Ücok, Manuel Franco, P. Theodoropoulou, R. Salinas, Paul Bergmans, Dagmar Hoeben, Christophe Tessier
- 197.** *Suicide attempts in the SCoP study*
Marc-Antoine Crocq, Aurélia Mittoux, Per Tanghøj, Dieter Naber
- 198.** *The Profile of Cognitive Impairment in Schizophrenia: Implications for Therapeutic Treatment Strategies*
Keith Wesnes, Helen Brooker, Chris Edgar, Howard Hassman
- 199.** *Serum BDNF levels are determined by functional polymorphism Val66Met and associated with cognitive impairment in chronic schizophrenia*
Mei H Xiu, Xiang Y Zhang
- 200.** *The initial phase of therapy with clozapine: beyond white blood cell screening*
Dan Cohen
- 201.** *Prevalence and severity of antipsychotic related constipation*
Marc A F De Hert, Bie Peuskens, Liesbeth Dockx, Kim Sweers, Stefan Leucht, Joseph Peuskens
- 202.** *Prolactin serum levels in institutionalized schizophrenic patients.*
Ricardo Gallardo, Emilio González, Carlota Botillo, Fidel García, Carlos F. Salgado, Ignacio Herreros, Guillermo Hoyos



- 203.** *Tardive Dyskinesia and other movement disorders in First Episode Schizophrenic Patients treated with Second Generation Antipsychotics.*
Carlos Garcia-Ribera, Natasha Bennett, Melissa Naraine, Serge Sevy, Delbert Robinson
- 204.** *Adolescent rats show a reduced neurochemical reaction compared to adults in response to cannabinoid administration.*
Victoria S. Dalton, Katerina Zavitsanou
- 205.** *Redox dysregulation affects parvalbumine interneuron's integrity and neural synchronisation in ventral but not dorsal hippocampus*
Jan-Harry Cabungcal, Pascal Steullet, Anita Frank, Rudolf Kraftsik, Chen Ying, Timothy P. Dalton, Michel Cuenod, Kim Q. Do
- 206.** *Adult-onset glutamate receptor expression deficits in the hippocampus of glutaminase-deficient mice*
Inna Gaisler-Salomon, Yvonne Wang, Scott M McKinney, Amy J Ramsey, Etienne Sibille, Stephen Rayport
- 207.** *The puzzle box as simple and efficient behavioral test for impairments of general cognition and executive functions in mouse models of schizophrenia*
Peter Gass, Nada BenAbdallah, Johannes Fuss, Massimo Trusel, Mike Galsworthy, Robert Deacon, Marco Riva, Christoph Kellendonk, Rolf Sprengel, Hans-Peter Lipp
- 208.** *Is there a relationship between Toxoplasma gondii and psychiatric disorders?*
Selina A. Henriquez, David M. Thompson, Fiona L. Henriquez, James Alexander, Judith Pratt, Ros Brett, Craig W. Roberts
- 209.** *The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.*
Caitlin A. Jones, Janice W. Smith, Angus M. Brown, Dorothee P. Auer, Kevin C. F. Fone
- 210.** *Cannabinoids: environmental risk factors for a neuregulin 1 mouse model for schizophrenia?*
Tim Karl, Rose Chesworth, Jonathon Arnold, Leonora Long
- 211.** *Effects of systemic phencyclidine on neuronal activity of ventral tegmental area in a classical conditioning paradigm*
Tadahiro Katayama, Eiichi Jodo, Masahiro Okamoto, Yoshiaki Suzuki, Ken-Yo Hoshino, Yukihiro Kayama
- 212.** *The Effects of the Cannabinoid CB2 Receptor Antagonist, AM630, on Isolation Rearing-Induced Behavioural Deficits in rats.*
Asma Khan, David A. Kendall, Kevin C. F. Fone
- 213.** *The timing of prenatal immune challenge determines the extent of white matter microstructural anomalies relevant to schizophrenia.*
Grainne M. McAlonan, Charlton Cheung, Qi Li, Cheung Vinci, Edward S.K. Hui, Wei Ran, Priscilla Wong, Siew E. Chua, Ed. X. Wu

- 214.** *Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis*
Urs Meyer, Irene Knuesel, Myriel Nyffeler, Joram Feldon
- 215.** *The effect of non-competitive NMDA receptor antagonist MK801 on hippocampus-prefrontal cortex synaptic responses and executive cognitive function in rats*
Kevin Blot, Shin-ichi Kimura, Anne Kemp, Denise Manahan-Vaughan, Bruno Giros, Satoru Otani
- 216.** *Targeting planning and problem solving versus basic cognition in cognitive remediation for patients with schizophrenia*
Matthias Weisbrod, Katlehn Rodewald, Mirjam Rentrop, Daniel Holt, Daniela Roesch-Ely, Matthias Backenstrass, Joachim Funke, Stefan Kaiser
- 217.** *Feasibility Study of Multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN)*
Richard Keefe, Sophia Vinogradov, Alice Medalia, Peter Buckley, Stanley Caroff, Deepak D'Souza, Phillip Harvey, Karen Graham, Steve Marder, Del Miller, Steve Olson, Jayendra Patel, Dawn Velligan, Trina Walker, Adam Haim, Scott Stroup
- 218.** *Conceptual background of imaging studies in psychotherapy research: the example of CBT interventions in patients with schizophrenia*
Tilo Kircher, Axel Krug, Henrik Walter, Georg Winterer, Bernhard Müller, Jutta Herrlich, Georg Wiedemann, Kai Vogeley, Andreas Wittorf, Alexander Rapp, Stefan Klingberg
- 219.** *Attributional reasoning biases, paranoia and depression in first-episode schizophrenia*
Robyn A Langdon
- 220.** *Schema Questionnaires: psychometric properties and associations with symptoms in a psychotic population receiving CBT*
Natalie J Maples, Elisa M Medellin, Xueying Li, Dawn I Velligan
- 221.** *Admixture analysis of Age at onset in Schizophrenia and Schizophrenia Spectrum Disorders*
Vincenzo De Luca, Rahul Manchanda, Ross Norman
- 222.** *Workshops The DJ's choices: An interactive program to support adherence in patients with first psychotic episode.*
Marie-France Demers, Julie Bourbeau, Jacinthe Leblanc, Lysanne Gauthier, Véronique Vachon
- 223.** *A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After 2 Years in First-episode Schizophrenia*
Lupe Martinez, Robin Emsley, Piet Oosthuizen, Liezl Koen, Dana Niehaus
- 224.** *A meta-analytic study on cognition and functional outcome in non- affective psychosis: much variance left unexplained*
Anne-Kathrin Fett, Maria de Gracia Dominguez, Wolfgang Viechtbauer, David Penn, Jim van Os, Lydia Krabbendam



- 225.** *Cognitive Dysfunction after Recovery from Schizophrenia*
Amresh Shrivastava, Megan E. Johnston, Nilesh Shah, Meghana Thakar, Larry Stitt
- 226.** *Using the IPAP Algorithm to Predict Time to Treatment Response in Recent-Onset Schizophrenia*
Monica Kayo, Ivson Tassell, Vivian Y. Hiroce, Anny K.P.M. Menezes, Graça M. Oliveira, Sandra Iso, Helio Elkis
- 227.** *Validating an Industry-sponsored Model Comparing the Cost-effectiveness of Atypical Antipsychotics in the Treatment of Schizophrenia*
Christopher N. Graham, Josephine Mauskopf, Anthony H. Lawson, Haya Ascher-Svanum, David Bruhn, Peter R. Watson
- 228.** *The Malaga Schizophrenia case-register (RESMA): Follow-up analysis of a schizophrenic cohort and their pathways in specialist mental health care: Hospitalization as a measure of outcome*
Fermin Mayoral, Olga Perez, Francisco Becerra, Rocio Dominguez, Berta Moreno
- 229.** *Longitudinal study of first-episode psychosis within the Université de Montréal network: 3 years outcome*
Clairéline Ouellet-Plamondon, Luc Nicole, Amal Abdel-Baki, Béatrice Granger, Laurence Artaud, Emmanuel Stip, Alain Lesage, Pierre Lalonde
- 230.** *Relationships among Multiple Outcome Measures in the Study of Schizophrenia*
Lei Chen, Glenn A. Phillips, Joseph Johnston, Virginia Stauffer, Bruce J. Kinon, Haya Ascher-Svanum, Sara Kollack-Walker, Paul Succop, Dieter Naber
- 231.** *Concordance between measures of functioning, symptomatology and change: GAF, CGI-S, CGI-C and PANSS*
Jonathan Rabinowitz, Stephen Levine, Guadalupe Martinez
- 232.** *Improvement in Polypharmacy after introduction of treatment algorithm*
Rajaprabhakaran Rajarethinam, Julie Paavola, Fahd Syed, Beena Philip, Darrin Hanna, David Ballenberger, Matcheri Keshavan
- 233.** *Recent characteristics of suicide and suicidal behavior in patient with schizophrenia*
Kenji Yamamoto, Michiko Takai-Kamiya, Hiroaki Yamamoto, Seiichi Tatematsu, Masami Yukawa-Inui, Shingo Miyaji, Yumi Iwamitsu, Hitoshi Miyaoka
- 234.** *Attitudes toward schizophrenia in the general population, psychiatric staff, physicians, and psychiatrists: A web-based survey in Japan*
Hiroaki Hori, Misty Richards, Hiroshi Kunugi
- 235.** *The Temporal Stability and the Determinants of Subjective Well-being under Antipsychotic Medication in First-Episode Psychosis*
Ally Ryder, Tim J. Lambert, Alex Blaszczyński
- 236.** *Open Poster Board*
- 237.** *Open Poster Board*

- 238.** *The Effects of Experiencing Simulated Auditory Hallucinations on Attitudes to Schizophrenia in Final Year Medical Students*
Cherrie A. Galletly, Cassandra A. Burton
- 239.** *Vicarious embarrassment and vicarious shame experiences in schizophrenia.*
Sören Krach, Jana Montag, Bernd Hanewald, Christian Schales, Tilo Kircher, Frieder Paulus
- 240.** *Theory of mind impairment in schizophrenia reflects a difficulty in perspective-taking*
Robyn Langdon
- 241.** *Predictors and correlates of optimism in individuals with a severe mental illness*
Tania Lecomte, Marc Corbière, Laurence Thérout
- 242.** *Going back to work or to study after a first-episode psychosis : the impact of an early intervention program over 5 years*
Amal Abdel-Baki, Genevieve Letourneau, Albert Ng, Caroline Morin
- 243.** *The Development of the Mental-State Reasoning Training (MSR) Program: Phase I and II*
Pamela J. Marsh, Robyn Langdon, Jonathan McGuire, Anthony Harris, Gemma Lockett, Vince Polito, Max Coltheart
- 244.** *Structural and Semantic Aspects of Dyadic Discourse in Schizophrenia and Asperger: Similarities and Divergencies*
Jussi Niemi, Pertti Hella, Lidia Otsa, Aleksandra Evtyukova, Mira Lakkonen, Maija Koivukangas, John Niemi
- 245.** *Personality traits and schizophrenia: evidence from a case-control study and meta-analysis*
Kazutaka Ohi, Ryota Hashimoto, Yuka Yasuda, Motoyuki Fukumoto, Naomi Iike, Hidenaga Yamamori, Hitoshi Tanimukai, Shinji Tagami, Takashi Morihara, Masayasu Okochi, Toshihisa Tanaka, Takashi Kudo, Masao Iwase, Hiroaki Kazui, Masatoshi Takeda
- 246.** *The Challenge of Patient Ascertainment in Clinical Trials - New Data*
Michael Detke, Janet Williams, Kenneth Kobath, Amy Ellis, Earl Giller, Andrew Leon, Scott Reines, John Kane
- 247.** *Using the Global Functioning Social and Role Scales in a First Episode Sample*
Danijela Piskulic, Jean Addington, Andrea A. Auther, Barbara A. Cornblatt
- 248.** *Staff attitudes towards schizophrenia, ward atmosphere and the use of seclusion and restraint*
Eila S. Sailas, Hanna Putkonen, Toshie Noda, Grigori Joffe
- 249.** *Do Cognitive Status and Motivation Predict Treatment Utilization in Cognitive Remediation Groups for Individuals with Schizophrenia?*
Alice Medalia, Amanda Gooding, Monica Rivera Mindt, Jimmy Choi
- 250.** *The influence of individual and contextual factors on quality standards of continuity of care for adults with schizophrenia living in the USA*
Joseph M. Guada, Cynthia Fontanella, Suzanne Bartle-Haring, Gary Phillips



- 251.** *Impact of initial hospitalization on 3-year outcome in patients with first episode psychosis in Hong Kong*
May M.L. Lam, Jennifer Y.M. Tang, Cindy P.Y. Chiu, Christy L.M. Hui, Gloria H.Y. Wong, C.W. Law,
Dicky W.S. Chung, Kathy PM Chan, Steve Tso, SF Hung, Eric YH Chen
- 252.** *Assertive Community Treatment (ACT) as part of Integrated Care versus Standard Care: a 12-month trial in patients with first- and multiple-episode schizophrenia-spectrum disorders treated with quetiapine IR (ACCESS trial)*
Martin Lambert, Dieter Naber, Benno Schimmelmann
- 253.** *"Too much": A multivariate predictive model of attitudes to use of LAI antipsychotics.*
Tim J. Lambert
- 254.** *Model based meta-analysis of Positive and Negative Syndrome scale (PANSS Negative subscale) in stable chronic schizophrenic patients for monotherapy and adjunct therapies*
Sima Ahadiéh, Jing Liu, Anindita Banerjee, Nicholas DeMartinis, Thomas G. Tensfeldt
- 255.** *The association between semantic categorization deficit and symptoms in first-episode schizophrenia*
Christy L.M. Hui, Eric Y.H. Chen, Eva L.W. Dunn, May Y.K. Miao, W.S. Yeung, C.K. Wong, W.F. Chan,
W.N. Tang
- 256.** *Open Poster Board*
- 257.** *Exploring Schizotypy*
Michael P. Kelley
- 258.** *Vitamin D levels and cardiometabolic status in patients with psychotic disorders.*
Tim J. Lambert, Roger Chen, Libby Dent, Jeff Snars
- 259.** *Perceived Stigma and Recovery for Korean Schizophrenics in Psychiatric Rehabilitation Centers: A Comparison between the Club House Model and the Rehabilitation Skills Training Model*
Gyungsook Lee, Sookhee Jung
- 260.** *Saliency, anhedonia, and the intermediate phenotypes of schizophrenia*
Richard J. Linscott, Sarah E. Morton, Lucy M. Devlin, Chew Wuei Chong, Neil McNaughton
- 261.** *Specific program for intervention in Incipient Psychosis introduced in Catalonia (Spain)*
Montse S. Moix, Teresa F. Garcia, Monica A. Sentis, Xavier L. Grau, Joan F. Barceló, Francisca M. Bosch
- 262.** *Ultra High Risk (UHR) for psychosis groups: Are there different levels of risk for transition to psychosis?*
Barnaby Nelson, Kally Yuen, Hok Pan Yuen, Alison Yung
- 263.** *Metacognitive thinking and auditory hallucinations in ultra-high risk individuals: An experience sampling study.*
Jasper E. Palmier-Claus, Shon W. Lewis, Graham D. Dunn, Tony A. Morrison, Hannah E. Taylor

- 264.** *The Cognitive Biases Questionnaire for Psychosis (CBQp)*
Emmanuelle Peters, Steffen Moritz, Zoe Wiseman, Kathryn Greenwood, Elizabeth Kuipers, Mathias Schwannauer, Catherine Donaldson, Ruth Klinge, Kerry Ross, Rebecca Ison, Sally Williams, Jan Scott, Aaron Beck, Philippa Garety
- 265.** *Social Cognition in Schizophrenia: A Quantitative Review of the Literature*
Danijela Piskulic, Jean Addington, Paul Maruff
- 266.** *Exploring the biology of iloperidone responder profiles in treatment of schizophrenia using a mechanistic disease model*
Hugo Geerts, Athan Spiros, Robert Carr
- 267.** *Evidence for aberrant salience network connectivity during information processing in schizophrenia*
Thomas P White, Verghese Joseph, Susan T. Francis, Peter F. Liddle
- 268.** *Do social and cognitive dysfunctions mediate the association between advanced paternal age and schizophrenia?*
Mark Weiser, Nomi Werbeloff, Avi Reichenberg, Rinat Yoffe, Gadi Lubin, Asaf Caspi, Michael Davidson
- 269.** *Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia*
Ignacio Mata, Rocio Perez-Iglesias, Roberto Roiz-Santianez, Diana Tordesillas-Gutierrez, Andres Gonzalez-Mandly, Ana Berja, Jose L. Vazquez-Barquero
- 270.** *A Study Comparing the MATRICS Battery with the CDR System in Schizophrenia*
Keith Wesnes, Helen Brooker, A. Eden Evins



Posters, Tuesday 13 April

1. *Clinical relevance of self-disorders (Ich-Störungen) in schizophrenia: a review of studies on diagnosis, factor structure and outcome.*
Konstantinos Papageorgiou, A. Oliver Pintsov
2. *The Social Environment matters! Hearing impairment and psychosis, the role of social exclusion and social complexity*
Margriet van der Werf, Ruud van Winkel, Jim van Os
3. *Cycloid Psychosis and Brief Psychotic Disorder: a comparative study.*
Rafael Rodríguez, Alba Roca, Cristina Pujol, Irene Ramos, Sara Cardona, Cristina Marqueta, Yesika Galindo, Benjamín Piñero
4. *The Prevalence of Anxiety Disorders in Schizophrenia. A Meta-Analysis and Critical Review on a Significant Association.*
Marc-André Roy, Amélie Achim, Roch-Hugo Bouchard, Éric Raymond, Chantal Mérette, Michel Maziade
5. *Psychotypal disorder: Criteria for a new psychosis spectrum category covering risk-state related clinical syndromes*
Stephan Ruhrmann, Frauke Schultze-Lutter, Joachim Klosterkötter
6. *DSM-V: Implications for schizophrenia research*
Carol Silberberg
7. *Three levels of rater performance in standardized PANSS training.*
Graciete Lo, William C. Yavorsky, Mark G.A. Opler, Ashleigh DeFries
8. *Paranoia, Schizotypy, and Social Anxiety: Factor Structure and Experience in Daily Life*
Leslie H. Brown, Neus Barrantes-Vidal, Thomas R. Kwapił
9. *Coping with stigma while caring for a family member with first-episode psychosis: The experience of first-time primary caregivers.*
Terence V. McCann, Dan I. Lubman, Eileen Clark
10. *Factor Structure of Clinical Symptoms in 197 Consecutive Cases of First Episode Psychoses*
L. Kola Oyewumi, Christopher R. Bowie
11. *The theoretical basis of self-disorders (Ich-Störungen) in schizophrenia: a review of neurobiological and neuropsychological studies.*
Konstantinos Papageorgiou, A. Oliver Pintsov
12. *Personality in the Spectrum: the elusive face of vulnerability*
Andrea Raballo, Josef Parnas

- 13.** *First Rank Symptoms in First Episode Psychosis and their Relationship to the Duration of Untreated Illness*
Nicolas M. Ramperti, Mansoor Anwar, Niall Turner, Sharon Foley, Stephen McWilliams, Deirdre Jackson, Laoise Renwick, Caragh Behan, Marie Sutton, Niall Turner, Anthony Kinsella, Eadbhard O'Callaghan
- 14.** *Proverbs and nonliteral language in schizophrenia: a systematic methodological review of all studies published 1931-2010*
Alexander Rapp, Phoebe Schmierer
- 15.** *Basic symptom and ultra-high risk criteria in the prediction of first-episode psychosis*
Stephan Ruhrmann, Frauke Schultze-Lutter, Joachim Klosterkötter
- 16.** *The role of personality disorder and accentuation in the conversion to psychosis*
Frauke Schultze-Lutter, Joachim Klosterkötter, Stephan Ruhrmann
- 17.** *Assessment of Smell Function in Schizophrenia during Acute Psychotic Episode and Correlation with Clinical Symptomatology*
Rael Strous, Netta Shoenfeld, Nancy Agmon-Levin, Revital Mann, Bat-Sheva Katz Porat, Yehuda Shoenfeld
- 18.** *Inhomogeneity of the nondeficit syndrome among patients with schizophrenia*
Istvan Szendi, Mihaly Racsmány, Gabor Csifcsak, Zoltan A Kovacs, Nora Domjan, Gyorgy Szekeres, Csongor Cimmer, Gabriella Galsi, Krisztina Boda, Gergely Gulyas, Jozsef Dombi, Zoltan Janka
- 19.** *Impact of substance use disorder on functional outcome in first-episode psychosis: a 2 years prospective study within the Université de Montréal network*
Emilie Salvat, Amal Abdel-Baki, Luc Nicole, Stéphane Potvin, Clairéline Ouellet-Plamondon, Laurence Artaud, Béatrice Granger, Emmanuel Stip, Alain Lesage, Pierre Lalonde
- 20.** *First-episode psychosis: gender differences in substance use*
Luis San, Belen Arranz, Victor Perez, Bernardo Sanchez, Montse Dolz, Marta Pardo, Enric Alvarez
- 21.** *Cognition and Impulsivity Related Brain Volume Changes in Schizophrenia-Addiction Co-morbidity*
Boris Schiffer, Bernhard W. Müller, Elke R. Gizewski
- 22.** *Cognitive, executive and social functioning in schizophrenia with and without comorbid cannabis use.*
Brin FS Grenyer, Colleen M Respondek, Susan Gordon, Natalie Potter, Nadia Solowij
- 23.** *Alterations of hippocampal shape in cannabis users with and without schizophrenia.*
Nadia Solowij, Mark Walterfang, Colleen Respondek, Sarah Whittle, Brin Grenyer, Valentina Lorenzetti, Alex Fornito, Dan Lubman, Dennis Velakoulis, Christos Pantelis, Murat Yücel
- 24.** *Brief Schizophrenia Addiction Scale (BSAS): a pilot study*
Martin L. Vargas, Sonia Lopez-Lorenzo
- 25.** *Cigarette smoking in patients with schizophrenia in China: a prospective, multi-center study*
YT Xiang, Chuan-Yue Wang



- 26.** *Profile of polysubstance abusers with the acute psychotic episode*
Milan Zdravkovic
- 27.** *The Australian Schizophrenia Research Bank (ASRB): An example of eResearch*
Frans Henskens, Vaughan Carr, Stan Catts, Assen Jablensky, Patricia Michie, Carmel Loughland, Kathryn McCabe, Bryan Mowry, Aslam Nasir, Christos Pantelis, Paul Rasser, David Paul, Jacki Richards, Ulrich Schall, Rodney Scott
- 28.** *Influence of gender and age on schizotypal personality features in a non-clinical sample of university students*
Leila Gassab, Aymen Lahmar, Slah Smairi, Fawzia Beltaief, Lotfi Gaha, Anwar Mechri
- 29.** *Prevalence and burden of at-risk criteria of psychosis and help-seeking behaviour – a population survey – prevalence*
Frauke Schultze-Lutter, Chantal Michel, Noemi Schaffner, Benno G. Schimmelmann
- 30.** *Influence of paternal age in schizophrenia*
Franck schurhoff, Alexandre Hubert, Andrei Szoke, Alexandre Meary, Marion Leboyer
- 31.** *The influence of maternal sensitivity, parental relationship and childhood sexual abuse on adult delusional-like experiences: a birth cohort study*
James G. Scott, John J. McGrath, Jake M. Najman
- 32.** *Schizophrenia and 1957 pandemic of influenza: meta-analysis*
Jean-Paul Selten, Aleida Frissen, Gerty Lensvelt-Mulders, Vera Morgan
- 33.** *Real-life use of sertindole: A Danish registry-based cohort analysis*
Marianne T. Severinsen, Alice Rouleau, Rikke B. Nielsen, Sinna P. Ulrichsen, Dominique Milea, Mette Nørgaard
- 34.** *Absolute Risk versus Risk Ratio in Framingham Scoring Algorithm for Prevention of Cardiovascular Risk*
Cynthia Siu, Carla Brambilla
- 35.** *Invariance testing of the 4-factor solution of Schizotypal Personality Questionnaire across age, sex and ethnicity.*
Richard P. Smallman, Alex Wood, John. Maltby, Emma Barkus, Shon Lewis, Teresa Rushe
- 36.** *A population-based elaboration on premorbid functioning in schizophrenia during the Early Teenage Years: Comparison, Incidence and Onset*
Vardit zerem ullman (PhD), Stephen Z. Levine (PhD), Jonathan Rabinowitz (PhD)
- 37.** *Childhood trauma, FKBP5 and risk of psychosis.*
Ruud van Winkel, Marieke Wichers, Gunter Kenis, Catherine Derom, Evert Thiery, Jim van Os, Inez Myin-Germeys

- 38.** *Detection of subjects with prodromal syndrome for psychosis in a general population sample*
Juha Veijola, Pirjo Mäki, Erika Jääskeläinen, Graham Murray, Peter Jones, Jouko Miettunen
- 39.** *Activities of daily living, social functioning and their determinants in persons with psychotic disorder*
Satu Viertiö, Annamari Tuulio-Henriksson, Jonna Perälä, Samuli I. Saarni, Seppo Koskinen, Marja Sihvonen, Jouko Lönnqvist, Jaana Suvisaari
- 40.** *Gender Differences Among Schizophrenic Differences Among Schizophrenic Patients Admitted to the Psychiatric Emergency Room and the Insufficiency of Outpatient Care in Brazil*
Fernando M. Volpe, Eliane M. Silva, Terezinha N. Santos, Daniel E. Freitas
- 41.** *Risk for suicide among individuals with schizophrenia*
Nomi Werbeloff, Abraham Reichenberg, Gad Lubin, Rinat Yoffe, Assaf Caspi, Michael Davidson, Mark Weiser
- 42.** *Examining interactions between risk factors for schizophrenia*
Stanley Zammit, Glyn Lewis, Christina Dalman, Peter Allebeck
- 43.** *High prevalence of psychosis continuum in a highly urbanized area of Turkey: TürkSch study*
Tolga Binbay, Hayriye Elbi, Feride Aksu, Ferda Özkinay, Hüseyin Önay, Marjan Drukker, Jim van Os, Köksal Alptekin
- 44.** *Neuroanatomical Correlates of Dermatoglyphic Complexity Index in Antipsychotic-naïve Schizophrenia*
Naren P. Rao, Ganesan Venkatasubramanian, Sunil V. Kalmady, Rishikesh V. Behere, Rashmi Arasappa, Bangalore N. Gangadhar
- 45.** *Cortisol responsivity and prodromal symptoms among individuals at clinical high risk for psychosis*
Gisela Sugranyes, Judy Thompson, Renee Saenger, Scott Schobel, Anjali Singh, Lauren Bodkin, Cheryl M. Corcoran
- 46.** *The effect of extreme prematurity and very low birth weight in early developmental markers: A Dermatoglyphic Study*
Nadia Vilahur, Matthew P. G. Allen, Muriel Walshe, Chiara Nosarti, Larry Rifkin, Robin Murray, Araceli Rosa
- 47.** *A Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Flexibly dosed Oral Ziprasidone in Adolescent Subjects with Schizophrenia*
Robert L. Findling, Idil Cavus, Elizabeth Pappadolulos, Mary Backinsky, Jeffrey H. Schwartz, Douglas G. Vanderburg
- 48.** *Correlations between hippocampal volumes and memory performance in early onset schizophrenia*
Monica Juuhl-Langseth, Rune Thormodsén, Inge-André Rasmussen jr, Lars M. Rimol, Aina Holmén, Ingrid Agartz, Bjørn R. Rund
- 49.** *Neural Correlates of Verbal Working Memory Dysfunction in Early-Onset Schizophrenia: A Functional Magnetic Resonance Imaging Study.*
Marinos Kyriakopoulos, Danai Dima, Matthew Kempton, Sophia Frangou



- 50.** *Evidence mapping for early psychotic disorders in young people*
Ping Liu, Alexandra Parker, Sarah Hetrick, Rosemary Purcell
- 51.** *Cognition and psychosocial functioning in adolescents with schizophrenia*
Olga Puig, Imma Baeza, Vanessa Sánchez-Gistau, Rafael Penadés, Elena De la Serna, Laia Fonrodona, Miquel Bernardo, Josefina Castro-Fornieles
- 52.** *Higher rates of psychopathology in the children and adolescents at genetic high risk of Bipolar Disorder and Schizophrenia compared to healthy controls: preliminary results*
Vanessa Sanchez-Gistau, Elena de la Serna, Soledad Romero, Montse Vila, Inma Baeza, Fina Castro
- 53.** *Inter-rater reliability in the assessment of paediatric schizophrenia using the PANSS: training results from a Russian cohort.*
Mark GA Opler, Evgenia Ivanova, William C Yavorsky, Stacy Liechti, Gil Zalsman
- 54.** *Executive function impairments in schizophrenia in comparison with normal healthy controls*
Da Young Yun, Samuel S Hwang, Jung Seo Yi, Hee Yeon Jung
- 55.** *Neurocognitive functioning in schizophrenia spectrum disorders: Is there a difference between remitted and non-remitted patients?*
Alexandra Kaufmann, Alex Hofer, Georg Kemmler, Nicole Pfaffenberger, Maria A. Rettenbacher, Nursen Yalcin, Wolfgang W. Fleischhacker
- 56.** *Executive deficits in First Episode Psychosis accurately predict 90% of the final diagnosis of Schizophrenia: a longitudinal study.*
Natalia Ojeda, Javier Peña, Rafael Segarra, Pedro Sánchez, Edorta Elizagarate, Jose I. Eguiluz, Jesus Ezcurra, Miguel Gutierrez
- 57.** *Theory of Mind and Empathy: the two sides of the same coin?*
Ilaria Riccardi, Roberta Pacifico Pacifico, Paolo Stratta, Alessandro Rossi
- 58.** *Cognitive deficits as intermediate phenotype in schizophrenia*
Raffaella Romano, Barbara Gelao, Paolo Taurisano, Annamaria Porcelli, Marina Mancini, Annabella Di Giorgio, Grazia Caforio, Leonardo Fazio, Marco Colizzi, Luciana Lo Bianco, Apostolos Papazacharias, Gianluca Ursini, Marcello Nardini, Giuseppe Blasi, Alessandro Bertolino
- 59.** *Using schizotypy to investigate semantic memory deficits in schizophrenia*
Susan L. Rossell
- 60.** *NPAS3 and SOX family genes: Transcriptional control of neuronal proliferation and differentiation and its relation to psychiatric illness*
Li Sha, Marry Molly, Douglas Blackwood, Ben Pickard
- 61.** *Familial co-segregation of cognitive performance and negative symptoms in schizophrenia*
Armin Shazad, Piotr Quee, Cecile Henquet, GROUP* .

- 62.** *Study of neurological soft signs in Japanese schizophrenic patients.*
Tamiko Shibata, Mie Matsui, Satoshi Kobayashi, Ayumi Takeuchi, Raymond C Chan, Michio Suzuki, Tatsuru Shibata
- 63.** *Address Unknown: How a Story Reveals a Theory of Mind Deficit in Schizophrenia*
Emmanuel Stip
- 64.** *A self administered "ecological" questionnaire (BRIEF-A) provides a sensitive measure of executive deficits in schizophrenic subjects*
Ewa Bulzacka, Jeanne Vilain, Franck Schürhoff, Alexandre Méary, Marion Leboyer, Andrei Szöke
- 65.** *Social cognition in "ultra high risk" (putatively prodromal) and first episode psychosis cohorts: Preliminary findings on degree of impairment*
Andrew Thompson, Cali Bartholomeusz, Alicia Papas, Barnaby Nelson, Stephen Wood, Alison R. Yung
- 66.** *First-rank (passivity) symptoms: neuropsychological and neurophysiological performance, and social functioning*
F. Waters, A. Jablensky
- 67.** *Bias or deficit? Differences in IQ and insight in first episode psychosis patients who demonstrate a 'jumping to conclusions' response on the beads task*
Ben Wiffen, M. Aurora Falcone, Jennifer O'Connor, Manuela Russo, Robin Murray, Anthony David
- 68.** *Misattributing speech and jumping to conclusions: a prospective study of cognitive biases and outcome in people with prodromal signs of psychosis*
Toby T. Winton-Brown, Louise C Johns, Matthew R Broome, Paul Allen, Isabel Valli, Philippa A. Garety, Philip K McGuire
- 69.** *Are Cognitive Impairments in Patients Who Only Suffer From Delusions the Same as Schizophrenia Patients? An Exploratory Study*
Krista M. Wisner, Joel E. Kleinman, Daniel R. Weinberger, Brita Ellevåg
- 70.** *Neuropsychological Changes over One Year in Youth at Clinical High Risk for Psychosis*
Kristen A. Woodberry, William R. McFarlane, Anthony J. Giuliano, Mary B. Verdi, William L. Cook, Larry J. Seidman
- 71.** *Gender differences in neuropsychological performance in patients with first episode of psychosis.*
Jolanta Zanelli, Abraham Reichenberg, Kevin Morgan, Paul Fearon, Caroline Zanelli, Paola Dazzan, Craig Morgan, Arsime Demjaha, Peter Jones, Gillian A Doody, Robin M. Murray
- 72.** *Motor performance in patients with schizophrenia and schizophrenia spectrum disorders after first psychotic episode*
Yuliya Zaytseva, Nataliya Korsakova, Isaac Gurovich, Andreas Heinz, Michael Rapp
- 73.** *Verbal episodic memory in first episode and at risk mental state for psychosis patients compared to depressive patients and healthy controls*
Ronan Zimmermann, Ute Gschwandtner, Marlon O. Pflueger, Carla Schulze, Anita Riecher-Rössler



- 74.** *A SNAP25 promoter variant is associated with schizophrenia and a disturbed SNAP25b/SNAP25a expression ratio in patients.*
Alexandre Meary, Anne Dumaine, Pierre-Michel Llorca, Christophe Lancon, Franck Schurhoff, Andrei Szoke, Marion Leboyer, Stephane Jamain
- 75.** *Association between the SELENBP1 Gene and Schizophrenia in a Japanese population*
Yuko Okahisa, Eriko Yokobayashi, Takeshi Ishihara, Masafumi Kodama, Manabu Takaki, Hiroshi Ujike
- 76.** *No association analysis between SHC3 and schizophrenia in a Japanese population*
Tomo Okochi, Taro Kishi, Masashi Ikeda, Yoko Kinoshita, Tsuyoshi Kitajima, Yoshio Yamanouchi, Kunihiro Kawashima, Takenori Okumura, Tomoko Tsunoka, Yasuhisa Fukuo, Toshiya Inada, Norio Ozaki, Nakao Iwata
- 77.** *Influence of genetic variations of FTO and SH2B1 genes On Weight Gain Induced By Antipsychotics*
Rocio Perez-Iglesias, Ignacio Mata, Jose A Amado, Ana Berja, M Teresa García-Unzueta, Obdulia Martínez-García, M Jesús Arranz, Jose L Vázquez-Barquero, Benedicto Crespo-Facorro
- 78.** *The effect of the COMT Val158Met polymorphism on cognitive stability and cognitive flexibility*
Elise C. Rosa, Jose Apud, Daniel Weinberger, Brita Ellevåg
- 79.** *Interactive effects of COMT and MTHFR moderate stress sensitivity in psychosis*
Bart Rutten, Odette Peerbooms, Dina Collip, Marielle Lardinois, Tineke Lataster, Viviane Thewissen, Marjan Drukker, Gunter Kenis, Jim van Os, Inez Myin-Germeys, Ruud van Winkel
- 80.** *FOXP2 and schizophrenia*
Julio Sanjuan, Amparo Tolossa, Adam Dagnall,, Maria D. Molto, Rosa de Frutos
- 81.** *Plasma levels and genetic polymorphisms of Interleukin 6 and Interleukin 10 in Schizophrenia*
Daimei Sasayama, Chisato Wakabayashi, Hirofumi Uchiyama, Yoshimi Iijima, Takashi Fujii, Hiroshi Kunugi
- 82.** *Glial cell line-derived neurotrophic factor receptor alpha 2 is associated with tardive dyskinesia*
Renan P. Souza, Gary Remington, Herbert Y. Meltzer, Jeffrey A. Lieberman, Steve G. Potkin, James L. Kennedy, Albert H. Wong
- 83.** *Fibroblast growth factors and brain volume in schizophrenia patients and healthy controls*
Afke F. Terwisscha van Schel, Steven C. Bakker, Neeltje E.M. van Haren, Hilleke E. Hulshoff Pol, Wiepke Cahn, Roel A. Ophoff, René S. Kahn
- 84.** *Association study of CNVs with brain volume and brain volume change over 5 years in schizophrenia patients and healthy controls*
Afke F. Terwisscha van Schel, Steven C. Bakker, Neeltje E.M. van Haren, Hilleke E. Hulshoff Pol, Wiepke Cahn, Jacobine E. Buizer-Voskamp, Thomas E. Gladwin, Jacob A.S. Vorstman, Roel A. Ophoff, René S. Kahn
- 85.** *Preliminary association of ESR1 genetic variation with schizophrenia and working memory performance*
Giovanna Todarello, Ileana Andriola, Annabella Di Giorgio, Miriam Rizzo, Rita Masellis, Gianluca Ursini, Chiara Castellana, Raffaella Romano, Barbara Gelao, Maria Teresa Attrotto, Giuseppe Blasi, Grazia Caforio, Marcello Nardini, Alessandro Bertolino

- 86.** *DISC1 conditioned genome-wide association study of psychosis proneness in a large Finnish birth cohort*
Liisa Tomppo, William Hennah, Jesper Ekelund, Dirk Lichtermann, Juha Veijola, Jouko Miettunen,
 Stacey Gabriel, Marjo-Riitta Järvelin, Nelson Freimer, Leena Peltonen
- 87.** *Cognitive Performance in the Schizophrenia Spectrum: The Influence of COMT and BDNF Polymorphisms*
Hanan D. Trotman, Joseph F. Cubells, Michael T. Compton, Elaine F. Walker
- 88.** *COMT Genotype and Memory Performance in Schizophrenia*
Elizabeth W. Twamley, Lea Vella, Cynthia Z. Burton, Gauri N. Savla, Jami J. Guidry, Arpi Minassian,
 Robert M. Bilder, John R. Kelsoe
- 89.** *Disrupted in Schizophrenia 1 genotype and response to antipsychotics in first episode psychosis.*
Javier Vazquez-Bourgon, Ignacio Mata, Rocio Pérez-Iglesias, Jose Manuel Rodríguez-Sánchez,
 Eugenio Carrasco-Marín, Jose Luis Vázquez-Barquero, Benedicto Crespo-Facorro
- 90.** *AKT1 gene is associated with attention and brain morphology in patients with schizophrenia*
Yuka Yasuda, Ryota Hashimoto, Hironori Takamura, Kazutaka Ohi, Motoyuki Fukumoto, Kiyotaka Nemoto,
 Takashi Ohnishi, Hidenaga Yamamori, Hidetoshi Takahashi, Naomi Iike, Kouzin Kamino, Yetsuhiko Yoshida,
 Ryohei Ishii, Masao Iwase, Hiroaki Kazui, Masatoshi Takeda
- 91.** *Obsessive compulsive symptoms in first episode psychosis and in subjects at ultra high risk to develop psychosis; onset and relationship to psychotic symptoms.*
Bouke Sterk, Kay Landreijer, Don Linszen, Lieuwe de Haan
- 92.** *Voxel-based morphometry comparison between schizophrenia patients responder and non-responder to a typical treatments*
Vicente Molina, Carmen Martín, Alejandro Ballesteros, Juan A. Hernández
- 93.** *Glutamate receptor delta 1 (GRID1) genetic variation and brain structure in schizophrenia*
Igor Nenadic, Raka Maitra, Sigrid Scherpiet, Christian Gaser, Christoph Schultz, Claudia Schachtzabel,
 Stefan Smesny, Juergen Reichenbach, Jens Treutlein, Thomas W. Muehleisen, Sven Cichon,
 Marcella Rietschel, Markus M. Noethen, Heinrich Sauer, Ralf G. Schloesser
- 94.** *P53 genetic variability is associated with frontal white matter volume in schizophrenic patients*
Sergi Papiol, Vicente Molina, Javier Sanz, Araceli Rosa, Bárbara Arias, Mar Fatjó-Vilas, A. Ballesteros,
 G. Galindo, Benjamín Cortés, Lourdes Fañanás
- 95.** *White Matter Tracts as predictors of treatment outcome*
Tiago Reis Marques, Heather Taylor, Andy Simmons, Flavio Dell'Acqua, Robin Murray, Paula Dazzan
- 96.** *Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder*
Lars M. Rimol, Cecilie Hartberg, Ragnar Nesvåg, Christine Fennema-Notestine, Don Hagler Jr., Chris J. Pung,
 Robin G. Jennings, Unn K. Haukvik, Elisabeth Lange, Per H. Nakstad, Ingrid Melle, Ole A. Andreassen,
 Anders M. Dale, Ingrid Agartz



- 97.** *Insular cortex thinning in first episode schizophrenia patients. Correlations with clinical variables, symptomatology and cognitive functioning.*
Benedicto Crespo-Facorro, Roberto Roiz-Santiañez, Rocío Pérez-Iglesias, Carlos Quintero, Diana Tordesillas-Gutiérrez, Ignacio Mata, Rosa Ayesa, José Manuel Rodríguez Sánchez, Agustín Gutiérrez, Elena Sanchez, Victor Ortiz-García de la F., José Luis Vázquez-Barquero
- 98.** *Multimodal imaging reveals convergent evidence of medial prefrontal cortex pathology in schizophrenia*
Edith Pomarol-Clotet, Erick Jorge Canales-Rodríguez, Raymond Salvador, Salvador Sarró, Jesús J. Gomar, Peter John McKenna
- 99.** *Grey Matter Deficits in Chronic Psychosis not Present at First Episode*
Heike C. Schmidt, John McFarland, Mohamed Ahmed, Mark A. Elliott, Dara M. Cannon, Colm McDonald
- 100.** *Mapping Reliability of Multicenter MRI: Cortical Thickness and Voxel-based Morphometry*
Hugo G. Schnack, Neeltje E.M. van Haren, Rachel M. Brouwer, G. Caroline M. van Baal, Marco Picchioni, Matthias Weisbrod, Heinrich Sauer, Tyrone D. Cannon, Matti Huttunen, Claude Lepage, D. Louis Collins, Alan Evans, Robin M. Murray, Rene S. Kahn, Hilleke E. Hulshoff Pol
- 101.** *Diffusion Tensor Imaging of the Cingulum Bundle in First Episode Schizophrenia*
Jason S. Schneiderman, Thomas J. Whitford, Paula E. Pelavin, Douglas P. Terry, Tali Swisher, Raquelle I. Mesholam-Gately, Larry J. Seidman, Jill M. Goldstein, Robert W. McCarley, Marek Kubicki, Martha E. Shenton
- 102.** *Open Poster Board*
- 103.** *Alterations in white matter microstructure associated with the onset of psychosis”*
Francesco Carletti, James Woolley, Matthew Broome, Elvira Bramon, Louise Johns, Paolo Fusar Poli, Lucia Valmaggia, Vincent Giampietro, Gareth Barker, Philip McGuire
- 104.** *A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia*
Tsutomu Takahashi, Michio Suzuki, Shi-Yu Zhou, Ryoichiro Tanino, Kazue Nakamura, Yasuhiro Kawasaki, Hikaru Seto, Masayoshi Kurachi
- 105.** *Global and regional cortical thinning in first-episode schizophrenia patients: Relationships with clinical and cognitive features*
Benedicto Crespo-Facorro, Roberto Roiz-Santiañez, Rocío Pérez-Iglesias, Jose Manuel Rodríguez-Sánchez, Ignacio Mata, Diana Tordesillas-Gutierrez, Elena Sánchez, Rafael Tabarés-Seisdedos, Nancy Andreasen, Vincent Magnotta, José Luis Vázquez-Barquero
- 106.** *Cortical thickness in schizophrenia and bipolar disease: a twin MRI study of disease-specific and comorbid endophenotypes*
G. Caroline M. Van Baal, Hilleke E. Hulshoff Pol, Hugo G. Schnack, Rachel M. Brouwer, Rachel G.H. Brans, René S. Kahn

- 107.** *Automatic classification of magnetic resonance scans in first episode schizophrenia: an exploratory investigation using linear support vector machines*
Eileen Joyce, Sheena Waters-Metenier, John Ashburner, Gary Price, Elvina Chu, Maria A Ron
- 108.** *Progressive structural brain changes are associated with onset of psychosis*
Sanne de Wit, Tim B. Ziermans, Patricia F. Schothorst, Hugo G. Schnack, René S. Kahn, Herman van Engeland, Sarah Durston
- 109.** *Disrupted theory of mind network processing in response to idea of reference evocation in schizophrenia*
Il Ho Park, Jeonghun Ku, Hyeongrae Lee, So Young Kim, Sun I. Kim, Kang Jun Yoon, Jae-Jin Kim
- 110.** *Effect of BDNF Met66Val polymorphism on hippocampal structure and function: a meta-analysis*
Joseph P. Kambeitz, Sagnik Bhattacharyya, Lana M. Ilankovic, Isabel Valli, Philip McGuire
- 111.** *Why Protocadherin IIXY (PCDHIIXY) and no other gene will explain the sex differences in psychosis*
Tim Crow
- 112.** *Brain activation patterns during rTMS treatment of schizophrenia*
Radovan Prikryl, Libor Ustohal, Michal Mikl, Tomas Kasparek, Hana Prikrylova Kucerova, Eva Ceskova
- 113.** *Interaction between DRD2 gene and prefrontal cortex activity during different working memory phases*
Tiziana Quarto, Leonardo Fazio, Raffaella Romano, Annabella Di Giorgio, Paolo Taurisano, Luciana Lo Bianco, Francesca Ferrante, Mariangela Martone, Apostolos Papazacharias, Grazia Caforio, Giuseppe Blasi, Marcello Nardini, Alessandro Bertolino
- 114.** *Power Spectrum Scale Invariance of fMRI time series identifies prefrontal dysregulation in schizophrenia*
Anca R. Radulescu, Denis Rubin, Lilianne R. Mujica-Parodi
- 115.** *Verbal Thought Generation in schizophrenia patients is associated with aberrant activation in a Neural Network involving Task-Positive and Task-Negative aspects.*
Lucile Rapin, Paul Metzack, Jennifer Whitman, Marion Dohen, H el ene Loevenbruck, Marc Sato, Todd Woodward
- 116.** *Neural networks for emotional discourse comprehension in schizophrenia*
Annick Razafimandimby, Mathieu Vigneau, Perrine Brazo, Nicolas Delcroix, Gregory Simon, Bernard Mazoyer, Nathalie Tzourio-Mazoyer, Sonia Dollfus
- 117.** *Resting-state network correlates of psychotic symptoms in schizophrenia.*
Anna Rotarska-Jagiela, Vincent van de Ven, Viola Oertel-Kn ochel, Peter J. Uhlhaas, Kai Vogeley, David E.J. Linden
- 118.** *Altered cognitive and emotional modulation of brain activity in schizophrenia*
Aur elie Royer, Fabien Schneider, Adrianna Mendrek, Emmanuel Stip
- 119.** *Severity Demonstrated by Multimodal Morphometry and Functional MR Imaging in Auditory Hallucinations*
Julio Sanjuan, Eduardo J. Aguilar, Gracian Garcia-Marti, Luis Marti-Bonmati, Maria de La Iglesia



- 120.** *The neural correlates of severe cognitive impairment in schizophrenia*
Peter John McKenna, Jordi Ortiz Gil, Edith Pomarol-Clotet, Raymond Salvador, Erick Jorge Canales-Rodríguez, Salvador Sarro
- 121.** *Reduced cortical thickness in first episode schizophrenia*
C. Chr. Schultz, Kathrin Koch, Gerd Wagner, Martin Roebel, Heinrich Sauer, Ralf GM Schlösser
- 122.** *Functional Magnetic Resonance Imaging of Inner Speech in Schizophrenia*
Sukhi S Shergill, Derek K Tracy, Kiran Sanghera, Owen O'Daly, James Gilleen, Maria Dominguez, Lydia Krabbendam, Claudia Simons
- 123.** *Striatal dopamine function in dizygotic twin pairs discordant for schizophrenia*
J Paul Shotbolt, Paul Stokes, Oliver D Howes, Paul M Grasby
- 124.** *Brain activation preceding auditory verbal hallucinations*
Kelly M. Diederer, Antoin D. de Weijer, Sebastiaan F. W. Neggers, Jan Dirk Blom, René S. Kahn, Iris E. Sommer
- 125.** *Neuroplasticity-based cognitive training improves reality monitoring in schizophrenia patients: Behavioral and fMRI assessments*
Karuna Subramaniam, Tracy Luks, Stephanie Aldebot, Adelaide Hearst, Arul Thangavel, Melissa Fisher, Gregory V. Simpson, Srikantan Nagarajan, Sophia Vinogradov
- 126.** *The neural basis of associative emotional learning in schizophrenia and the relationship with alexithymia*
Marte Swart, Richard Bruggeman, Rudie Kortekaas, Durk Wiersma, André Aleman
- 127.** *Interaction between DARPP-32 and DRD2 genetic variants on Anterior Cingulate Cortex activity during attentional control in healthy subjects*
Paolo Taurisano, Giuseppe Blasi, Apostolos Papazacharias, Raffaella Romano, Gianluca Ursini, Annabella Di Giorgio, Leonardo Fazio, Linda Antonucci, Barbara Gelao, Grazia Caforio, Rita Masellis, Luciana Lo Bianco, Lorenzo Sinibaldi, Teresa Popolizio, Wolfgang Sadée, Alessandro Bertolino
- 128.** *Brain activation during the N-Back task as a predictor of future treatment response in first episode psychosis patients*
Heather Taylor, Tiago Reis Marques, Andy Simmons, AAT Simone Reinders, Rowena Handley, Valeria Mondelli, Sara Pozzoli, Marta Di Forti, Anthony David, Robin M Murray, Carmine M Pariante, Paola Dazzan
- 129.** *Allelic variation in NKCC1 is associated with hippocampal and dorsolateral prefrontal cortex activation during working memory*
Lauren R. Testa, Joseph H. Callicott, Yukitaka Morita, Bhaskar Kolachana, Richard E. Struab, Daniel R. Weinberger, Thomas M. Hyde
- 130.** *Altered brain function during working memory in adolescents and young adults at genetic risk for bipolar disorder: Preliminary findings.*
Heidi W. Thermenos, Susan Whitfield-Gabrieli, Nikos Makris, Ariel B. Brown, Erica Lee, Anthony Giuliano, Stephen Faraone, MIng T. Tsuang, Larry J. Seidman

- 131.** *Functional correlates of the non self-serving attributional bias – a pilot study*
Renate Thienel, Katharina Pauly, Thilo Kellermann, Bianca Voss, Tilo Kircher
- 132.** *Aberrant coupling within the default-mode network during self-referential processing in healthy siblings of schizophrenia patients*
Mariët van Buuren, Matthijs Vink, René S. Kahn
- 133.** *Functional connectivity in schizophrenia*
Martijn P. van den Heuvel, René C.W. Mandl, Thomas Scheeuwe, Wiepke Kahn, René S. Kahn, Hilleke E. Hulshoff Pol
- 134.** *Auditory verbal hallucinations are related to decreased beta-band power in the anterior superior frontal gyrus – An MEG study*
Remko Van Lutterveld, Arjan Hillebrand, Cornelis J. Stam, René S. Kahn, Iris E. Sommer
- 135.** *Decreased language lateralization in medication naive schizophrenia*
Janna Marie Hoogendam, Nicoletta M. van Veelen, Matthijs Vink, René S. Kahn
- 136.** *Evidence for decreased fronto-striatal functioning in schizophrenia during working memory.*
Christian G. Widschwendter, Matthijs Vink, Bram B. Zandbelt, René S. Kahn
- 137.** *Modulation of auditory and visual processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI study*
Toby T. Winton-Brown, Paul Allen, Sagnik Bhattacharrya, Stefan J. Borgwardt, Fusar-Poli Paolo, Jose A. Crippa, Mark L. Seal, Rocia Martin-Santos, Colin O'Carroll, Dominic ffytche, Zerrin Atakan, Philip K. McGuire
- 138.** *Glutamate in schizophrenia - a review*
Anouk Marsman, Martijn P. Van den Heuvel, René C.W. Mandl, René S. Kahn, Hilleke E. Hulshoff Pol
- 139.** *Multi-regional 1H magnetic resonance spectroscopy reveals local differences in concentrations of N-acetylaspartate (NAA) and glutamate in patients at Ultra High Risk (UHR) to develop psychosis.*
Berko Milleit, Alexander Gussew, Reinhard Rzanny, Susan Thiel, Christine Milleit, Heinrich Sauer, Jürgen R Reichenbach, Stefan Smesny
- 140.** *Interaction between hippocampal glutamate and striatal dopamine – relationship to subsequent onset of psychosis*
James M Stone, Howes Oliver, Alice Egerton, Joseph Kambeitz, Paul Allen, David Lythgoe, Ruth O'Gorman, Mary McLean, Gareth Barker, Philip McGuire
- 141.** *Impaired Cross-Spectral Phase Coherence in Schizophrenia*
S. Bert G. Park, Peter F. Liddle
- 142.** *Electrophysiological Correlates of Working Memory in Adolescents At-Risk of Psychosis and Matched Controls*
Caroline C. Rawdon, Jennifer B. Murphy, Mathieu M. Blanchard, Fergal Kavanagh, Ian Kelleher, Mary Clarke, Richard A.P. Roche, Mary Cannon



- 143.** *An electrophysiological evidence for enhanced local but reduced global integration of visual information in schizophrenia*
Igor Riecansky, Tomas Kasperek, Jitka Rehulkova
- 144.** *Memory consolidation during sleep in schizophrenia*
Gudrun Sartory, Anna vanBeekum, Thomas Lohrmann, Reinhard Pietrowsky
- 145.** *Phenotyping of schizophrenia by multi-modal brain imaging*
Ulrich Schall, Paul E. Rasser, Ross Fulham, Juanita Todd, Patricia T. Michie, Philip B. Ward, Patrick Johnston, Paul M. Thompson
- 146.** *Reduced event-related low frequency EEG activity in early onset schizophrenia patients and their unaffected siblings*
Molly Simmonite, Alan T. Bates, Madeleine J. Groom, Debasis Das, Georgina M. Jackson, Chris Hollis, Peter F. Liddle
- 147.** *Local field potential and single unit activity in the rat medial prefrontal cortex and anterior cingulate cortex during a sustained attention task*
Nelson K. Totah, Mark Jackson, Bitá Moghaddam
- 148.** *High-frequency gamma-band oscillations during perceptual organisation in chronic and first-episode schizophrenia patients*
Peter Uhlhaas, Christine Gruetzner, Michael Wibral, Markus Leweke, Wolf Singer
- 149.** *Impact of pro-psychotic drugs on single unit and oscillatory field activity in prefrontal cortex subregions of the rat*
Jesse T Wood, Yunbok Kim, Bitá Moghaddam
- 150.** *QEEG spectral power and negative symptoms in the detection of beginning psychosis*
Ute Gschwandtner, Ronan Zimmermann, Marlon O. Pflueger, Anita Riecher-Rössler, Peter Fuhr
- 151.** *Alterations of microcirculation in skin and muscle in patients suffering from schizophrenia*
Karl-J. Bär, Anna K. Israel, Tobias Rachow, Sandy Berger, Sylvio Koch, Andreas Voss
- 152.** *Autonomic Dysfunction in Unaffected First-Degree Relatives of Patients Suffering From Schizophrenia*
Sandy Berger, Karl-J. Bär, Maria Metzner, Michael K. Boettger, Steffen Schulz, Vikram Yeragani
- 153.** *Source Localization of sensory gating: a combined EEG and fMRI study in healthy volunteers*
Nikolaj Bak, Birte Glenhøj, Egill Rostrup, Henric Larsson, Bob Oranji
- 154.** *Visual scan paths to affective facial expressions in individuals at high risk and healthy controls*
Julia Paruch, Alexandra Nikolaidis, Joachim Klosterkötter, Stephan Ruhrmann
- 155.** *P50 Gating and Neurocognitive Function in Schizophrenia*
Jose L. Santos, Ana I. Aparicio, Clara Villanueva, Roman Solano, Eva M. Sanchez-Morla

- 156.** *No association between COMT, BDNF and NRG-1 polymorphisms and P50 sensory gating in psychosis*
Madiha Shaikh, Mei-Hua Hall, Katja Schulze, Anirban Dutt, Muriel Walshe, Ian Williams, Miguel Constante, Marco Picchioni, Timothea Touloupoulou, David Collier, Fruhling Rijdsdijk, John Powell, Maria Arranz, Robin M Murray, Elvira Bramon
- 157.** *Application of the dynamical analysis of the Electroencephalogram (EEG) in the study of cognitive dysfunctions in Schizophrenia*
Monica Sigaudó, Tullia Mongini, Antonella Pollo, Elisa Carlino, Sergio Vighetti, Fabrizio Benedetti, Paola Rocca
- 158.** *Characterization of RO4583298 as a highly potent, dual antagonist with in vivo activity at tachykinin NK1 and NK3 receptors*
Pari Malherbe, Frédéric Knoflach, Lucinda Steward, Maria-Clemencia Hernandez, Torsten Hoffmann, Patrick Schnider, Richard H. Porter, Theresa M. Ballard, Will Spooren
- 159.** *Time-Dependent Changes in Gamma Oscillations and Parvalbumin Immunoreactive Cell Density in the CA2/3 Region of the Rat Hippocampus following Sub-chronic Phencyclidine Treatment*
Samantha L. McLean, Mike K. Harte, Samuel Marsh, Gareth A. Jones, Ceri Davies, Marie L. Woolley, Jo C. Neill
- 160.** *Niacin skin flush response in schizophrenia linked to soluble interleukin 2 receptor serum levels*
Berko Milleit, Christine Milleit, Uta-Christina Hipler, A. Köhler, C. Schneider, M Rudzok, U. Cyriax, Heinrich Sauer, Stefan Smesny
- 161.** *Increased Interleukin-17 and Decreased Baff Serum Levels in Acute Phase of Schizophrenia*
Yousri Elkissi, Samar Samoud, Mouna Ayachi, Neila Hannachi, Bechir Belhadjali, Jalel Boukadida
- 162.** *Decreased mu opioid receptor availability in subjects with schizophrenia who died by suicide.*
Elizabeth Scarr, Tammie Money, Brian Dean
- 163.** *n-3 Fatty acid supplementation influences associations between membrane fatty acids and phospholipase A2 activity in patients at risk to develop psychosis*
Stefan Smesny, Berko Milleit, Miriam R Schaefer, Christine Milleit, Marieluise Otto, Uta-Christina Hipler, Heinrich Sauer, Paul G. Amminger
- 164.** *Recruitment of ErbB1-ERK signalling by antipsychotic drugs: a novel treatment target in schizophrenia?*
Suresh Sundram, Avril Pereira, Betty Y.H. Zhang, George Fink, Peter Malcolm
- 165.** *Inflammation in Psychotic Disorders: A Population-Based Study*
Jaana Suvisaari, Britt-Marie Loo, Suoma E. Saarni, Jonna Perälä, Samuli Saarni, Antti Jula
- 166.** *Enhancement of Cognition in Schizophrenia via Inhibition of Phosphodiesterase-1B and Potentiation of Dopamine D1 Receptor Signaling.*
Lawrence Wennogle, Gretchen Snyder, Peng Li, Kimberly Vanover, Robert Davis, Allen Fienberg, Joseph Hendrick, Sharon Mates



- 167.** *Dysbindin1 and NRG1 genes expression in immortalized lymphocytes from patients with schizophrenia*
Hidenaga Yamamori, Ryota Hashimoto, Hironori Takamura, Louise Verral, Yuka Yasuda, Kazutaka Ohi, Motoyuki Fukumoto, Akira Ito, Masatoshi Takeda
- 168.** *Paranoid schizophrenia is characterised by increased cannabinoid CB1 receptor binding in the dorsolateral prefrontal cortex*
Katerina Zavitsanou, Victoria S Dalton
- 169.** *Regulation of Psychosis Gene NPAS3 by MicroRNA During Postnatal Development and in Schizophrenia*
Cyndi S Weickert, Carlotta Duncan, Natalie Beveridge, Jenny Wong, Maree J. Webster, Murray Cairns
- 170.** *Delusions of Reference, Excessive Top-down Processing, and Default Mode Network in First-episode Schizophrenia*
Gloria HY Wong, Haojuan Tao, Zhong He, Haihong Liu, Cindy P.Y. Chiu, Sherry W.K. Chan, May M.L. Lam, Christy L.M. Hui, Jennifer Y.M. Tang, Yunhua Wang, Zhimin Xue, Zhening Liu, Eric Y.H. Chen
- 171.** *Interaction Between Estrogen Receptor Alpha and TrkB Suggest Convergence in Developmental Pathways Implicated in Schizophrenia*
Jenny Wong, Cynthia Shannon Weickert
- 172.** *Analysis of the hypothalamic-pituitary adrenal axis in psychiatric disorders*
Divya Krishnamurthy, Paul C. Guest, Laura Harris, Maree J. Webster, Sabine Bahn
- 173.** *Placebo response in antipsychotic trials: a systematic review and meta-analysis*
Ofer Agid, Steven Potkin, Gary Remington, Shitij Kapur, Douglas Vanderburg, Eric Watsky, Cynthia Siu
- 174.** *One Week Tolcapone Treatment in Psychotic Patients: Effects on Gating, Working Memory and Clinical Picture*
Evangelia M. Tsapakis, Stella Giakoumaki, Panos Roussos, Anna Chrysoulaki, Ismini Kopsahili, Vassilis Koudas, Panos Bitsios
- 175.** *Lurasidone in the Treatment of Acute Schizophrenia: Results of the Double-Blind, Placebo-Controlled Pearl 2 Trial*
Josephine Cucchiaro, Robert Silva, Masaaki Ogasa, Jane Xu, Debra Phillips, Doreen Simonelli, Amir Kalali, Antony Loebel, Herbert Meltzer
- 176.** *Community treatment orders, ethnicity, conditions and psychotropic medication: The first six months (N=126)*
Maxine X. Patel, Jane Matonhodze, James Gilleen, Jane Boydell, David Taylor, George Szmukler, Tim Lambert, Anthony S. David
- 177.** *Long Acting Antipsychotics: comparison of first- and second-generation antipsychotic drugs in a community setting*
Jose Maria Pelayo-Teran, Oscar Fernandez Torre, Pedro Luis Trabajo-Vega, Jovita Martinez-Diez, Cesar Ordoñez-Prieto, Rocío Casado-Martinez, Maria Consolacion Fonseca-Rodríguez, Maria Jesus Castela-Lorenzo, Noelia Varela-Aller, Maria Teresa Alvarez-Bermejo, Vicente Quintana-Gonzalez, Carmen Villaverde-Amieva

- 178.** *Risperidone injectable long-acting treatment vs other oral antipsychotics in first episode psychosis: one year longitudinal study*
Rafael Segarra, Natalia Ojeda, Jon Garcia, Javier Peña, Elena Bravo, Jose I. Eguiluz
- 179.** *Impact of Ethnicity on Efficacy and Safety During Treatment with Olanzapine in Schizophrenia*
Virginia L. Stauffer, Jennifer Sniadecki, Kevin Piezer, Jennifer Gatz, Sara Kollack-Walker, Vicki Poole Hoffmann, Robert Conley, Todd Durell
- 180.** *Remission in schizophrenia: results of population and pharmacotherapeutic studies of schizophrenic outpatients*
Andrey V. Potapov, Eduard E. Tsukarzi, Sergey N. Mosolov
- 181.** *Longitudinal Trajectory Analysis of Placebo Response: Short-term and Long-term Randomized Controlled Trials*
Steven Potkin, Ofer Agid, Gary Remington, Shitij Kapur, Eric Watsky, Douglas Vanderburg, Cynthia Siu
- 182.** *Efficacy and tolerability among patients with recent onset schizophrenia treated with risperidone long-acting injectable (RLAI)*
Oleksandr Napryeyenko, Benjaminas Burba, Guadalupe Martinez, Nikolay Neznanov, Tsvi Fischel, Franck Baylé, Giulio Corrivetti, Enrico Smeraldi, Jonathan Rabinowitz
- 183.** *Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine*
Hans Rasmussen, Bjorn H Ebdrup, David Erritzoe, Bodil Aggernaes, Bob Oranje, Jan Kalbitzer, Lars H Pinborg, William Baaré, Claus Svarer, Henrik Lublin, Gitte M Knudsen, Birte Glenthoj
- 184.** *Risperidone vs placebo in the treatment of schizophrenia*
Ranga Rattehalli, Mahesh Jayaram, Michael Smith
- 185.** *A Five year follow-up study: Outcome of schizophrenic patients*
Teresa Bel, Isabel Frigola, Vincente Fabregat, Carlos Conesa, Raquel Borregl, Antoni Corominas
- 186.** *Long acting antipsychotic; atypical versus conventional. 48 months of follow-up.*
Samuel L. Romero Guillena, Nieves Casas Barquero, Juan L. velez noguera
- 187.** *Aripiprazole Treatment Effects on Metabolic Syndrome Parameters in Schizophrenia Patients: Preliminary Results*
Mas A. Said, Ahmad H. Sulaiman, Mohd H. Habil
- 188.** *Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Oral Olanzapine*
Andreas Schreiner, Nesrin Dilbaz, Moshe Kotler, Fernanda Rosa, Dagmar Hoeben, Periklis Paterakis, Vihra Milanova, Christophe Tessier, Anatoly Smulevich
- 189.** *A Flexible-dose Study of Paliperidone ER in Non-Acute Patients with Schizophrenia Previously Unsuccessfully Treated with Aripiprazole*
Andreas Schreiner, Dagmar Hoeben, Marjolein Lahaye, Christophe Tessier, Dieter Naber, Jozef Peuskens, Roland Vauth, Miroslava Jasovic Gasic, Elmars Rancans, Roy Didi



- 190.** *Predictors for high treatment response in acute patients with schizophrenia*
Andreas Schreiner, Dagmar Hoeben, Christophe Tessier, Liana Don, Stephan Heres, Valentinas Maciulis, Zeev Kaplan, Miroslav Herceg, Leszek Bidzan, Michel Blanc, Alberto Siracusano
- 191.** *Adjunctive Varenicline Treatment With Antipsychotic Medications in Patient with Schizophrenia: A Placebo-Controlled Trial*
Joo-Cheol Shim, Do-Un Jung, Sung-Soo Jung, Young-Soo Seo, Bo-Geum Kong, Min-Kyung Oh, Robert P McMahon, Deanna L Kelly
- 192.** *Metabolic parameters in a subset of patients in the SCoP study.*
Marc De Hert, Aurélia Mittoux, Yuan He, Joseph Peuskens
- 193.** *Detection of Drug-Placebo Difference in Schizophrenia Clinical Trials: Site-Related Factors*
Antony Loebel, Josephine Cucchiaro, Amir Kalali, David Daniel, Cynthia Siu
- 194.** *A Systematic Review of Levomepromazine for Schizophrenia*
Parthipan Sivaraman, Mahesh B. Jayaram, Ranganath D. Rattehalli
- 195.** *Symptomatic and Functional Recovery Index for Negative Symptoms in a 40-Week Randomized, Double-Blind Study of Ziprasidone versus Haloperidol Followed by a 3-Year Double-Blind Extension Trial*
Douglas Vanderburg, Stephen M. Stahl, Ashok Malla, John W. Newcomer, Steven G. Potkin, Peter J. Weiden, Philip Harvey, Antony Loebel, Eric Watsky, Cynthia Siu, Steve Romano
- 196.** *The Heterogeneity of Antipsychotic Response in the Treatment of Schizophrenia*
Virginia L. Stauffer, Michael Case, Haya Ascher-Svanum, Robert Conley, Shitij Kapur, John M. Kane, Sara Kollack-Walker, Jayanthi Jacob, Bruce J. Kinon
- 197.** *Depressive symptoms in the first episode of schizophrenia – analysis of Polish results of the EUFEST Study.*
Tomasz Szafrański, Marek Jarema, Marcin Olajossy, Jolanta Rabe-Jabłońska, Janusz K. Rybakowski
- 198.** *Low Dose vs. Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: A Systematic Review and Meta-analysis*
Hiroyuki Uchida, Takefumi Suzuki, Hiroyoshi Takeuchi, Tamara Arenovich, David C. Mamo
- 199.** *ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses*
Kimberly E. Vanover, Gretchen L. Snyder, Joseph P. Hendrick, Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates, Robert E. Davis
- 200.** *Time to rehospitalization of patients discharged on a regimen of conventional antipsychotics, non-clozapine second generation antipsychotics and clozapine*
Helio Elkis, Ana P. Werneck, Jaime Hallak, Eduardo Nakano
- 201.** *Childhood Adversity, Offending and Violence in a First Episode Sample: Findings from the AESOP First Onset Psychosis Study*
Dionne M. Harleston, Helen Fisher, Craig Morgan, Paul Fearon, Robin Murray, Paola Dazzan, Peter Jones, Gillian Doody, Kimberlie Dean

- 202.** *Prevalence of the metabolic syndrome among schizophrenia patients on antipsychotics in Nigeria*
Bawo O. James, Ambrose A. Lawani, Modupe Okolo, Olufemi Morakinyo
- 203.** *Antipsychotics and haematological toxicity.*
Evangelos G. Neroutsos, George N. Vagionis, Markella P. Fiste, Afroditi C. Retziou, Aikaterini D. Roupaka, Konstantoula G. Ouzonidou
- 204.** *Alterations of glucose metabolism in patients treated with Ziprasidone vs. Clozapine*
Maria A Rettenbacher, Christoph Ebenbichler, Alex Hofer, Georg Kemmler, Monika Edlinger, W Wolfgang Fleischhacker
- 205.** *Male sexual dysfunction in schizophrenia: relationship with drug treatment, prolactin and DRD2 genotype*
Gavin P Reynolds, XiangRong Zhang, Zhijun Zhang
- 206.** *Cognitive impairment following prenatal immune challenge in mice correlates with prefrontal cortical AKT1 deficiency*
Joram Feldon, Byron Bitanhirwe, Urs Meyer
- 207.** *Dopamine transporter (DAT) activity regulates the induction of synaptic plasticity in rodent prefrontal cortex*
Jing Bai, Victor Gorgievski, Eleni Tzavara, Marika Nosten-Bertrand, Bruno Giros, Satoru Otani
- 208.** *Differential effects of chronic adolescent vs. adult THC exposure in COMT knockout mice on phenotypes relevant to psychosis*
Colm M. O'Tuathaigh, Magdalena Hryniewiecka, Aine Behan, Orna Tighe, Mary Cannon, Maria Karayiorgou, Joseph A Gogos, David R. Cotter, John L Waddington
- 209.** *Validation of localised brain region specific adeno-associated viral-mediated gene manipulation*
Clare Paterson, Colin P. glover, Brian J. Morris, James D. Storey, Judith A. Pratt, Catherine A. Winchester
- 210.** *Individual differences in the expression of prepulse inhibition predict the magnitude of amphetamine behavioural sensitization in C57BL/6 mice*
Daria Peleg-Raibstein, Jonas Hauser, Luis L. Lopez, Pascual Á. Gargiulo, Joram Feldon, Ben K. Yee
- 211.** *Distinct aspects of prefrontal cortex dysfunction in schizophrenia modelled by acute and repeated PCP treatment: impact of modafinil*
Judith A. Pratt, Neil Dawson, Catherine L. Winchester, David M. Thomson, Brian J. Morris
- 212.** *Nicotine Restores Cognitive Impairments Following Sub-chronic Ketamine Exposure in a Rodent Odour Span Task.*
Samantha L. Rushforth, Thomas Steckler, Mohammed Shoab
- 213.** *Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia-gating of auditory evoked potentials and prepulse inhibitions*
Brian Villumsen Broberg, Bob Oranje, Birte Glenthøj, Niels Plath, Jesper Frank Bastland



- 214.** *C3H alpha7 nicotinic receptor heterozygote mice as a new model of schizophrenia*
Karen E. Stevens, Catherine E. Adams, Joan Yonchek, Lijun Zheng, Allan C Collins
- 215.** *Ex Vivo Analysis of Asenapine-, Olanzapine-, and Risperidone-Induced Dopamine D1 and D2 Receptor Occupancy in Rat Brain*
Yong Kee Choi, Matthew Gardner, Taylor Moran-Gates, Brian Henry, Mohammed Shahid, Frank I. Tarazi
- 216.** *Alteration of AKT1 and Neuregulin-1 gene expression in frontal cortex and dentate gyrus may be associated with schizophrenia: perinatal asphyxia model in rat*
Tomoyasu Wakuda, Shiro Suda, Keiko Iwata, Katsuaki Suzuki, Norio Mori, Nori Takei
- 217.** *Hippocampal dysfunction in a maternal immune activation (MIA) animal model of schizophrenia.*
Amy R. Wolff, Kirsten R. Cheyne, David K. Bilkey
- 218.** *South Asians' attitudes towards Cognitive Remediation after first episodes of psychosis*
Claire J. Press, Richard J. Drake, Nusrat Husain
- 219.** *Cognitive deficit in schizophrenia and its remediation*
Hana Prikrylova Kucerova, Helena Fejfarova, Petra Navratilova, Radovan Prikryl
- 220.** *Mobus project – Randomised study of an Assistive technology for improving cognition and autonomy of patients with schizophrenia: exploring preliminary data*
Juliette Sablier, Emmanuel Stip, Nicolas Franck, Mobus Group
- 221.** *Unipolar sequential fronto-temporal repetitive transcranial magnetic stimulation in the treatment of schizophrenia*
Libor Ustohal, Radovan Prikryl, Hana Prikrylova, Lenka Havlaskova, Eva Ceskova
- 222.** *Results of the NEUROCOM trial: The effect of computer-assisted cognitive training combined with a psychosocial treatment programme on cognition and daily-life competencies of first-episode schizophrenia patients*
Lone Vesterager, Birthe Olsen, Marianne Melau, Gertrud Krarup, Torben Christensen, Merete Nordentoft
- 223.** *The profile of non-affective first episode psychosis patients with and without moderate to severe depressive symptoms at entry to treatment*
Sue M. Cotton, Martin Lambert, Benno Schimmelmann, Andrew Mackinnon, John Gleeson, Michael Berk, Patrick McGorry, Philippe Conus
- 224.** *Cognitive Factors in Long Term Outcome of First Episode Psychosis*
Amresh Shrivastava, Megan E. Johnston, Nilesh Shah, Meghana Thakar, Larry Stitt
- 225.** *Relationship between personality traits and prognosis in schizophrenia*
Ana Saenz Ballobar, Olga Gonzalez Irizar, Maud Rubio Bravo, Sara Arranz Garcia, Joaquín Valero Oyarzabal, Antonio Labad Alquezar
- 226.** *Suicidal behaviour and insight in schizophrenia*
Purificacion Salgado, Juan A Estallo, Anna Mane, Daniel Berge

- 227.** *Axis I diagnoses and transition to psychosis in high risk patients. Results of the EPOS project.*
Raimo K R Salokangas, Stephan Ruhrmann, Markus Heinimaa, Tanja Svirskis, Tiina Laine,
 Heinrich Graf von Reventlow, Georg Juckel, Don Linszen, Peter Dingemans, Max Birchwood,
 Paul Patterson, Joachim Klosterkötter
- 228.** *Predictors of Real World Functional Behavior in Bipolar Disorder and Schizophrenia*
Christopher R. Bowie, Philip D. Harvey, John McGrath, Ann Pulver
- 229.** *Clinical and cognitive correlates of perceived extent of recovery in Chinese patients with psychosis*
Jennifer Y.M. Tang, Cindy P.Y. Chiu, Christy L.M. Hui, Kevin, K.S. Chan, May M.L. Lam, Sherry K.W. Chan,
 Gloria H.Y. Wong, Eric Y.H. Chen
- 230.** *Differential profile of cognitive functioning in first episodes of non-affective psychosis and bipolar disorder: a one-year longitudinal study.*
Benedicto Crespo-Facorro, Elsa Gómez-Ruiz, Jesús Artal-Simón, Teresa Moreni-Calle,
 Jaqueline Mayoral van Son, Patricia Caballero, Sara González-González, Jose Manuel Rodriguez,
 Rosa Ayesa-Arriola, Jose Luis Vazquez-Barquero
- 231.** *Protective and Risk Factors for Psychosis Relapse in Patients with First Episode Schizophrenia Spectrum Psychosis: 3 Years Follow-up*
Suzana M. Tosic Golubovic, Vladica M. Sibinovic, Dragoslava D. Gugleta, Violeta V. Slavkovic,
 Nada B. Djordjevic
- 232.** *Health monitoring in schizophrenia: time for action*
Frank M.M.A. van der Heijden, Pauline M.J. Steylen, Marcel W.P. Hoogenbosch, Anouk Slaar, Hans D.H. Kok,
 Hans L.M. Hendrikx, Willem M.A. Verhoeven
- 233.** *Non-adherence to oral antipsychotics in schizophrenia: Relapse and therapeutic strategies in a 12-month observational study*
Antonio Ciudad, Luis San, Miguel Bernardo, José M. Olivares, Pepa Polavieja, Amparo Valladares,
 Inmaculada Gilaberte
- 234.** *DUP, Remission and Recovery in First Episode Psychosis*
Lex Wunderink, Sjoerd Sytema, Nynke Boonstra, Durk Wiersma
- 235.** *Health-related and subjective quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders*
Samuli I Saarni, Satu Viertiö, Jonna Perälä, Seppo Koskinen, Jaana Suvisaari, Jouko Lönnqvist
- 236.** *Psychosocial Processes Influencing Weight Management Among Persons Newly Prescribed Atypical Antipsychotic Medications*
Sarah Xiao, Cynthia Baker
- 237.** *Physical activity of daily living in patients with Schizophrenia*
 Hiroaki Yamamoto, Kenji Yamamoto, Shingo Miyaji, Masami Yukawa-Inui, Michiko Takai-Kamiya,
Seiichi Tatematsu, Motoki Yutani, Hitoshi Miyaoka



- 238.** *Associations between objective and self-administered assessment of symptoms in psychotic patients*
Jung-Seo Yi, Yang-Whan Jeon, Seung Hyun Kim
- 239.** *Social Functioning in Urban, Predominantly African American, Socially Disadvantaged Patients with First-Episode Nonaffective Psychosis*
Sandra M. Goulding, Lauren Franz, Erin Bergner, Michael T. Compton
- 240.** *Natural Contact and Psychophysiological Reactions Towards Schizophrenics: Challenge or Threat?*
Ruth Elaine Graves, Shona T Chandon, Jeffrey E Cassisi
- 241.** *The relationship between insecure attachment and specific psychotic symptoms: Preliminary Results*
Nikie Korver, Carin Meijer, Lieuwe de Haan
- 242.** *Remediation of facial emotion recognition in schizophrenia: Functional predictors, generalisability, and concomitant visual scanning of novel face stimuli.*
Pamela J. Marsh, Melissa J. Green, Tamara Russell, Jonathan McGuire, Gemma Lockett, Anthony Harris, Max Coltheart
- 243.** *A quantitative and qualitative research on Recovery from severe mental illness: the Italian Study on Recovery (S.I.R.)*
Alessandro Svettoni, Ileana Boggian, Dario Lamonaca, Andreas Conca
- 244.** *Metacognitive profile of paranoia and depression; Are there moderation effects of metacognition into psychological wellbeing?*
Filiberto Fuentesnebro, Carmen Valiente, Diego Gómez, José M^a Prados
- 245.** *The association between adversities and beliefs in a just world in paranoia: the role of interpersonal trauma.*
Filiberto Fuentesnebro, Regina Espinosa, Carmen Valiente, María Provencio, Carmelo Vázquez, Patricia Villavicencio
- 246.** *Tolerance of Unfairness and Costly Punishment in Schizophrenia*
Julia Wischniewski, Martin Brüne
- 247.** *Facial Affect Recognition in Remitted Patients with Schizophrenia and Bipolar Disorder I*
Nursen Yalcin, Alex Hofer, Susanne Baumgartner, Cord Benecke, Falko Biedermann, Eberhard Deisenhammer, Armand Hausmann, Christine Hörtnagl, Georg Kemmler, Moritz Muehlbacher, Georg Schwitzer, Wolfgang Fleischhacker
- 248.** *Psychosocial Functioning in Schizophrenia: A Trialog of Patient's, Relative's and Therapist's Perspective*
Daniela Schaub, Verena Zimmermann, Martin Brüne, Georg Juckel
- 249.** *Schizophrenia Victims of Nazi Euthanasia: The duty to remember or the obligation to protect confidentiality?*
Rael D. Strous

- 250.** *A Cross-Sectional Comparison Study of Glycaemic Control among Diabetic Patients with and without Schizophrenia*
Edwin Lee, Ronald Ma, Chi-Ming Leung
- 251.** *Early-rehospitalization rates of individuals with psychotic disorder and bipolar disorder in São Paulo, Brazil*
Alexandre A. Loch
- 252.** *A randomised clinical trial of the effect of five-years versus two-years specialised assertive intervention for first episode psychosis – the OPUS-II trial*
Marianne Melau, Mette Bertelsen, Pia Jeppesen, Gertrud Krarup, Merete Nordentoft, Anne Thorup, Lone Petersen, Christian Gluud
- 253.** *Type of mental health professionals (psychiatric and nurses) are associated to use of ambulatory services among patients with schizophrenia. A RESMA case register study*
Berta Moreno-Kustner, Desiree Navas, Fermin Mayoral, Pedro Angona, Jose Garcia-Herrera, Patricia Moreno, Olga Perez
- 254.** *Long-term safety, tolerability and efficacy of risperidone long-acting injectable and oral atypical antipsychotics in schizophrenic patients: Two year naturalistic study*
Bernd Ibach, Jonathan Rabinowitz, Andreas Schreiner, Ludger Hargarter, Bettina Diekamp
- 255.** *Cardiometabolic Health behaviours of community-treated patients with psychosis*
Tim J Lambert, GAbriel Feiler, Christos Pantelis
- 256.** *Social cognition and functional outcome as separate domains in schizophrenia*
Danijela Piskulic, Jean Addington
- 257.** *Mapping of Human Brain for Glucose-Dependent Insulinotropic Polypeptide (GIP) and GIP Receptors Expression: Implications in Schizophrenia*
Amarendra N. Singh, Dipa Basu, K.J. Skoblenick, J.M. Castellano, G. Pontoriero, N. Thomas
- 258.** *Optimization of Treatment and Management of Schizophrenia in Europe: The OPTiMiSE Trial*
Metten Somers, Iris E Sommer, René S Kahn, for the OPTiMiSE Consortium
- 259.** *Exploring cognitive insight in schizophrenia.*
Hélène Tastet, Joel Swendsen, Antoinette Prouteau
- 260.** *Experience of trauma and conversion to psychotic disorder in individuals at ultra high risk (“prodromal”) of developing first episode psychosis*
Andreas Bechdolf, Andrew Thompson, Barnaby Nelson, Sue Cotton, Steve Leicester, Shona Francey, Catherine McNabb, Helen Krstev, Anna Sidis, Magenta Simmons, Patrick D McGorry, Alison R Yung
- 261.** *Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis*
Eva Velthorst, Dorien Nieman, Hiske Becker, Reinaud van de Fliert, Peter Dingemans, Rianne Klaassen, Lieuwe de Haan, Thérèse van Amelsvoort, Don Linszen



- 262.** *Familiarity of subclinical symptoms within healthy siblings of patients with schizophrenia*
Kim Verweij, Tineke Lataster, Eske Derks, GROUP Project
- 263.** *Unique Opportunity for Coherent Insights into the Nature of Earth/Space Natural Radiation Effects on Man's Brain Disorders*
Serge V. Volovyk, Richard S. Keefe
- 264.** *Daily variations in sleep-wake patterns and severity of psychosis*
F.A. Waters, C. Sinclair, D. Rock, A. Jablensky, K. Wulff, R. Foster
- 265.** *Do Psychiatric Case Registers Provide Accurate Estimates of True Rates of Schizophrenia?*
Rinat Yoffe, Nomi Werbeloff, Bruce Dohrenwend, Itzhak Levav, Michael Davidson, Mark Weiser
- 266.** *Effect of the G72 putative risk haplotype on cognitive functions in healthy subjects*
Andreas Jansen, Sören Krach, Axel Krug, N. Jon Shah, Markus M. Nöthen, Marcella Rietschel, Tilo Kircher
- 267.** *Incidence of psychosis in an early intervention for psychosis service in England: first epidemiological evidence from a diverse, predominantly rural setting*
Emilio Fernandez, Frances Cheng, James B Kirkbride, Belinda Lennox, Jesus Perez, Kim Masson, Kathy Lawrence, Katherine Hill, Lisa Feeley, Michelle Painter, Olwyn Gallagher, Graham Murray, Ed Bullmore, Peter B. Jones
- 268.** *BMI and rs1455832 SNP of the ROBO1 gene: association analysis in patients using antipsychotics.*
Jelle Vehof, Asmar FY Al Hadithy, Huibert Burger, Arne Risselada, Bob Wilffert, Dan Cohen, Johan Arends, Hans Mulder, Richard Bruggeman
- 269.** *Altered medial temporal activation related to local glutamate in subjects with prodromal signs of psychosis*
Isabel Valli, James M. Stone, Andrea Mechelli, Sagnik Bhattacharyya, Marie Raffin, Paolo Fusar Poli, Paul Allen, Marc L. Seal, Philip K. McGuire
- 270.** *Excessive focal brain changes in schizophrenia: Different age trajectories measured with longitudinal MRI*
Hugo G. Schnack, Neeltje E.M. van Haren, Wiepke Cahn, Hilleke E. Hulshoff Pol, Rene S. Kahn
- 271.** *Evidence for altered asymmetry of frontal cortex T2 relaxation time in patients at clinical high-risk for psychosis*
Stephen J. Wood, Alex Kline, Alison R. Yung, Dennis Velakoulis, Barnaby Nelson, Patrick D. McGorry, Christos Pantelis
- 272.** *Can low-frequency rTMS really relieve medication-resistant Auditory Verbal Hallucinations? Negative results from a large RCT.*
Christina W. Slotema, Jan Dirk Blom, Hans W Hoek, René S Kahn, Iris E Sommer
- 273.** *Prevalence of depressive symptoms and the effectiveness of antidepressants in routine clinical practice of schizophrenia*
Irene Lako, Katja Taxis, Richard Bruggeman, Rikus Knegtering, Durk Wiersma, Cees Slooff

Index of Presenters and Authors

Aadamsoo K.	87	Allin M.	54, 79	Arranz Garcia S.	112
Aas M.	76, 84	Alptekin K.	97	Artal-Simón J.	113
Abadi S.	22	Altmann D. R.	69	Artaud L.	90, 95
Abdel-Baki A.G.	22, 90, 91, 95	Alvarez B.	82	Asarnow R.	52
Abel K. M.	50	Alvarez E.	95	Ascher-Svanum H.	29, 62, 64, 90, 110
Abi-Dargham A.G.	35,82	Alvarez-Bermejo M. T.	108	Ash D. J.	68
Achim A.	51, 94	Alvarez-Jimenez M.	67	Ashburner J.	103
Ada R.	64	Alvina N.	34	Atakan Z.	57, 105
Adams C. E.	112	Alwi M. N. M.	40	Atkinson R.	83
Adams C. E.	66, 85	Amaddeo F.	45	Attotto M. T.	100
Ad-Dab'bagh Y.	55	Amado I.	52, 75	Auer D. P.	58, 81, 88
Addington J.	34, 50, 66, 72, 91, 93, 115	Amado J. A.	100	Aukes M. F.	50, 60
Adres M.	51	Amador M.	56	Auther A. A.	47, 91
Afolayan G. O.	79	Amaro E.	57	Awad A. G.	32
Afroditi R. C.	73, 111	Amato D.	65	Ayachi M.	61, 107
Agartz I.	56, 79, 97, 101	Amminger P. G.	62, 107	Ayesa-Arriola R.	49, 66, 67, 80, 113
Agerbo E.	74	Anand H.	64	Ayre M.	69
Aggernæs B.	52, 56, 109	Anand R.	53	Azechi M.	61, 70, 82
Agid O.	29, 62, 71, 85, 108, 109	Andersen R.	52, 53	Azizian A.	52
Agius M.	62	Anderson C.	73	Crespo-Facorro B.	35, 49, 67, 77, 100, 101, 102, 113
Agmon-Levin N.	95	Andiappan M.	57	Baaré W.	56, 109
Aguilar E. J.	58, 103	Andreasen N.	102	Baas F.	61
Aguilera M. C.	72	Andreassen O. A.	78, 79, 101	Baccalá L.	57
Ahadieh S.	92	Andreasson K. T.	63	Bachmann S.	60
Ahmed M.	78, 102	Andres S.	75	Backenstrass M.	89
Aikaterini R. D.	73, 111	Andriola I.	100	Backinsky M.	97
Air T.	68	Andruskevicius S.	60	Bacon E.	52
Aitchison K. J.	84	Angona P.	115	Bae K-Y.	86
Akbarian S.	19, 42	Anne W.	73	Baeza I.	61, 75, 80, 98
Akdeniz A.	53	Anselmo K.	81	Baharnoori M.	65
Akimoto K.	67	Antonucci L.	57, 82, 104	Bahk W.	86
Aksu F.	97	Antti J.	74, 107	Bai J.	111
Al Hadithy A. FY	116	Anwar M.	95	Bais L.	58
Wilson A.	34, 50, 66, 72, 91, 93, 115	Aparicio A. I.	54, 106	Bak N.	106
Albert N.	35	Apter A.	51	Baker A.	49, 69
Albrecht W.	64	Apud J. A.	57, 100	Baker C.	113
Aldebot S.	104	Arango C.	31, 32, 36, 51, 55, 56, 76, 80, 84	Bakker P. R.	40
Aleman A.	57, 58, 77, 81, 82, 104	Arasappa R.	97	Bakker S. C.	100
Alemán Y.	51	Araújo A.	49	Bakst S.	51
Alemaný S.	65, 68, 74	Arcuri S. M.	57	Ballard T. M.	107
Alexander J.	88	Arends J.	116	Ballenberger D.	90
Alias A. G.	61	Arendt M. C.	49	Ballesteros A.	101
Alison Y.	19, 32, 34, 48, 52, 72, 92, 99, 115, 116	Arenovich T.	29, 85, 110	Balshaw R.	69
Alizadeh B. Z.	60	Arias B.	55, 72, 79, 101	Banerjee A.	92
Allardyce J.	48, 70	Arima K.	62	Bang-Andersen B.	62
Allebeck P. R.	33, 97	Arinami T.	78	Bansal S.	64
Allen M. P. G.	97	Arkoma S.	80	Bär K-J.	61, 83, 106
Allen P.	53, 57, 99, 105, 116	Armando M.	48	Barakat A.	62
		Arnold J. C.	45, 65, 88	Barceló J. F.	92
		Arnt J.	62	Bark N.	69
		Arranz B.	95	Bark W. M.	86
		Arranz M.	107	Barker G. J.	72, 80, 102, 105



- Barkus E. 96
Barlow K. B. L. 87
Barnaby N. 32, 34, 35, 48, 52,
72, 92, 99, 115, 116
Barnes S. A. 65
Barnes T. R. E. 34, 66, 69, 86
Barnett A. S. 59
Barnett J. 76
Barr A. M. 49, 55, 65
Barraco A. 64
Barrantes-Vidal N. 48, 71, 85, 94
Bartels-Velthuis A. A. 32, 48
Bartholomeusz C. F. 55, 99
Bartko J. J. 48
Bartle-Haring S. 91
Bartolomé L. 77
Bartsch J. 65
Basso A. M. 65
Basterra V. 48, 49
Basu D. 115
Bates A. T. 81, 106
Battaglia M. 51
Batty R. A. 52, 75
Baumgartner S. 53, 114
Baylé F. 74, 109
Bearden C. E. 80
Beaucousin V. 52
Becerra F. 90
Bech P. 63
Bechdolf A. 69, 115
Bechi M. 54
Beck A. 93
Beck D. 69
Becker H. E. 47, 68, 71, 78, 115
Beedie S. A. 60, 61
Begemann M. 78
Behan A. 111
Behan C. 95
Behere R. V. 97
Behr J. 65
Bel T. 109
Belhadjali B. 107
Bell M. D. 52
Bellack A. S. 67
Bellani M. 61
Beltaief F. 73, 96
Belujon P. 61
Belvederi Murri M. 84
Ben Hadj Ali B. 61
BenAbdallah N. 88
Benecke C. 53, 114
Benejam B. 53
Bennett M. 65
Bennett N. 88
Bennett V. 69, 74
Benno S. G. 51, 67, 68, 73, 74,
80, 92, 96, 112
Benoit A. 57
Benseler F. 78
Benson P. J. 60, 61
Bentaleb L. A. 57, 81
Bergami A. 61
Berge D. 112
Berger G. 62
Berger S. 61, 83, 106
Bergmans P. 87
Bergner E. 114
Berhongeray R. 58, 68
Berja A. 93, 100
Berk M. 112
Berle J. Ø. 81
Bernardo M. 61, 69, 75, 77, 78,
98, 113
Bertelsen M. 22, 35, 115
Bertolino A. 26, 27, 31, 57, 58,
80, 81, 82, 98, 100, 103, 104
Bervoets C. 63
Betcheva E. 78
Beveridge N. 108
Bhagat N. 66
Bhagat V. 66
Bhardwaj S. 65
Bhat S. P. 52
Bhattacharyya S. 57, 103, 116
Bhoopathy P. 66
Bickeböller H. 78
Bidzan L. 110
Biedermann F. 53, 63, 114
Bilder R. M. 52, 101
Bilkey D. K. 112
Binbay T. 97
Birbaumer N. 35
Birchwood M. 22, 32, 41, 43, 48
113
Birnbaum M. L. 68
Bitanirhwe B. K. Y. 65, 111
Bitner R. S. 65
Bitsios P. 65, 108
Bittner R. A. 58
Blaine G. 65
Blanc M. 110
Blanc O. 68
Blanchard M. M. 105
Blasi G. 57, 58, 80, 81, 82,
98, 100, 103, 104
Blaszczynski A. 90
Blom J. D. 48, 104, 116
Blot K. 89
Bockaert J. 85
Boda K. 95
Bodatsch M. 60, 82
Bodkin L. 97
Bodnar M. 55, 57
Boersma M. 55
Boettger M. K. 61, 106
Bogers J. 63
Boggian I. 114
Boggs D. 72
Boklage C. E. 73
Boks M. 48, 50, 60, 70
Bombín I. 55
Bonsack C. 68
Booij J. 61
Bookheimer S. 52
Boomsma D. 33
Boonstra G. 55
Boonstra N. 41, 50, 71, 113
Boos H. B. M. 55
Boot E. 61
Bore M. 69
Børglum A. 32, 74
Borgwardt S. J. 21, 57, 105
Bormans G. 33
Borrego R. 109
Borroni E. 59
Bosch F. M. 92
Boshes R. A. 54
Bosia M. 54
Bota R. G. 48
Botillo C. 87
Bouchard R-H. 51, 94
Boucher A. A. 45, 65
Boukadida J. 61, 107
Bourbeau J. 89
Bourdel M-C. 52, 74, 75
Bowie C. R. 94, 113
Boyda H. N. 65
Boydell J. 33, 108
Braff D. 83
Bralet M. C. 67
Brambilla C. 62, 96
Brambilla P. 61
Brammer M. J. 57
Bramon E. 52, 54, 80, 81, 102,
107
Brandon N. 21, 85
Brans R. G.H. 102
Brasfield J. 50
Bravo E. 109
Brazo P. 52, 103
Breen G. 77
Breetvelt E. J. 70
Brennan J. 85
Brett R. 88
Breuer R. 54

Brewer W. J	34, 52	Campanera S.	85	Champagne M.	75
Brinkmeyer J.	60, 82	Campos Mangas M. C.	63	Chan K. P. M.	67, 92
Brnabic A. J. M.	64	Can Saka M.	50	Chan K. K. S.	53, 68, 113
Broberg B. V.	111	Canales-Rodríguez E.J.	102, 104	Chan R. C.	99
Brocco M.	64	Cannon A.	79	Chan S. K. W.	53, 68, 108, 113
Brockhaus-Dumke A.	60, 82	Cannon D. M.	78, 102	Chan W-F.	69, 92
Bromme M. R.	57	Cannon M.	41, 45, 50, 59, 65, 67, 73, 83, 105, 111	Chandon S. T.	114
Brooker H.	87, 93	Cannon T. D.	33, 34, 50, 66, 72, 80, 84, 102	Chang W. C.	67
Broome M. R.	99, 102	Caño A.	53	Charalambides M. A.	63
Brose N.	78	Cantor R.	54	Chen C-H.	48, 54
Broussard C. M.	34, 35, 52	Cantor-Graae E.	74	Chen E. Y-H.	17, 53, 67, 68, 69, 92, 108, 113
Brouwer R. M.	55, 102	Canuet L.	61, 82	Chen J.	85
Brown A. M.	88	Carbutto M.	32	Chen L.	29, 90
Brown A. B.	81, 104	Cardona S.	74, 94	Chen R.	92
Brown J.	65	Carletti F.	102	Cheng F.	116
Brown K.	59	Carlson C.	79	Chesworth R.	88
Brown L. H.	94	Carmeli C.	60	Cheung C.	88
Brown T.	22, 99, 105	Caroff S.	89	Cheyne K.	112
Bruggeman R.	66, 77, 104, 116	Carpenter W.	8, 17, 19	Chiliza B.	72
Bruhn D.	90	Carr V.	34, 49, 51, 73, 96	Chin C-L.	65, 66
Brüne M.	59, 114	Carra G.	27	Chiu C. P. Y.	53, 67, 68, 92, 108, 113
Bruxner A. L.	34, 35, 52	Carrasco-Marín E.	101	Cho H.	86
Bucardo J.	42	Carroll L. S.	78	Cho H-W.	51
Buchanan R. W.	25	Carter C.	58	Choi C-H.	80
Buchanan T.	55	Carter T.	68	Choi J.	91
Buchy L.	55, 57	Casadio P.	32, 74	Choi J. H.	56
Buckley P.	26, 89	Casado-Martinez R.	108	Choi J-S.	80
Buizer-Voskamp J. E.	50, 100	Case M.	110	Choi K. M.	59
Buka S. L.	81	Caseiro-Vázquez O.	67	Choi Y. K.	112
Bullmore E. T.	58, 116	Caspi A.	34, 93, 97	Chong C. W.	92
Bulzacka E.	99	Cassisi J. E.	114	Christensen T.	22, 35, 112
Burba B.	74, 109	Castelao-Lorenzo M.J.	108	Chrysoulaki A.	64, 108
Burdick K. E.	28, 71	Castelein S.	66	Chu E. M.	69, 103
Burger H.	55, 116	Castellana C.	81, 100	Chua S. E.	88
Burkin M.	86	Castellano J. M.	115	Chun J. W.	59
Burne T. H.	33, 65, 73	Castillo D.	34	Chung D. W. S.	92, 67
Burton C. A.	68, 91	Castillo F.	82	Chung M. Y.	56
Burton C. Z.	101	Castro-Fornieles J.	55, 61, 75, 80, 98	Chuo L-J.	64
Butera J.	85	Catalán R.	77, 80	Cichon S.	101
Bymaster F.	62	Caton C.	45	Cimmer C.	95
Byrne L.	76	Catts S.	73, 96, 51	Ciudad A.	113
Byrne M.	49	Cavallaro R.	54	Claes S.	54
Caballero P.	113	Cavus I.	60, 97	Clark E.	72, 94
Cabungcal J-H.	88	Caxton-Martins E. A.	79	Clarke M.	65, 105
Cadenhead K. S.	34, 50, 66, 72, 83	Cealicu Toma F.	67	Clasen L.	75
Caforio G.	57, 58, 80, 81, 82, 98, 100, 103, 104	Ceccarini J.	33	Claudia D.	48
Cahn W. J	33, 55, 77, 100, 116	Cellard C.	51	Cobo J.	63
Cairns M.	108	Celso A.	9, 31, 32, 36, 51, 55, 56, 76, 80, 84	Cohen D.	65, 87, 116
Calama J.	79	Cerruti S.	61	Cohen J.	52
Calhoon G. G.	66	Ceskova E.	56, 103, 112	Cohen M.	49
Calhoun V.	26	Chaddock C. A.	57	Cohen M.	62
Callicott J. H.	26, 57, 104	Chae J-H.	51	Cole J.	79
Cammoun L.	55			Colizzi M.	98



- Collier D. 36, 54, 81, 107
Collins A. C. 112
Collins D. L. 102
Collip D. 33, 70, 100
Coltheart M. 91, 114
Compton M. T. 34, 68, 101, 114
Conca A. 114
Conesa C. 109
Conley R. R. 62, 109, 110
Connolly C. 59
Connolly N. 62
Connor C. 41
Connor D. J. 50, 67
Conroy R. 50
Constant E. 63
Constante M. 54, 107
Contreras F. 53
Conus P. 67, 68, 112
Cook C. 84
Cook W. L. 99
Corbière M. 91
Corcoran C. M. 97
Cornblatt B. A. 19, 34, 50, 66, 72, 91
Corominas A. 109
Correll C. U. 29, 46, 65
Corrivetti G. 74, 109
Cortés B. 79, 101
Corvin A. 54
Costanzo E. Y. 68, 58
Cotes R. O. 63
Cotter D. R. 37, 50, 62, 85, 111
Cotton S. M. 67, 68, 112, 115
Coutinho E. S. F. 85
Cowie T. 61
Craig H. 55
Craig T. K.J. 32
Crespo J. M. 53
Crespo-Facorro B. 35, 49, 67, 77, 100, 101, 102, 113
Crippa J. A. 57, 105
Crocq M-A. 87
Croft M. L. 50
Crow T. J. 54, 103
Csifcsak G. 95
Csomor P. A. 32
Cubells J. F. 71, 101
Cucchiario J. 64, 85, 108, 110
Cuenod M. 55, 60, 88
Cuesta M. J. 48, 55, 77
Cui X. 33
Curcic-Blake B. 81
Currais A. 61
Curzon P. 65
Cutler N. 77
Cyriax U. 107
Cyril M. 53
Daalman K. 48, 58
Dagher A. 35
Dagnall A. 100
D'Agostino R. B. 33, 73
Dale A. M. 101
Dallapiccola B. 58, 80
Dalman C. 33, 50, 65, 97
Dalton T. P. 88
Dalton V. S. 88, 108
Daniel D. G. 36, 48, 110
D'Arcangelo M. 77
Das D. 81, 106
David A. S. 75, 76, 99, 104, 108
David M. 73
Davidson M. 41, 53, 75, 93, 116
Davies C. 107
Davies N. 49
Davis A. 62
Davis R. E. 107, 110
Dawson N. 58, 111
Day M. 65, 66
Dazzan P. 32, 34, 41, 49, 59, 63, 79, 84, 99, 101, 104, 110
de Achaval D. 42, 58, 68
de Cort P. 68
de Frutos R. 100
de Graaf R. 74
de Haan L. 35, 47, 68, 71, 77, 78, 84, 101, 114, 115
De Hert M. A. F. 33, 50, 54, 65, 70, 87, 110
De Jonge P. 71
De la Fuente-Sandova C. 59
De la Iglesia-Vaya M. 58
De la Serna E. 61, 75, 98
De Lepeleire J. 68
De Luca V. 89
De Nanteuil G. 64
De Sanctis P. 83
De Sonnevile L. 51
De Usabel P. 49
De Weijer A. D. 48, 58, 104
De Wit S. 103
Deacon R. 88
Dean B. 61, 62, 107
Dean K. 110
Debilly S. 59
Decker M. W. 65
Decoster J. 70
Decot H. 57
DeDonno M. 50
DeFries A. 94
Deisenhammer E. A. 53, 114
Dekeyne A. 85, 87
DeLapp N. 62
Delcroix N. 103
Delespaul P. 45, 74
Delgado A. 68
DeLisi L. E. 20, 24, 33, 37, 47, 54
Delisle M-C. 81
Dell'Acqua F. 101
DeMartinis N. 92
Dembinskiene L. 87
Demers M-F. 89
Demjaha A. 34, 49, 99
Demontis D. 32, 74
Dempster E. 54
Demunter H. 50
Deng H. 63
Dent L. 92
Denys D. 71
DePatoul A. 63
Derks E. M. 48, 54, 55, 116
Derom C. 96
DeRosse P. 71
Desage A. 69
Desco M. 51, 56, 80
Detke M. 91
Deulofeu R. 61
Devlin L. M. 92
Devlin N. M. 50, 73
Devrim-Üçok M. 60, 83
Di forti M. 32, 69, 74, 84, 104
Di Giorgio A. 57, 58, 80, 81, 82, 98, 100, 103, 104
Di Prinzio P. 50
Dicker P. 62, 85
Dickinson D. 75
Didi R. 109
Diederer K. M. 48, 58, 104
Diekamp B. 115
Díez-Revuelta Á. 53
Dilbaz N. 72, 87, 109
Dima D. 97
Dingemans P. 47, 113, 115
Dittmann R. W. 67
Diukova A. 58, 81, 82
Dixon L. 20, 27
Djordjevic N. B. 72, 113
Djukic-Dejanovic S. 64
Do K. Q. 51, 60, 88
Do T. K. 55
Dockx L. 87
Doege K. 58, 79
Dohen M. 103
Dohrenwend B. 116

Dollfus S.	52, 103	Elliott M. A.	102	99, 110	
Dollings P.	85	Elliott R.	58	Federspiel A.	80
Dolz M.	95	Ellis A.	91	Feeley L.	116
Dombi J.	95	El-Sayeh H.	66	Feeney L.	68
Domènech C.	63, 67	Eltanaihi- Futhmü N.	63	Feiler G.	115
Dominguez M.	50, 89, 104	Elvevåg B.	99, 100	Fejfarova H.	112
Dominguez R.	90	Emsell L.	78	Feldman S.	72
Domjan N.	95	Emsley R.	72, 89	Feldon J.	65, 66, 89, 111
Don L.	110	Enez-Darcin A.	72	Felmingham K.	59
Donaldson C.	93	Eng S. M.	33, 73	Fennema-Notestine C.	101
Donoghue K.	49	Engel R.	53	Ferchiou A.	55
Donohoe G.	54, 59	English J.	62	Fernandez E.	116
Doody G. A.	32, 49, 99, 110	Engström G.	50	Fernandez V.	52
Dora S.	72	Ereshefsky L.	86	Fernandez Torre O.	108
Doron J.	69	Eriksson H.	85	Fernandez-Egea E.	61, 69
Douer J.	58, 68	Eriksson L. R.	64	Ferrante F.	58, 103
Dragasek J.	63	Erlang M.	60	Ferraro L.	73
Dragt S.	68, 71	Erritzoe D.	109	Ferro A.	61
Drake R. J.	58, 71, 86, 112	Escamilla R. I.	64	Fett A-K.	53, 89
Drapalski A.	67	Escarti M. J.	58	Ffytche D.	105
Drees J. M.	69	Eskelinen S.	69	Fienberg A. A.	107, 110
Drukker M.	70, 97, 100	Espinosa R.	68, 114	Findling R. L.	97
Druss B.	68	Estallo J. A.	112	Fink G.	107
D'Souza D. C.	32	Esterberg M. L.	50, 68, 71	Finn M.	20
Duarte J. M. N.	51	Estrada G.	55, 72	Firl A.	58
Dubovsky S. L.	63	Ettinger U.	57, 61	Fischel T.	74, 109
Dumaine A.	100	Evans A.	15, 55, 102	Fisher D. J.	83
Duncan C.	85, 108	Evieta E.	48	Fisher H. L.	32, 84, 110
Dunn E. L-W.	69, 92	Evin G.	62	Fisher M.	84, 104
Dunn G. D.	86, 92	Evins A. E.	93	Fiste M. P.	73, 111
Dunn M. J.	62, 85	Evtjukova A.	91	Flach C.	32, 74
Duñó R.	67	Ewing S. G.	66	Fleischhacker W.	17, 18, 25, 36, 53, 63 98 , 111, 114
Dupuis D. S.	64	Eyles D. W.	33, 65, 73	Flint J.	29
Durell T.	109	Ezcurra J.	76, 98	Flynn G.	59
Durston S.	103	Fabregat V.	109	Föcking M.	62, 85
Dutt A.	54, 107	Fagel S.	51	Foerde K.	52
Dutta R.	33	Fagerlund B.	52, 53	Fohlmann A.	49
Dyachkova Y.	64	Fahrer R.	58, 68	Foley S.	95
Eastman L.	77	Faich G.	33, 73	Fone K. C. F.	88
Ebdrup B. H.	52, 56, 109	Falcone M. A.	32, 69, 74, 76, 99	Fonrodona L.	98
Ebenbichler C.	63, 111	Falgàs I.	63, 67	Fonseca-Rodríguez M. C.	108
Edgar C.	87	Falkai P.	77, 78	Fontanella C.	91
Edlinger M.	111	Fañanas L.	36, 55, 65, 68, 72, 74, 79, 85	Ford J.	60
Egerton A.	57, 105	Farahmand B.	50	Fornito A.	3, 28, 58, 95
Eguiluz J. I.	49, 98, 109	Faraone S. V.	33, 51, 76, 104	Foss J. K.	86
Ehrenreich H.	78	Fargerlund B.	51, 52, 53	Foster R.	116
Ekelund J.	101	Faries D.	62	Foussias G.	71, 85
Elander J.	32	Fatima K.	84	Fox G. B.	65, 66
Elbi H.	97	Fatjó-Vilas M.	36, 55, 72, 79, 85, 101	Foxe J.	83
Eliez S.	56, 79	Favila R.	59	Francey S.	115
Elizagarate E.	76, 98	Fazio L.	57, 58, 80, 81, 82, 98, 103, 104	Francis A.	52, 75
Elkis H.	90, 110	Fearon P.	32, 41, 49, 63, 79, 99, 110	Francis S. T.	93
Elkissi Y.	61, 107			Franck N.	112
El-Kordi A.	78			Franco M. A.	77, 87
Ellenbroek B.	29				



- Franco-Martín M. Á. 53
Frangou S. 22, 97
Frank A. 88
Frank Bastlund J. 111
Franz L. 114
Freeman D. 69
Freimer N. B. 54, 101
Freitas D. E. 97
Friedrichs H. 78
Frigola I. 109
Friis S. 41
Frissen A. 96
Frobose C. 63
Frodli T. 54
Frommann I. 60
Fu C. H. 81
Fuentenebro F. 68, 114
Fuhr P. 83, 106
Fujii T. 62, 100
Fujita K. 87
Fukumoto M. 61, 70, 82, 91, 101, 108
Fukuo Y. 77, 100
Fulham R. 106
Fullerton J. M. 77
Fumeros G. 77
Fung S. J. 62, 85
Funke J. 89
Furlan R. 61
Furukawa O. 87
Fusar Poli P. 46, 57, 102, 105, 106
Fuss J. 88
Gaabout S. 61
Gabriel S. 101
Gabrieli J. D. E. 33
Gabrieli S. W. 33, 81, 104
Gade A. 52, 53
Gadel R. 75
Gaebel W. 60
Gaggiotti M. 83
Gaha L. 73, 74, 96
Gaisler-Salomon I. 18, 88
Gajwani R. 32, 69
Gal G. 70
Gali S. 69
Galindo G. 79, 101
Galindo Y. 74, 94
Gallagher H. 72
Gallagher K. B. 65
Gallagher O. 116
Gallarda T. 75
Gallardo R. 87
Gallego J. A. 71
Gallego J. 78
Galletly C. A. 68, 91
Galsi G. 95
Galsworthy M. 88
Gangadhar B. N. 97
Gao C. 63
Garavan H. 59
García D. 81
García J. 49, 109
García T. F. 92
García C. 80
García F. 87
García J. A. 77
García de Eulate R. 81
García-Amador M. 56
García-Herrera J. 115
García-Martí G. 58, 103
García-Mellado J. 53
García-pares G. 63
García-Ribera C. 64, 88
García-Rizo C. 61, 69, 77
García-Unzueta M. T. 100
Gardner M. 112
Garety P. A. 93, 99
Gargiulo P. Á. 111
Garrett C. T. 84
Remington G. 34, 71, 78, 85, 100, 108, 109
Gaser C. 78, 79, 81, 101
Gass P. 88
Gassab L. 73, 96
Gatz J. 109
Gaur R. 64
Gauthier L. 89
Gaysina D. 77
Geerts H. 93
Geffen Y. 53
Geier J. 33, 73
Geigling I. 61
Gejman P. 20, 24
Gelao B. 57, 58, 80, 81, 82, 98, 100, 104
Gendron A. 85
Genevsky A. 84
Georgieva L. 80
Geramita M. A. 59
Gerasimova O. V. 83
Gertsik L. 86
Gewrólé L. 53
Giakoumaki S. 64, 108
Giampietro V. 80, 102
Gibbons A. 61
Giethlen B. 62
Gigandet X. 55
Gil R. 82
Gil S. 77
Gilberte I. 113
Gilbert E. 51
Gilhooley M. 62
Gill K. M. 60
Gill M. 54
Gillberg C. 71
Gilleen J. 59, 104, 108
Giller E. 91
Giráldez M. 76, 84
Girard C. 53
Girardon S. 87
Giró M. 63, 67
Giros B. 89, 111
Giuliano A. J. 34, 76, 99, 14
Gizewski E. R. 95
Gladwin T. E. 54, 100
Gleeson J. 67, 112
Glenthøj B. Y. 56, 57, 60, 83, 84, 109
Glover C. P. 111
Gluud C. 49, 115
Glynn S. 32
Göde E. 52, 83
Goebel R. 58
Goff D. C. 25
Goff K. P. 76
Gogos J. A. 111
Gogtay N. 39, 43, 75
Gold J. M. 75
Goldberg T. 34
Goldberg X. L. 65, 68, 74
Goldstein J. M. 33, 81, 102
Gomar J. J. 102
Gomez J. 82
Gómez D. 114
Gómez-Benito J. 77
Gómez-Ruiz E. 80, 113
González E. 87
Gonzalez Irizar O. 112
Gonzalez-Blanch C. 49
González-González S. 113
Gonzalez-Mandly A. 93
González-Pinto A. 80
Gooding A. 91
Gordon S. 95
Gordon T. L. 68
Gorgievski V. 111
Goti J. 61
Goulding S. M. 68, 114
Gourion D. 74
Govardhan K. 69
Grace A. A. 21, 35, 44, 60, 61
Graell M. 51, 56, 80
Graf von Reventlow H. 113
Graff A. 59, 81

Graham C. N.	90	Haim A.	89	Heishman S.	72
Graham K.	89	Haley S.	48	Heleven I.	50
Granger B.	90, 95	Halkin V.	63	Hella P.	91
Granger R. E.	64	Hall M-H.	60, 107	Helldin L.	87
Grasby P. M.	103	Hallak J.	110	Hendrick J. P.	107, 110
Grau X. L.	92	Halldin C.	62	Hendrikx H. L. M.	113
Grauer S.	85	Hallqvist J.	65	Hennah W.	101
Graves R. E.	114	Halpin S.	83	Hennekam E. A. M.	50
Gray R.	20	Hamaie Y.	76	Hennig-Fast K.	53
Grayson B.	62, 86	Hamdi A.	65	Henquet C.	25, 70, 98
Grayson D.	42	Hammer T. B.	60	Henriksson K. M.	50
Green A.	47	Hamtat M-L.	69	Henriquez F. L.	88
Green M. J.	28, 53, 114	Han D. H.	78	Henriquez S. A.	88
Green M. F.	25, 75, 76	Han H. R.	78	Henry B.	112
Greenstein D.	75	Handley R. C.	84, 104	Henskens F.	51, 73, 96
Greenwood K.	93	Haneda M.	76	Hepgul N.	84
Greig T. C.	52	Hanewald B.	91	Herceg M.	110
Grenyer B. F. S.	95	Hanna D.	90	Heres S.	110
Grobbee D. E.	55	Hannachi N.	61, 107	Hernandez M-C.	107
Grondin O.	69	Hargarter L.	115	Hernández A. I.	79
Gronenschild E.	56, 78	Harleston D. M.	110	Hernández J. A.	79, 101
Groom M. J.	81, 106	Harley M.	50, 67	Herold C. J.	54, 75
Gross R.	70	Haro J. M.	67	Herreros I.	87
Group M.	112	Harrington H.	34	Herrlich J.	89
Gruber O.	77	Harris A.	59, 91, 114	Hesse A.	82
Gruetter R.	51	Harrison I.	66	Hetrick S.	98
Gruetzner C.	84, 106	Harrison J.	36	Higham D.	58
Gschwandtner U.	83, 99, 106	Harrison M.	34	Higuchi T.	85
Guada J. M.	91	Harrison P.	19, 37	Hilker R.	51
Gueorguieva R.	60	Hart J.	49	Hill K.	116
Guevremont C.	66	Hartberg C. B.	56, 101	Hill M.	68
Gugleta D. D.	72, 113	Harte M. K.	54, 74, 86, 107	Hillebrand A.	105
Guglielmino R.	60	Harvey P. D.	42, 85, 89, 110, 113	Hipler U-C.	62, 84, 107,
Guidotti A.	42	Hashimoto N.	75	Hiroce V. Y.	90
Guidry J. J.	101	Hashimoto R.	61, 70, 82, 91, 101, 108	Hjorthøj C. R.	49
Guilera G.	77	Hashimoto T.	67	Hoeben D.	64, 87, 109, 110
Guillem F.	74	Hassman H. A.	48, 87	Hoek H. W.	116
Guillen F.	82	Hattori K.	62	Hoekert M.	58
Guinjoan S. M.	58, 68	Hauf M.	80	Hofer A.	17, 53, 63, 98, 111, 114
Gulyas G.	95	Haukvik U. K.	56, 79, 101	Hoffman L.	77
Gulyás B.	62	Hauser J.	111	Hoffmann T.	107
Gur R.	26	Hausmann A.	53, 114	Hollis C.	81, 106
Gurovich I.	99	Havlaskova L.	112	Holmén A.	97
Gussew A.	60, 105	Hayhurst K.	86	Holt D.	89
Gustafsson J-E.	33	He Y.	110	Holtzman C. W.	72
Gutierrez M.	49, 76, 98	He Z.	108	Honer W. G.	49, 55, 69, 85
Gutiérrez A.	102	Hearst A.	104	Hong Y.	72
Gyertyan I.	86	Hedman A. M.	56	Hons J.	83
Haahr U.	41	Hehir S.	78	Hoogenbosch M. W.P.	113
Habets P.	44, 56, 78	Heinimaa M.	33, 113	Hoogendam J. M.	105
Habil M. H.	109	Heinisch C.	59	Hooker C.	81
Haenschel C.	56, 58, 79	Heinssen R.	34, 50, 66, 72	Hopwood M.	52
Haertling F.	58	Heinz A.	99	Hori H.	62, 85, 90
Hagler Jr. D.	101			Hörtnagl C.	53, 114
Hagmann P.	55				



Horváth A.	62	Israel A. K.	83, 106	Joffe G.	86, 91
Hosanagar A.	75	Ito A.	108	Joffe M.	86
Hoshino K-Y.	88	Ito F.	59,76	Johannesen J. O.	41
Hougaard D. M.	32, 73, 74	Ito S.	76	Johannesen J. K.	52
Houts R.	34	Ivanov M. V.	64	John C. E.	66
Howells T.	57	Ivanova E.	98	Johns L. C.	99
Howes O. D.	35, 57, 104	Suridjan I.	34	Johns L.	102
Hoyos G.	87	Iwamitsu Y.	90	Johnsen E.	86
Hradil V.	66	Iwase M.	61, 70, 82, 91, 101	Johnston A.	59
Hryniewiecka M.	111	Iwata K.	112	Johnston J.	90
Hua M-S.	75	Iwata N.	64, 70, 77, 87, 100,	Johnston M. E.	90, 112
Huber C. G.	67	Iyer S.	22	Johnston P. J.	49, 106
Huber R.	63	Izaute M.	52	Johnstone E. C.	33
Hubert A.	96	Jaana S.	62, 68, 74, 84, 97,	Jomphe V.	51
Hubl D.	80	107, 113	Jääskeläinen E.	Jon D.	86
Huddy V. C.	53	Jablensky A. V.	76, 97	Jones C. A.	88
Hudson L.	62	116	Jablensky A. V.	Jones E. M.	50
Huf G.	85	Jackson D.	50, 51, 73, 96, 99,	Jones G. A.	107
Hugdahl K.	49, 81	Jackson G. M.	116	Jones P. B.	32, 33, 41, 49, 76,
Hui C. L-M.	53, 67, 68, 69, 92,	Jackson M.	95	79, 86, 97, 99,110	
108, 113		Jacob J.	81, 106	Jonna P.	62, 74, 97, 107,
Hui E. S. K.	88	Jacobson S. C.	106	113	
Hulshoff Pol H. E.	33, 43, 55, 56, 100,	Jagodzinski P.	110	Jönsson E. G.	56, 78, 79
102, 105, 116		Jahchan C.	59, 80	Joo Y. H.	72
Hundemer H. P.	67	Jakovljevic M.	78	Joober R.	22, 55, 57
Hung SF	67, 92	Jamain S.	83	Joost J.	51, 56, 80
Hunt S.	83	James A.	64	Jørgensen L.	65
Hunter M.	34	James B. O.	100	Jørgensen H. A.	81, 86
Hurtig T.	33	Jang J. H.	22	Jørgensen P.	22
Husain N.	112	Janka Z.	111	Joseph C.	32, 69,
Hutchinson G.	32	Jann K.	80	Verghese J.	93
Hutson P.	21	Jansen A.	95	Joukamaa M.	33
Huttunen M.	65, 84, 102	Jansen M.	80	Jouko L.	74, 84, 97, 113
Hwang S. S.	98	Janssen J.	78, 116	Joyce E. M.	34, 66, 69, 103
Hwu H-G.	48, 75	Jardri R.	58, 81, 82	Juckel G.	113, 114
Hyde T. M.	104	Jarema M.	51, 56, 80	Juelich R.	81
Ibach B.	115	Järvelin M-R.	59	Jula A.	74, 107
Ibañez I.	72	Jasani R.	110	Paruch J.	71, 106
Idris N.	86	Jasovic Gasic M.	101	Jung D-U.	110
Iedema J.	75	Javitt D. C.	69	Jung H. Y.	98
Iljima Y.	62, 100	Jayaram M. B.	109	Jung M. H.	80
Ilke N.	70, 82, 91, 101	Monestes J. L.	25	Jung S.	92
Ikedo M.	77, 100	Jenkins W. A.	53	Jung S-S.	110
Ikezawa K.	61, 70, 82	Jenkins W.	49	Jung W. H.	80
Ilankovic L. M.	53, 103	Jenner J. A.	55	Justicia A.	69
Illa J. M.	55	Jennings R. G.	32, 48	Juuhl-Langseth M.	97
Inada T.	77, 100	Jens P.	101	Kaakinen M.	33
Inkpen R.	83	Jeon Y.	34	Kaczorowski J. A.	71
Isabelle B.	34	Jeon Y.-W.	86	Kahn R. S.	31, 33, 34, 37, 48,
Ishihara T.	100	Jeong B.	83, 114	50, 55, 56, 58, 60, 70, 72, 82, 100,	
Ishii R.	61, 70, 82, 101	Jeppesen P.	59	102, 103, 104, 105, 115, 116	
Ishkhanyan B.	52	Jhee S.	22, 35, 115	Kahn W.	105
Ising H. A.	71	Joa I.	86	Kaiser S.	83, 89
Iso S.	90	Jodo E.	41	Kala K.	58
Ison R.	93		88	Kalali A.	108, 110

Kalbitzer J.	109	Kemp A.	89	Kline A.	116
Kalmady S. V.	97	Kempton M. J.	33, 97	Klingberg S.	82, 89
Kalogerakou S.	75	Kendall D. A.	88	Klinge R.	93
Kambeitz J. P.	53, 57, 81, 103, 105	Kendall K. M.	78	Klosterkötter J.	60, 71, 82, 94, 95, 106, 113
Kamino K.	101	Kenis G.	70, 96, 100	Knegtering H.	66
Kanaan R.	80	Kennedy B.	80	Knegtering R.	57, 58, 81, 116
Kane F.	80	Kennedy J. L.	24, 27, 78, 100	Knöchel C.	56, 79
Kane J. M.	17, 18, 19, 29, 32, 33, 47, 70, 73, 91, 110	Kenneth H.	49, 81	Knoflach F.	107
Kang J. I.	48	Kern R. S.	75, 76	Knott V. J.	83
Kang S. H.	78	Kesby J.	33	Knowles E. E. M.	75
Kaplan Z.	110	Keshavan M. S.	90	Knowlton B.	52
Kaprio J.	84	Keskin-Ergen H. Y.	60, 83	Knudsen G. M.	109
Kapur S.	29, 35, 41, 46, 57, 59, 62, 65, 81, 85, 87, 108, 109, 110	Keßler M. S.	59	Knuesel I.	89
Karagianis J.	64	Khan A.	88	Knyazeva M. G.	60
Karayal O. N.	33, 63, 73	Kido M.	56	Ko P.	73
Karayiorgou M.	29, 111	Kikinis R.	79	Kobath K.	91
Kargel C.	82	Killackey E.	28	Kobayashi H.	71, 76
Karl T.	45, 88	Kim B-S.	72	Kobayashi S.	99
Karlsogdt K. H.	22, 80	Kim C.	86	Koch E.	74
Karouzos C.	75	Kim E.	80	Koch K.	104
Kasai K.	37	Kim H.	86	Koch S.	106
Kaslow N. J.	68	Kim I.	72	Kodama M.	100
Kasperek T.	56, 103, 106	Kim J-J.	59, 103	Koen L.	72, 89
Katagiri N.	71, 76	Kim J-M.	86	Koethe D.	33
Katayama T.	88	Kim J. M.	83	Kohler S.	70
Katsura M.	76	Kim J. A.	83	Köhler A.	107
Katz Porat B-S.	95	Kim K.	56	Koivukangas M.	91
Kaufmann A.	98	Kim K. S.	86	Kok H. D. H.	113
Kausch O.	50	Kim K. R.	48	Kolachana B.	104
Kaushal S.	69	Kim S. H.	83, 114	Kollack-Walker S.	29, 86, 90, 109, 110
Kavanagh F.	105	Kim S. Y.	103	Kolliakou A.	69, 74
Kaviani H.	64	Kim S. I.	103	Kong B-G.	110
Kawamoto Y.	62, 85	Kim S. A.	69	Konigsberg W.	54
Kawasaki Y.	56, 102	Kim S-W.	86	Koning J. P.	40
Kawashima K.	64, 77, 100	Kim T. Y.	56	Konstantoula O. G.	73, 111
Kaya H.	72	Kim Y.	86, 106	Kontis D.	75
Kayama Y.	88	Kimura S-i.	89	Kopala L.	69
Kayo M.	90	King M. C.	20, 24	Kopsahili I.	64, 108
Kazui H.	70, 82, 91, 101	Kingdon D.	20	Korcsog P.	87
Keefe R. S. E.	17, 34, 42, 53, 75, 89, 116	Kinon B. J.	29, 86, 90, 110	Koren D.	51, 58
Keeley H.	73	Kinoshita Y.	62, 64, 77, 85, 100	Korsakova N.	99
Kegeles L. S.	82	Kinsella A.	95	Kortekaas R.	104
Kelin K.	64	Kircher T.	26, 78, 82, 89, 91, 105, 116	Korver N.	47, 114
Kelleher I.	50, 67, 73, 105	Kirkbride J. B.	116	Koskinen S.	97, 113
Kellendonk C.	88	Kirkpatrick B.	61, 69	Kotler M.	109
Kellermann T.	105	Kirner-Veselinovic A.	82	Koudas V.	108
Kelley M. P.	92	Kishi T.	77, 87, 100	Koutsouleris N.	21, 80
Kelly C.	59	Kiss B.	62, 86	Kovacs Z. A.	95
Kelly D. L.	72, 110	Kissling W.	70	Kowalchuck I.	69
Kelsoe J. R.	101	Kitajima T.	77, 100	Koyama T.	75
Kemmler G.	53, 63, 98, 111, 114	Klaassen R.	41, 71, 115	Krabbendam L.	53, 77, 89, 104
		Klaus S.	78	Krach S.	78, 82, 91, 116
		Kleinman J. E.	37, 99	Kraftsik R.	88
		Kleisas S.	75		



- Krakowski M. I. 83
Krarup G. 22, 35, 86, 112, 115
Kravariti E. 34
Krebs M.-O. 36, 52, 74, 75
Kreilgaard M. 62
Kremer C. 33, 73
Kremlak J. 83
Krishnamurthy G. 85, 108
Kroken R. A. 86
Krstev H. 115
Krug A. 78, 89, 116
Krystal J. 60
Ku J. 103
Kubicki M. 22, 59, 79, 102
Kudo T. 91
Kuepper R. 70
Kuipers E. 93
Kulak A. 51
Kumar D. 84
Kumra S. 46
Kunugi H. 62, 85, 90, 100
Kupferschmid S. 80
Kurachi M. 102
Kurimoto R. 61, 82
Kusumi I. 75
Kwapil T. R. 48, 71, 94
Kwon J. S. 80, 86
Kyriakopoulos M. 97
La Barbera D. 73
Laan W. 50
Labad Alquezar A. 112
Labelle A. 83, 85
Lacluyse K. 50
Lafuente A. 78
Lagodka A. 75
Laguerre A. 55
Lahaye M. 64, 87, 109
Lahmar A. 73, 96
Laine T. 113
Lakkonen M. 91
Lako I. 116
Lalonde F. 75
Lalonde P. 81, 90, 95
Lam J. 65
Lam M. M. L. 53, 67, 68, 92, 108, 113
Lambert M. 67, 68, 92, 112
Lambert T. J. 67, 70, 90, 92, 108, 115
Lamonaca D. 114
Lancon C. 68, 100
Landgraf S. 52
Landreijer K. 101
Lang D. J. 49, 55
Langbein K. 80, 81, 82
Langdon R. A. 89, 91
Lange E. H. 79
Lange E. 101
Lanktree M. 27
Lankveijer K. 84
Lappin J. 41, 63, 79,
Lardinois M. 33, 70, 100
Larkin C. 68
Larsen A-M. 49
Larsen T. 41
Larson M. K. 72
Larsson H. 106
Lässer M. M. 54, 75
Laszlovszky I. 62
Laszy J. 86
Lataster J. 33
Lataster T. 33, 69, 70, 100, 116
Latimer E. 22
Law A. 19
Law C. W. 67, 92
Lawani A. A. 111
Lawrence K. 116
Lawrie S. M. 21, 33
Lawson A. H. 90
Lázaro L. 55
Le Quach P. 22
Leblanc J. 89
Leboyer M. 55, 96, 99, 100
Lecardeur L. 52
Lechleitner M. 63
Lecomte T. 47, 91
Lee E. 115
Lee E. 104
Lee E. 48
Lee G. 92
Lee H. 103
Lee J-il 78
Lee J. S. 72
Lee N. 64
Lee S. 35
Lee S. 86
Lee S. 86
Lee S. Y. 48, 83
Lee Y. S. 51
Leeson V. C. 34, 66
Leff J. 32
Lehner T. 8, 24
Leicester S. 115
Leiderman E. A. 50
Leiguarda R. C. 58, 68
Leiner A. S. 68
Lencz T. 71
Lennox B. 116
Lensvelt-Mulders G. 96
Leon A. 91
León-Ortiz P. 59
Lepage C. 55, 102
Lepage M. 55, 57
Lesage A. 90, 95
Lesnikova N. 69
Lester H. 41
Lesturgeon J-A. 68
Letourneau G. 57, 91,
Leucht S. 29, 87
Leung C-M. 115
Levav I. 70, 116
Levine S. Z. 51, 90, 96
Levinson D. 54
Levy D. L. 60
Lewandowski K. E. 48
Leweke F. M. 25, 33, 106
Lewin T. 34
Lewis D. A. 19, 39, 43
Lewis G. 33, 97
Lewis S. W. 80, 86, 92, 96
Leza J. C. 84
Li K. 63
Li P. 107
Li Q. 88
Li X. 89
Libiger J. 83
Lichtermann D. 101
Liddle E. B. 79, 81
Liddle P. F. 58, 79, 81, 82, 93, 105, 106
Lieb R. 33, 50, 70
Lieberman J. A. 78, 100
Lieberman H. M. 86
Liechti S. 98
Liemburg E. J. 81
Light G. 83
Lim M. P. 85
Lin A. 34, 35, 52
Lincoln T. 27
Linden D. E. J. 56, 58, 79, 103
Links T. P. 58
Lino B. J. 53
Linscott R. J. 92
Linszen D. H. 35, 47, 61, 68, 71, 78, 84, 101, 113, 115
Lipp H-P. 88
Lipp O. 81
Lisanby S. H. 82
Liu A. 65
Liu C-C. 48, 75
Liu F. 72
Liu H. 108
Liu J. 92

Liu P.	98	Madsen M. T. R.	49	Marshall M.	41, 71
Liu Z.	108	Maeda K.	67	Marshall N.	54
Llorca P-M.	68, 100	Magalona C.	57	Marsman A.	105
LLorente C.	76	Magerkurth J.	79	Marti-Bonmati L.	58, 103
Lloyd K. J.	86	Magnotta V.	102	Martín C.	79
Lo G.	94	Magnusson C.	65	Martín C.	101
Lo S.	72	Maher B.	51	Martín M.	55
Lo Bianco L.	57, 58, 80, 81, 82, 98, 103, 104	Mahowald T.	60	Martine R.	53
Løberg E-M.	49, 81	Maitra R.	78, 79, 101	Martinez G.	74, 89, 90, 109
Loch A. A.	115	Major B.	28	Martinez U.	82
Lodge D. J.	60, 84	Mäki P. H.	33, 76, 97	Martínez-Arán A.	77
Loebel A.	64, 85, 86, 108, 110	Makris N.	33, 81, 104	Martínez-Díez J.	108
Loevenbruck H.	103	Malcolm J.	79	Martínez-García O.	67, 100
Lohrmann T.	106	Malcolm P.	107	Martínez-Vizcaino V.	54
Loiseau F.	87	Malherbe P.	107	Martino G.	61, 84
Lomeña F.	78	Malhotra A. K.	27, 71	Martin-Santos R.	57, 105
Long L.	88	Malla A.	22, 55, 57, 110	Martone M.	103
Longden E.	48	Mallikarjun P.	58, 79, 81, 82	Maruff P.	93
Lönnqvist J.	74, 84, 97, 113	Maltby J.	96	Marzullo G.	51, 73
Loo B-M.	74, 107	Malzahn D.	78	Mas S.	78, 109
Loo C.	34	Mamo D. C.	110	Masana G.	77
Loos S.	82	Manahan-Vaughan D.	89	Masellis R.	82, 100, 104
Lopez J.	58, 68	Manchanda R.	89	Mashal N.	81
Lopez L. L.	111	Mancini-Marie A.	57, 98	Masson K.	116
Lopez P.	81, 82	Mandl R. C. W.	105	Mata I.	22, 35, 49, 66, 67, 93, 100, 101, 102
Lopez-Lorenzo S.	95	Mane A.	78, 112	Mateos J. J.	78
Lorenzetti V.	95	Mann R.	95	Mateos-Pérez J. M.	51
Lorenzi C.	54	Mann S.	71	Mates S.	107, 110
Loughland C. M.	34, 51, 69, 73, 96	Mannoury La Cour C.	64, 85	Mathalon D.	60
Loukkola J.	76	Manon H.	70	Mathieu F.	55
Fañanás L.	36, 55, 65, 68, 72, 74, 79, 85, 101	Manschreck T. C.	51, 54	Matonhodze J.	108
Louvrier J.	87	Mao X.	82	Matsui M.	75, 99
Loze J. Y.	63	Maples N. J.	34, 89	Matsumoto K.	59, 76
Lubin G.	93, 97	Parellada M.	51, 55, 56, 76, 80, 84	Matsuo J.	62, 85
Lublin H.	56, 87, 109	Marcelis M.	56, 78	Matsuoka H.	59, 76
Lubman D. I.	72, 94, 95	Marcepoil A.	64	Mattai A.	75
Lucas E.	77	Marco de Lucas E.	80	Mattay V. S.	57
Luckett G.	91, 114	Marder S. R.	14, 25, 32, 64, 75, 89	Mattheisen M.	54
Lugnegård T.	71	Marecek R.	56	Matura S.	79
Lukacsova I.	63	Marek G.	66	Maurer K.	58
Luks T.	104	Marenco S.	59	Mausbach B.	42
Lum M.	66	Marin J.	81	Mauskopf J.	90
Lungu O. V.	81	Marin P.	85	Maximilian B.	48
Luzi S.	74	Marinelli V.	61	Mayoral F.	90, 115
Lyne J.	68	Marino C.	51	Mayoral M.	56, 76
Lythgoe D.	105	Markku H.	74	Mayoral van Son J.	113
Ma R.	115	Marques T.	32, 59, 84, 101, 104	Maziade M.	51, 94
MacEwan G. W.	49, 55, 69, 85	Marqueta C.	74, 94	Mazoyer B.	103
Maciulis V.	110	Marquis K.	85	Mazzoncini R.	49
Mackinnon A.	112	Marsh P. J.	91, 114	M'Bailara K.	69
Madill A.	48	Marsh S.	107	McAlonan G. M.	88
Madsen A.	87	Marshall K. M.	54	McCabe K. L.	34, 51, 73, 96
				McCann T. V.	72, 94
				McCarley R. W.	37, 85, 102



McCarthy L.	41	Menezes A. K. P. M.	90	Moffitt T.	34
McCarthy P.	78	Meng H.	74	Moghaddam B.	18, 106
McCormick R.	50	Menon M.	81	Moilanen I. K.	33, 76
McDermott M.	63	Merchán-Naranjo J.	76	Moix M. S.	92
McDonald C.	52, 54, 78, 80, 102	Mérette C.	51, 94	Molero P.	82
McDonald S.	53	Merino V.	53, 77	Molina V.	53, 79, 101
McDowell K.	84	Mesholam-Gately R. I.	76, 102	Molloy C.	50
McFarland J.	78, 102	Meskaldji D.	55	Molto M. D.	110
McFarlane W. R.	99	Metzak P.	103	Mondelli V.	32, 84, 104
McGlashan T. H.	34, 41, 50, 66, 72	Metzner M.	106	Monducci E.	48
McGorry P. D.	34, 35, 44, 52, 55, 67, 68, 112, 115, 116	Meuli R.	55	Money T.	107
McGrath J. J.	33, 41, 65, 73, 96, 113	Meyer E. C.	34	Monfort A.	55, 79
McGreal S.	67	Meyer J.	77	Mongil B.	77
McGregor I. S.	45	Meyer U.	65, 66, 89, 111	Montag J.	91
McGuffin P.	77	Meyer V.	69	Montero I.	27
McGuire J.	91, 114	Meyer-Lindenberg A.	31, 43, 45	Montgomery W.	64
McGuire P. K.	21, 31, 41, 46, 49, 57, 59, 72, 80, 81, 99, 102, 103, 105, 116	Mezler M.	66	Moolchan E.	72
McGurk S.	20	Miao M. Y-K.	69, 92	Moorhead T. W. J.	33
McIntosh A.	28, 43, 80	Micheau J.	45	Mora M. C.	58, 68
McIntyre A.	69	Michel C.	51, 73, 96	Morakinyo O.	111
McKenna P. J.	102, 104	Michie P. T.	51, 73, 83, 96, 106	Moran-Gates T.	112
McKie S.	58	Micó J. A.	84	Morelli C.	66
McKinney S. M.	88	Miettunen J.	33, 76, 97, 101	Moreno C.	51, 56, 84
McKinzie D.	62	Mikl M.	56, 103	Moreno D.	51, 56, 80
McLean M.	105	Milanova V.	109	Moreno P.	115
McLean S. L.	107	Milanovic S. M.	33, 81	Moreno-Calle T.	35
McMahon R. P.	72, 110	Milea D.	96	Moreno-Kustner B.	115, 90
McNabb C.	115	Millan M. J.	64, 85, 87	Morgan C.	41
McNaughton N.	92	Milleit B.	60, 62, 84, 105, 107	Morgan C.	32, 34, 49, 63, 79, 84, 99, 110
McNeil T. F.	50, 56	Milleit C.	62, 84, 105, 107	Morgan K.	41
McQueen G.	32, 69	Millen B. A.	86	Morgan K. D.	32, 49, 63, 79, 99
McWilliams S.	95	Miller B.	69	Morgan V. A.	50, 73, 96
Meador Woodruff J.	37	Miller D.	89	Mori N.	112
Méary A.	55, 96, 99, 100	Millet B.	64	Morihara T.	91
Mechelli A.	72, 81, 116	Millette C.	74	Morin C.	91
Mechri A.	73, 74, 96	Minassian A.	101	Morita K.	71, 76
Medalia A.	40, 66, 89, 91	Mingoa G.	80, 81	Morita Y.	104
Medellin E. M.	89	Miralles M. L.	55	Moritz S.	93
Medoff D.	67	Miret S.	55, 85	Moriwaki M.	64, 87
Meffre J.	85	Mirnic K.	19, 37, 42	Morrens M.	63
Meier W.	60	Mitchel S.	64	Morris B. J.	58, 111
Meijer C.	114	Mitchell K. J.	55	Morris D.	54
Meijer J. H.	78	Mitchell P. B.	53	Morris R. G.	57
Meiron O.	71	Mitelman S.	67	Morrison J. M.	76
Meisenzahl E.	31, 80	Mitjans M.	72	Morrison T. A.	92
Melau M.	112, 115	Mittoux A.	64, 87, 110	Mors O.	32, 74
Mellacqua Z. B.	69, 74, 79	Miyaji S.	90, 113	Mortas P.	59
Melle I.	41, 79, 101	Miyakoshi T.	59	Mortensen H. B.	87
Meltzer H. Y.	78, 100, 108	Miyaoka H.	90, 113	Mortensen P. B.	32, 73, 74
Menchón J. M.	53	Mizrahi R.	34	Morton S. E.	92
Mendrek A.	81, 103	Mizuno M.	71, 76	Mosolov S. N.	109
		Moamai J.	67	Mouttet F.	65
		Moberg P.	77	Mowry B.	51, 73, 96
		Modinos G.	82	Moya J.	72

Muehlbacher M.	114	Neggers S. F. W.	58 , 82, 104	O'Carroll C.	105
Muehleisen T. W.	101	Neill J. C.	54, 62, 65, 74, 86, 107	O'Connor J. A.	32, 69, 74, 76, 99
Mueller D. J.	27	Nelson B.	32, 34, 35, 48, 52, 72, 92, 99, 115, 116	O'Daly O.	104
Mueser K. T.	17, 20, 27, 28	Nelson D.	62	Oddi M.	49
Mühlbacher M.	53	Nemethy Z.	86	O'Donnell P.	18, 66
Mujica-Parodi L. R.	103	Nemoto K.	101	O'Donoghue B.	68
Mukkala S.	76	Nemoto T.	71, 76	O'Donovan M. C.	54, 78, 80
Mulder H.	116	Nenadic I. T.	78, 79, 80, 81, 82, 101	Oertel-Knöchel V.	56, 79, 103
Mulder N. C. L.	77	Neroutsos E. G.	73, 111	Ogasa M.	64, 85, 86, 108
Mule' A.	73	Nesvåg R.	56, 79, 101	O'Gorman R.	59, 105
Muller B. W.	82, 89, 95	Neuhaus D.	62, 84	Oh J. S.	80
Muller C.	65	Newcomer J. W.	110	Oh M-K.	110
Müller N.	53	Newell K.	49	Ohga H.	64
Müller R.	60, 82	Newton R.	64	Ohi K.	61, 70, 91, 101, 108
Muñoz M. J.	55	Neznanov N.	74, 109	Øhlenschläger J.	22
Muntjewerff J-W.	78	Ng A.	91	Ohmuro N.	59, 79
Murasaki M.	85	Ng H. P.	79	Ohnishi T.	101
Murphy J. B.	50, 83, 105	Nicole L.	90, 95	Ojeda N.	98, 109
Murray G.	33, 97, 116, 76	Nieboer R. M.	71	Ojeil N.	82
Murray R. M.	24, 25, 28, 32, 33, 34, 44, 41, 47, 49, 52, 54, 57, 59, 68, 69, 72, 73, 74, 78, 79, 81, 84, 97, 99, 101, 102, 104, 107, 110	Niehaus D.J.H.	87	Okahisa Y.	100
Musso F.	82	Niehaus D.	72, 89	Okamoto M.	88
Musso G.	71	Nielsen M. O.	57	Okamoto N.	62
Mustonen U.	84	Nielsen R. B.	96	Okay I. T.	72
Myhr G.	76	Nielsen S. M.	62	Okochi M.	91
Myin-Germeyns I.	26, 33, 40, 45, 69, 70, 72, 96, 100	Nieman D. H.	47, 68, 71, 95, 115	Okochi T.	77, 100
Naber D.	17, 67, 87, 90, 92, 109	Niemi J.	91	Okolo M.	111
Nadeau Marcotte F.	66	Niemi J.	91	Okumura T.	77, 100
Nagarajan S.	104	Nienhuis F. J.	71	Olajossy M.	110
Nagels A.	82	Nikkel A. L.	65	Olié J-P.	52, 75
Najman J. M.	96	Nikolaides A.	71, 106	Olivares J. M.	113
Nakahachi T.	61, 82	Nobrega J. N.	87	Oliveira G. M.	90
Nakamura K.	56, 102	Noda T.	91	Oliver H.	35, 57, 104, 105
Nakamura Y.	78	Noethen M. M.	101	Olivier G.	53
Nakano E.	110	Nolen W.	57	Olsen B.	112
Nakstad P. H.	101	Noordsy D. L.	32, 47, 63	Olson S.	89
Nanko S.	78	Nordentoft M.	22, 35, 49, 51, 84, 112, 115	Omori M.	62
Napryeyenko O.	74, 109	Nordholm D.	84	Önay H.	97
Naraine M.	88	Nørgaard M.	96	Ooms R.	58
Nardini F.	64	Norgaard-Pedersen B.	73	Oorschot M.	72
Nardini M.	57, 58, 80, 81, 82, 98, 100, 103	Norman R.	89, 22	Oosthuizen P.	72, 89
Nasir A.	96, 51, 73	Nosarti C.	79, 97	Ophoff R. A.	48, 50, 54, 60, 100
Natesan S.	65, 87	Nosten-Bertrand M.	111	Opjordsmoen S.	41
Nath G.	52	Nöthen M. M.	54, 78, 116	Opler M. G.	94, 98
Navarra R.	85	Novak G.	32	Oranje B.	52, 53, 56, 60, 83, 109, 111
Navarro M. E.	55	Novick D.	67	Ordoñez-Prieto C.	108
Navas D.	115	Nuechterlein K.	28, 75, 76, 80	Oresic M.	62, 84
Nave K-A.	78	Nyffeler M.	89	Orlova V. A.	83
Navratilova P.	112	Nygård M.	81	Ormel J.	75, 82
Navoaz R.	84	Nyilas M.	46	Ortet G.	55, 72
		Obembe A.	79	Ortiz Gil J.	104
		O'Callaghan E.	68, 95	Ortiz-García de la F.V.	102
				ortuño F.	81, 82
				Osuntokun O. O.	86
				Otani S.	89, 111



- Otero S. 80
Otsa L. 91
Otto M. 107
O'Tuathaigh C. M. 111
Ouellet-Plamondon C. 90, 95
Ousley O. 71
Ouzonidou K. G. 73, 111
Overø K. 63
Owen M. J. 24, 26, 54, 78
Owens D. G. C. 33
Owens S. 68
Owolabi O. O. 79
Oyewumi L. K. 94
Ozaki N. 77, 100
Ozeki Y. 85
Özkay F. 97
Paavola J. 90
Pacífico R. P. 98
Painter M. 116
Palaniyappan L. K. 79
Pallanti S. 53
Palmier-Claus J. E. 92
Palova E. 63
Pampín-Alfonso A. 49
Pan S. 63
Panagides J. 63
Pante J. 79, 56
Pantelis C. 21, 34, 37, 39, 46,
51, 52, 55, 61, 73, 75, 95, 96, 115,
116
Fiori Nastro P. 48
Fusar-Poli P. 102
Girardi P. 48
Papageorgiou K. 94
Papagni S. A. 81
Paparelli A. 32, 69, 74
Papas A. 76, 99
Papazacharias A. 103, 104, 57, 80
Papiol S. 55, 78, 79, 101
Pappadopulos E. 62
Paquet K. 49
Paradis M-È. 51
Pardo G. 67
Pardo M. 95
Parellada E. 70
Parellada M. 80, 84, 51, 55, 56 ,
76
Pariante C. M. 59, 74, 84, 104
Park E-J. 83
Park H-J. 59
Park H-Y. 80
Park I. H. 103
Park J. Y. 48
Park S. B. G. 105
Parker A. 98
Parnas J. 94, 51
Paruch J. 106, 71
Patel J. 89
Patel M. X. 108, 63
Paterakis P. 109
Pateron C. 111
Patterson P. 113, 32, 41
Patterson T. 42
Paul D. 96
Paulus F. 91
Pauly K. 105
Pausch M. 85
Pavia J. 78
Pearlson G. 78
Peck G. 49
Pedersen C. B. 32, 73, 74
Pedersen M. S. 74
Pedroso I. 77
Peerbooms O. 100, 54, 70
Pelavin P. E. 102, 79
Pelayo-Teran J. M. 35, 66, 108
Peleg-Raibstein D. 111, 65
Pelekanos M. 33
Peltonen L. 84, 101
Peña J. 49, 79, 98, 109
Penadés R. 77, 80, 98
Peng X. 62
Penn D. 89
Perälä J. 62, 74, 97, 107,
113
Peralta V. 48, 55, 85
Perea M. V. 53, 77
Pereira A. 107
Perez J. 116
Perez O. 115
Perez V. 95
Pérez-Iglesias R. 35, 66, 67, 100,
101, 102
Perkins D. O. 50, 66, 72
Perlini C. 61
Peters E. 43, 93
Petersen B. N. 32
Petersen L. 22, 35, 115
Peterson J. N. 63
Peterson M. 86
Peuskens B. 87
Peuskens J. 33, 50, 54, 63, 64,
70, 87, 109, 110
Pffaffenberger N. 98
Pflueger M. O. 83, 99, 106
Philip B. 90
Phillips D. 86, 108
Phillips G. 91
Phillips G. A. 90
Phiri P. 63
Picchioni M. M. 33, 34, 49, 52, 57,
68, 78, 79, 80, 81, 102, 107
Pieters G. 68
Pieterse J. 51
Pietersen C. Y. 85
Pietrowsky R. 106
Piezer K. 109
Pijnenborg M. 57
Pinborg L. H. 109
Piñero B. 74, 94
Pinfold V. 66
Pino O. 77
Pins D. 59
Pintsov A. O. 94
Pirovano A. 54
Piskulic D. 91, 93, 115
Pitschel-Walz G. 20, 27
Pitsi D. 63
Pittman B. 32
Pitts K. 85
Pla J. 82
Plath N. 111
Pletnikov M. 29, 45
Polavieja P. 113
Poldrack R. 52
Polito V. 91
Pomarol-Clotet E. 102, 104
Pontoriero G. 115
Poole Hoffmann V. 109
Popielek M. 85
Popolizio T. 57, 80, 82, 104
Pope F. C. 77
Porcelli A. 81, 98
Porteous D. J. 19, 55
Porter R. H. 107
Porto-Payán J. M. 53
Potapov A. V. 109
Potkin S. G. 31, 108, 109, 110
Potter N. 95
Potvin S. 95, 57
Poulsen H. 84
Poulsen M. N. 62
Poulton R. 34
Pousa E. 63, 67
Powell J. 54, 74, 110
Pozzoli S. 104
Prados J. M. 114
Prasad K. 59
Prata D. P. 54, 80, 81
Pratt J. A. 111, 58, 66, 88
Prescott C. 69
Press C. J. 112
Price G. 22, 103
Prikryl R. 56, 103, 112
Prikrylova Kucerova H. 103, 112

Procyshyn R. M.	49, 65	Razafimandimby A.	52, 103	Rivera Mindt M.	91
Prouteau A.	115	Rebollo I.	68	Rizzo M.	100
Provencio M.	68, 114	Rebsch C.	59	Roach B.	60
Puig O.	98	Reckless G. G.	87	Roberts C. W.	88
Pujol C.	74, 94	Reeder C.	53	Robinson D.	88
Pujol N.	77, 80	Regland B.	78	Roca A.	74, 94
Pulido G.	55	Regojo A.	52	Roche R. AP	83, 105
Pulver A.	113	Rehulkova J.	106	Rock D.	116
Pung C. J.	101	Reichenbach J. R.	60, 80, 101, 105	Roder V.	40
Purcell R.	98	Reichenberg A.	34, 75, 76, 93, 97, 99	Rodewald K.	83, 89
Putkonen H.	91	Reig S.	51, 56, 80	Rödiger K.	62, 84
Quarto T.	58, 80, 103	Reim K.	78	Rodríguez J. M.	113
Quee P. J.	77, 98	Reinders A. A. T. S.	59, 104	Rodríguez R.	74, 94
Quintana-Gonzalez V.	108	Reinders S.	41	Rodríguez Sánchez J. M.	35, 49, 66, 101, 102
Quintero C.	102	Reines S.	91	Roebel M.	104
Raaijmakers Q. A. W.	75	Reininghaus U.	32	Roebroek A.	58
Raballo A.	94	Reis Marques T.	32, 84, 101, 104	Roesch-Ely D.	89
Rabe-Jablonska J.	49, 79, 110	Reith W.	77	Roffman J.	78
Rabinowitz J.	51, 74, 90, 96, 109, 115	Rejas J.	77	Rogers B.	79
Rachow T.	83, 106	Rembeck B.	64	Roiser J.	46
Racsmany M.	95	Remington G.	34, 71, 78, 85, 100, 108, 109	Roiz-Santiañez R.	80, 93, 102
Radulescu A. R.	103	Renken R.	82	Rojo E.	77
Radyushkin K.	78	Rentrop M.	83, 89	Romano R.	57, 58, 80, 81, 82, 98, 100, 103, 104
Raffin M.	116	Renwick L.	95	Romano S.	110
Rais M.	33	Resch F.	74	Romero S.	75, 98
Raitsin S.	81	Respondek C. M.	95	Ron M. A.	34, 69, 103
Rajagopal L.	74	Rettenbacher M. A.	98, 111	Rosa A.	55, 64, 68, 74, 79, 97, 101
Rajarethinam R.	90	Retziou A. C.	73, 111	Rosa E. C.	100
Ramirez-Bonilla M. L.	35	Reynolds G. P.	111	Rosa F.	109
Ramos I.	74, 94	Reynolds R. F.	33, 73	Rosa P.	79
Ramperti N. M.	95	Reznick N.	51	Rose E.	54
Ramsey A. J.	88	Ribbe K.	78	Rosenheck R. A.	45
Ramsey N. F.	82	Ribchester T.	49	Ros-Morente A.	48
Ran W.	88	Riccardi I.	77, 98	Ross K.	93
Rancans E.	109	Richards J.	96	Ross N.	75
Ranganathan M.	32	Richards M.	90	Rossell S. L.	52, 75, 76, 98
Rao N. P.	97	Richardson C.	72	Rossi A.	77, 98
Rapado-Castro M.	80	Riecansky I.	106	Rosso I.	33
Rapin L.	103	Riecher-Rössler A.	83, 99, 106	Rostrup E.	57, 106
Rapp A.	89, 95	Riedel M.	53	Rotarska-Jagiela A.	56, 58, 79, 84, 103
Rapp M.	99	Rietdijk J.	71, 74	Roth A.	83
Rappaort J. L.	75	Rietschel M.	54, 78, 101, 116	Rothmond D. A.	85
Rasbash J.	33	Rifkin L.	79, 97	Rouleau A.	96
Rasetti R.	57	Riggert J.	78	Rouleau G.	36
Rasmussen H.	52, 56, 109	Rijnders C. A. T.	71	Rouleau N.	51
Rasmussen jr I-A.	97	Rijsdijk F.	33, 52, 107	Roupaka A. D.	73, 111
Rasser P. E.	49, 96, 106	Rim J.	69	Roussos P.	64, 108
Rathi Y.	79	Rimol L. M.	79, 97, 101	Roy M.-A.	94, 51
Rathod S.	20	Rinaldi M.	28	Royer A.	103
Rattehalli R. D.	109, 110	Riordan H.	77	Rubin D.	103
Rautanen M.	74	Risselada A.	116	Rubio Bravo M.	112
Rawdon C. C.	83, 105	Risterucci C.	59	Rudzok M.	107
Raymond É.	83, 94	Riva M.	88		
Rayport S.	88				



- Rueter L. E. 65
Ruhrmann S. 19, 71, 82, 94, 95,
106, 113
Ruiperez M. A. 72
Ruiz S. M. 35
Ruiz Feliu M. A. 63
Rujescu D. P. 24, 54, 60, 61, 77
Rumeo V. 73
Rund B. R. 41, 97
Rupp A. 60
Rurhmann S. 19
Rushby J. A. 34
Rushe T. 96
Rushforth S. L. 111
Rusjan P. 34
Ruskin J. 33, 73
Russell T. 114
Russo M. 32, 34, 69, 74, 76,
99
Rustay N. 66
Rutten B. 54, 70, 100
Rybakowski J. K. 110
Ryder A. 90
Rzanny R. 60, 82, 105
Saarni S. I. 62, 74, 97, 107,
113
Saarni S. E. 62, 74, 107
Saba R. 48
Sabbe B. 63
Sablier J. 66, 112
Sadée W. 80, 104
Saenger R. 97
Saenz Ballobar A. 112
Saetre P. 78
Saghy K. 86
Sahin S. 52, 60
Said M. A. 109
Sailas E. S. 91
Sajeev G. 85
Saks E. 13, 15
Sakuma A. 76
Saldias A. 71
Saleem M. M. 54
Salgado C. F. 87
Salgado P. 112
Salinas R. 87
Salisbury D. F. 60
Salokangas R. K. R. 113
Salte K. 65
Salvador R. 102, 104
Salvat E. 95
Sambataro F. 57
Sameshima K. 57
Samoud S. 61, 107
San L. 95, 113
Sanchez B. 95
Sanchez E. 102
Sánchez P. 76, 98
Sánchez-Gistau V. 75, 98
Sanchez-Morla E. M. 54, 106
Sanchez-Torres A. M. 48
Sanghera K. 104
Sanjuan J. 58, 100, 103
Santi S. D. 52
Santos J. L. 54
Santos T. N. 97
Sanz J. H. 80, 101
Sanz J. 79
Sarró S. 102, 104
Sartorius N. 48, 7, 14
Sartory G. 82, 106
Sasayama D. 100
Sato H. 76
Sato J. R. 57
Sato M. 103
Sauer H. 33, 60, 62, 78, 79,
80, 81, 82, 84, 101, 102, 104, 105,
107
Savina T. D. 83
Savla G. N. 101
Savostyanova A. A. 59
Sawa A. 18
Scarr E. L. 61, 62, 107
Schacht A. 67
Schachtzabel C. 101
Schaefer M. R. 62, 107
Schaer M. 56, 79
Schaffner N. 51, 73, 96
Schales C. 91
Schall U. 49, 51, 73, 83, 96,
106
Schaub D. 114
Schaus J. 62
Scheeuwe T. 105
Scherk H. 77
Scherpiet S. 80, 81, 101
Scheyer R. 51
Schiffer B. 95
Schimmelmann B. G. 51, 67, 68,
73, 74, 80, 92, 96, 112
Schimmenti A. 73
Schloesser R. G. 81, 101
Schlösser R. G. M. 80, 104
Schmid L. A. 54, 75
Schmidt C. 21
Schmidt H. 78, 102
Schmierer P. 95
Schmitz N. 22, 47, 78
Schnack H. H. G. 33, 51, 55, 56, 102
103, 116
Schneider C. 107
Schneider F. 103
Schneider-Axmann T. 77
Schneiderman J. S. 102
Schnider P. 107
Schnurr N. 69
Schobel S. 97
Schoeman R. 72
Schofield P. R. 77
Schönmeyer R. 56
Schooler N. 36, 46
Schothorst P. F. 103
Schreiner A. 64, 74, 87, 109,
110, 115
Schretlen D. J. 76
Schröder J. 54, 75
Schubart C. D. 70, 72
Schubert K. O. 85
Schultz C. 101, 104
Schultze-Lutter F. 19, 51, 60, 73, 74,
94, 95, 96
Schulz C. 26
Schulz S. 106
Schulze C. 99
Schulze K. 54, 107
Schulze T. G. 54
Schulze-Rauschenbach S. 69
Schurhoff F. 55, 68, 96, 99, 100
Schwab S. 20
Schwan R. 68
Schwannauer M. 93
Schwartz J. H. 97
Schwarz D. 56
Schwitzer G. 53, 114
Scott J. G. 96
Scott J. 93
Scott R. 51, 73, 96
Seal M. L. 22, 57, 75, 105,
116
Seeman P. 32
Segarra N. 77
Segarra R. 49, 98, 109
Seidl U. 54, 75
Seidman L. J. 33, 34, 50, 51, 66,
72, 76, 81, 99, 102, 104
Selten J-P. 96
Semenin V. 83
Seneca N. 86
Sentis M. A. 92
Seo J. H. 83
Seo Y-S. 110
Seppänen-Laakso T. 62, 84
Sergerie K. 55
Sergi M. 64
Serretti A. 27

Seto H.	102	Sinclair C.	116	Spalletta G.	54
Séveno M.	85	Singer W.	58, 84, 106	Sparks A.	53
Severinsen M. T.	96	Singh A. N.	115	Spiering M.	47
Severs J.	64	Singh A.	97	Spiliotacopoulos D.	34, 35, 52
Sevy S.	88	Singh N.	32	Spiro A.	65
Shah N. J.	78, 116	Singh S. P.	41, 69	Spiros A.	93
Shah N.	90, 112	Singh T.	68	Spolletini I.	54
Shahid M.	112	Sinibaldi L.	58, 82, 104	Spooren W.	107
Shaikh M.	54, 107	Siracusano A.	110	Sprengel R.	88
Shannon Weickert C.	38, 62, 77, 108	Sitaram R.	35	Sritharan S.	84
Shapiro D.	34	Sitskoorn M. M.	60	Srivastava L.	65
Sharma A.	52	Siu C.	62, 96, 108, 109, 110	St.Clair D. M.	60, 61
Sharma P.	34	Sivagnanasundaram S.	62	Staal W. G.	50
Shazad A.	98	Sivaraman P.	110	Stahl D.	33, 49, 57
Shen J.	59	Skimminge A.	56	Stahl S. M.	110
Shenton M. E.	79, 102	Skjei K.	57	Stam C. J.	105
Shergill S. S.	59, 104	Sklar P.	20	Stan C.	51, 73, 96
Shergill S.	80	Skoblenick K. J.	115	Stanford A.	82
Shi J.	63	Slaar A.	113	Stankevich B.	57
Shi J.	54	Slama H.	74	Stauffer V. L.	29, 90, 109, 110
Shibata T.	99	Slavkovic V. V.	72, 113	Steckler T.	111
Shibata T.	99	Slief E.	84	Steel C.	43
Shim G.	80	Slooff C.	116	Steinberg T.	51
Shim J-C.	110	Slotema C. W.	116	Stenberg J. H.	86
Shim R. S.	68	Smairi S.	73, 96	Stephano S.	59
Shin I-S.	86	Smallman R. P.	96	Stephens R.	85
Shoaib M.	111	Smeraldi E.	54, 64, 74, 109	Sterk B.	35, 84, 101
Shoenfeld N.	95	Smesny S.	60, 62, 82, 84, 101, 105, 107	Steullet P.	88
Shoenfeld Y.	95	Smith D.	50	Stevens K. E.	112
Shotbolt J. P.	104	Smith G.	69	Steward L.	107
Shrivastava A.	90, 112	Smith J. W.	86, 88	Steylen P. M. J.	113
Shu L.	63	Smith J.	47	Stilo S. A.	32, 69, 74
Shungu D. C.	82	Smith M.	109	Stip B.	57, 81
Sibille E.	88	Smulevich A.	109	Stip E.	57, 66, 74, 81, 85, 90, 95, 99, 103, 112
Sibinovic V. M.	113	Snars J.	92	Stitt L.	90, 112
Sicard G.	69	Sniadecki J.	109	Stojanov W.	83
Sicart D.	87	Snyder G. L.	107, 110	Stokes P.	104
Siddle R.	20	So H. S.	56	Stone J. M.	46, 105, 116
Sidis A.	115	Soekadar S.	35	Storey J. D.	111
Sihvonen M.	97	Søgaard B.	87	Stratta P.	77, 98
Silberberg C.	94	Soh M.	78	Striepens N.	69
Silva E. M.	97	Sokoliova J.	63	Strom B. L.	33, 73
Silva R.	64, 108	Sokoloff P.	8, 18	Stroup S.	89
Simard M.	53	Solano R.	106	Strous R. D.	95, 114
Simmonite M.	106	Solís-Rodríguez A.	53	Struab R. E.	104
Simmons A.	101, 104	Solowij N.	25, 95	Sturgess J.	27
Simmons M. B.	34, 35, 52, 115	Somers M.	115	Su W.	55
Simon G.	103	Sommer I. E. C.	48, 58, 60, 70, 80, 104, 105, 115, 116	Suarez D.	67
Simon J.	83	Sood P.	76	Subramaniam K.	104
Simonelli D.	108	Soto F.	77	Succop P.	90
Simons C.	104	Soulet M.	64	Suda S.	112
Simonsen E.	41	Souza R. P.	78, 100	Sugar C. A.	32, 75
Simonsen E.	41			Sugranyes G.	97
Simpson G. V.	104			Suk Kyoon A.	48, 83
Simpson J.	49				
Simu M. I.	64				



Sulaiman A. H.	109	Tancer M.	61	Thormodsen R.	97
Sumich A.	57	Tang H.	63	Thornton A.	49
Sun D.	84	Tang J. Y. M.	53, 67, 68, 92, 108, 113	Thorup A.	22, 35, 115
Sundram S.	61, 107	Tang J.	62, 84	Tianmei S.	31
Susser E.	45	Tang W-N.	69, 92	Tien Y-J.	48
Suto S.	85	Tanghøj P.	63, 64, 87	Tighe O.	111
Sutton M.	95	Tanimukai H.	91	Tiihonen J.	86
Suvisaari J.	62, 69, 74, 84, 97, 107, 113	Tanino R.	102	Tim M.	54
Suzana T. G. M.	72, 113	Tansella M.	61	Tiwari Y.	77
Suzuki K.	112	Tanskanen A.	65	Tobeña A.	67
Suzuki M.	99, 102, 56	Tao H.	108	Tobón-Arbeláez C.	53
Suzuki T.	110	Tarazi F.	46, 112	Todarello G.	100
Suzuki Y.	88	Tassell I.	90	Todd J.	106
Svarer C.	109	Tastet H.	115	Toga A. W.	84
Svensson K.	21	Tatematsu S.	90, 113	Togi N.	76
Svettini A.	114	Tatsumi M.	62	Tolossa A.	100
Svirskis T.	113	Taurisano P.	57, 58, 80, 81, 82, 98, 103, 104	Tomelleri L.	61
Swaab H.	51	Taxis K.	116	Tomppo L.	101
Swart M.	104	Taylor D.	108	Ton T.	67
Sweers K.	87	Taylor G.	60	Tonge B.	75
Swendsen J.	115	Taylor H. E.	92	Tordesillas-Gutierrez D.	80, 93, 102
Swisher T.	102	Taylor H.	84, 101, 104, 59, 69, 74	Toro J.	75
Syed F.	90	Taylor M.	52	Tosic Golubovic S. M.	113, 72
Sylvain H.	34	Tchoukhine E.	86	Totah N. K.	106
Sysi-Aho M.	84, 62	Tenback D. E.	40	Toth A.	64
Sytema S.	41, 50, 113	Tensfeldt T. G. M.	92	Tóth M.	62
Szafranski T.	110	Teraishi T.	62, 85	Toulopoulou T.	34, 49, 52, 57, 68, 78, 79, 80, 81, 107
Szekeres G.	95	Terevnikov V.	86	Toyomaki A.	75
Szendi I.	95	Terry D. P.	102	Trabajo-Vega P. L.	108
Szikra J.	86	Terwisscha van Schel A. F.	100	Tracy D. K.	104
Szmukler G.	108	Tessier C.	87, 109, 110, 64	Tranulis C.	66
Szöke A.	55, 96, 99, 100	Testa L. R.	104	Traum M.	63
Taanila A.	33	Testa R. R.	75	Treutlein J.	101
Tabarés-Seisdedos R.	102, 77	Thakar M.	90, 112	Trost S.	77
Tabuse H.	64	Thangavel A.	104	Trotman H. D.	50, 101
Tagami S.	91	Theochari E.	75	Trusel M.	88
Taira M.	67	Theodoropoulou P.	87	Tsai S-Y.	85
Takahashi H.	61, 70, 82, 101	Therman S.	33, 84	Tsaltas E.	75
Takahashi T.	56, 102	Thermenos H. W.	33, 81, 104	Tsapakis E. M.	64, 108
Takai-Kamiya M.	90, 113	Théroux L.	91	Tscherbakova N. P.	83
Takaki M.	100	Thewissen V.	70, 72, 100	Tse L.	65
Takamura H.	101, 108	Thiel S.	62, 105	Tsemberis S.	45
Takaya M.	70	Thienel R.	105	Tso S.	67, 92
Takeda M.	61, 70, 82, 91, 101, 108	Thierry E.	96	Tsuang M. T.	24, 33, 34, 50, 51, 66, 72, 81, 104
Takei N.	112	Thiran J. P.	55	Tsujino N.	71, 76
Takeshi K.	71, 76	Thomas N.	50, 115	Tsukarzi E. E.	109
Takeuchi A.	99	Thomas P.	59, 68	Tsunoka T.	77, 100
Takeuchi H.	110	Thompson A.	32, 76, 84, 99, 115	Turbelin M-R.	52
Takritii Y.	66	Thompson D. M.	88	Turczynski J.	64
Tamminga C.	4, 26	Thompson J.	97	Turkington D.	20
Tan E. C.	78	Thompson P. M.	49, 106	Turner K.	65
Tanaka H.	62	Thomson D. M.	111	Turner N.	95
Tanaka T.	91				

Tuulio-Henriksson A.	76, 97	Van Laere K.	33	Villaverde-Amieva C.	108
Twamley E. W.	40, 42, 101	van Lutterveld R.	66, 105	Villavicencio P.	114
Twomey D.	83	van Os J.	28, 32, 33, 35, 41, 45, 50, 54, 56, 70, 72, 74, 75, 78, 89, 94, 96, 97, 100	Viñas M. J.	77
Tzavara E.	111	van Reekum R.	71	Vincent P.	66
Tzotzoras T.	87	van Veelen N. M.	82, 105	Vinci C.	88
Tzourio-Mazoyer N.	52, 103	van Winkel R.	33, 50, 54, 70, 94, 96, 100	Vink M.	82, 105
Uchida H.	110	Vanderburg D. G.	62, 63, 97, 108, 109, 110	Vinogradov S.	84, 89, 104
Uchida T.	59, 76	Vanicek J.	56	Virginie T.	53
Uchiyama H.	62, 100	Vanover K. E.	107, 110	Visscher P.	24
Üçok A.	52, 60, 83, 87	Vansteelandt K.	63	Vogeley K.	89, 103
Udias J. M.	51	Varadi R.	69	Vollebergh W. A. M.	75
Uhlhaas P. J.	18, 39, 56, 84, 103, 106	Varela-Aller N.	108	Vollenweider F. X.	32
Ujike H.	100	Vares M.	78	Volovyk S. V.	116
Ulrichsen S. P.	96	Vargas M. L.	95	Volpe F. M.	97
Unenge Hallerbäck M.	71	Varrone A.	62	von Kienlin M.	59
Urban A.	83	Vauth R.	109	Vorstman J. A. S.	100
Ursini G.	58, 80, 82, 98, 100, 104	Vázquez C.	35, 49, 114	Voruganti L. N. P.	32
Ustohal L.	103, 112	Vázquez-Barquero J. L.	22, 67, 93, 100, 101, 102, 113	Voss A.	106
Vachon V.	89	Vázquez-Bourgon J.	101	Voss B.	105
Vagionis G. N.	73, 111	Vehof J.	116	Vossen H.	65, 74, 85
Vaglum P.	41	Veiga-Ramos I.	49	Vuillermot S.	66
Righetti V.	48	Veijola J. M.	33, 76, 97, 101	Waddington J. L.	29, 111
Valérie Y.	53	Velakoulis D.	55, 95, 116	Waelti C. M.	59
Valero Oyarzabal J.	112	Vella L.	101	Wagner G.	80, 81, 104
Valiente C.	68, 114	Velligan D. I.	34, 42, 89	Wagner M.	60, 69
Valladares A.	113	Velthorst E.	115	Wagshal D.	52
Vallejo J.	53	Venkatasubramanian G.	97	Wakabayashi C.	100
Valli I.	99, 103, 116	Vercammen A.	81	Wakuda T.	112
Valmaggia L.	33, 49, 102	Verdi M. B.	99	Walker E. F.	34, 44, 50, 66, 68, 71, 72, 101
Valuri G.	50	Verhaegh G.	22	Walker T.	89
van Amelsvoort T.	61, 115	Verhoeven W. M. A.	113	Walsh M.	80
van Baal G. C. M.	102	Verhulst F. C.	75	Walshe M.	52, 54, 79, 81, 97, 107
van Beekum A.	106	Verral L.	108	Walter H.	89
Van Bouwel L.	50	Verweij K.	116	Walterfang M.	95
van Busschbach J. T.	66	Vesterager L.	49, 112	Walters J.	54
van Buuren M.	105	Viechtbauer W.	89	Walther S.	83
van de Fliert J. R.	47, 68, 115	Vieira G.	57	Wang C.-Y.	95
van de Ven V.	56, 103	Viertiö S.	97, 113	Wang G.	63
Van de Willige G.	32, 48, 71	Vieta E.	77	Wang X.	63
Van den Heuvel M. P.	105	Vigne S.	52	Wang Y.	108
van der Gaag M.	43, 66, 71, 74	Vigneau M.	103	Wang Y.	88
van der Heijden F. M. M. A.	113	Vigo-Santamariña L.	49	Ward P. B.	49, 106
van der Meer L.	57, 77	Vila M.	98	Watanabe M.	67
van der Veen J.	59	Vilahur N.	65, 68, 74, 97	Waters F. A.	52, 99, 116
van der Werf M.	70, 94	Vilain J.	99	Waters-Metenier S.	57, 103
van Don J.	22	Vila-Rodríguez F.	49	Watsky E.	108, 109, 110
van Dorsselaer S.	75	Vilella E.	78	Watson P. R.	90
van Engeland H.	51, 103	Villa H.	72	Webb R. T.	50
van Erp T. G. M.	33, 80, 84	Villanueva C.	106	Webster M. J.	37, 108
van Gastel W. A.	70, 72	Villarreal M.	58, 68	Wehmeier P. M.	67
van Haren N. E. M.	33, 55, 56, 100, 102, 116			Wehring H.	72
van Harten P. N.	40			Weickert T. W.	34
				Weiden P. J.	110



Weinberger D. R.	31, 34, 42, 57, 59, 99, 100, 104	Wolff A. R.	112	Yoffe R.	93, 97, 116
Weisbrod M.	33, 60, 79, 82, 83, 89, 102	Wong A. H.	78, 100	Yokobayashi E.	100
Weiser M.	41, 75, 93, 97, 116	Wong C-K.	69, 92	Yolken R. H.	32
Weisinger B.	75	Wong D. M.	65	Yoller A. B.	76
Weiss P. S.	68	Wong G. H. Y.	53, 67, 68, 92, 108, 113	Yonchek J.	112
Weizman A.	71	Wong J.	85, 108	Yoon B.	86
Wennogle L. P.	107, 110	Wong P.	88	Yoon J-S.	86
Werbelloff N.	93, 97, 116	Woo T-U. W.	85	Yoon J.	58
Werge T.	77, 78	Woo W.	86	Yoon K. J.	103
Werneck A. P.	110	Wood A.	96	Yoshida Y.	101
Wesnes K.	87, 93	Wood J. T.	106	Young D. J.	50
Wettstein J. G.	59	Wood S. J.	21, 34, 52, 55, 99, 116	Young L.	81
Wexler B. E.	52	Woodberry K. A.	99	Yücel M.	95
White T. P.	93	Woods S. W.	19, 34, 50, 66, 72	Yuen H. P.	35, 52
Whitfield-Gabrieli S.	33, 104	Woodward T.	103	Yuen K.	92
Whitford T. J.	46, 102	Woolley J.	80, 102	Yukawa-Inui M.	90, 113
Whitman J.	103	Woolley M. L.	107	Yuksel C.	52, 60
Whittle S.	55, 95	Wouters L.	35	Yun D. Y.	98
Wibral M.	106	Wright J.	20	Yung A. R.	19, 32, 34, 35, 48, 52, 72, 92, 99, 115, 116
Wichers M.	45, 96	Wright K.	72	Yutani M.	113
Wicks S.	50, 65	Wu E. X.	88	Zabala A.	49
Widschwendter C.G.	105	Wulff K.	116	Zaccardi J.	85
Wiedemann G.	89	Wunderink L.	41, 50, 71, 113	Zai G.	27
Wiersma D.	32, 41, 48, 50, 66, 71, 77, 104, 113, 116	Wykes T.	20, 40, 43, 53	Zakzanis K. K.	71
Wiffen B.	32, 69, 76, 99	Xia J.	66	Zalsman G.	98
Wigman J. T. W.	75	Xiang Y. T.	87, 95	Zaman R.	62
Wildenauer D.	20	Xiao S.	113	Zammit S.	33, 97
Wilffert B.	116	Xie S.	63	Zandbelt B. B.	105
Willard D.	75	Xiu M. H.	87	Zanelli C.	99
Willems A. E.	60	Xu J.	108	Zanelli J.	49, 79, 99
Williams I.	54, 107	Xu X.	63	Zavitsanou K.	88, 108
Williams J.	36, 91	Xue Z.	108	Zaytseva Y.	99
Williams J. E.	86	Yalcin N.	53, 98, 114	Zdravkovic M.	96
Williams L.	59	Yalcin-Cavus S.	72	Zelaya F.	59
Williams N. M.	78	Yamamori H.	61, 70, 82, 91, 101, 108	zerem ullman V.	96
Williams R.	69, 85	Yamamoto H.	90, 113	Zhang B. Y. H.	107
Williams S.	93	Yamamoto K.	90, 113	Zhang H.	111
Williams S. S. C.	57	Yamamoto N.	62	Zhang L.	86
Williams S. C. R.	33, 59	Yamanouchi Y.	77, 100	Zhang M.	65, 66
Wiltfang J.	82	Yang J.	86	Zhang X. Y.	87
Winchester C. A.	111	Yang S-J.	86	Zhang X	111
Winchester C. L.	111	Yasuda Y.	61, 70, 82, 91, 101, 108	Zhang Z	111
Winterer G.	82	Yavorsky W. C.	94, 98	Zhao J.	63
Winton-Brown T. T.	99, 105	Ye W.	64	Zhao Y.	64
Wischniewski J.	114	Yee B. K.	111	Zheng L.	112
Wiseman Z.	93	Yeghiyan M.	52	Zhou S-Y.	102
Wisner K. M.	99	Yenilmez E.	72	Zhou W.	29
Witt S.	78	Yeragani V. K.	61, 106	Ziermans T. B.	103
Wittchen H-U.	33, 50, 70	Yeung W-S.	69, 92	Zimmermann R.	83, 99, 106
Witten L. M.	62	Yi J. S.	72, 83, 86, 96, 114	Zimmermann V.	114
Wittorf A.	89	Ying C.	88	Zinkstok J.	61
Wobrock T.	77			Zipursky R. B.	85
				Zuardi A. W.	57
				Zubieta J. L.	81

Otsuka



Supporting Continuing Research in Neuroscience



One day, we hope to make a medicine just for Maria. Today, patients with the same illnesses tend to get the same medicines. Yet all patients are different and each responds a little differently to medicines. So at Lilly, our scientists and physicians are researching ways to tailor medicines that better match an individual patient's needs. And while we're a long way from making medicines just for Maria, we're a lot closer to making sure she gets exactly what she needs. lilly.com

ITLLY00006 ©2010, Lilly USA, LLC. ALL RIGHTS RESERVED.

Lilly
Answers That Matter.



Schizophrenia
International
Research
Society